The rational design and synthesis of novel antifreeze(glyco)protein biomimetics for biomedical applications by Graham, Ben
A Thesis Submitted for the Degree of PhD at the University of Warwick
Permanent WRAP URL: 
http://wrap.warwick.ac.uk/146813 
Copyright and reuse:
This thesis is made available online and is protected by original copyright.
Please scroll down to view the document itself.
Please refer to the repository record for this item for information to help you to cite it. 
Our policy information is available from the repository home page.
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk
warwick.ac.uk/lib-publications
The rational design and synthesis of novel 





A thesis submitted to the University of Warwick in partial fulfilment 
of the requirements for the degree of 
Doctor of Philosophy 
 
 
University of Warwick, Department of Chemistry 
June 2019 
ii 
Table of Contents 
__________________________________________________ 
Chapters and Sections            iii 
List of Figures             vi 
List of Schemes           xiv 
List of Tables                       xvi 
List of Equations                    xviii 
Abbreviations                      xix 
Acknowledgements          xxii  
Declaration                     xxvi 
Abstract                   xxviii 
  
iii 
Chapters and Sections 
 
Chapter 1___________________________________ ______ 
Introduction                 1 
 1.1 – Antifreeze Glycoproteins           4 
 1.2 – Antifreeze Proteins            7 
 1.3 – Mechanisms of Action            9 
 1.4 – Applications of AF(G)P’s         17 
 1.5 – Synthetic AF(G)P Mimetics         20
 1.6 – Protein Mimics in Biomedicine         35
 1.7 – Summary           38
 1.8 – Project Aims and Overview         39
 1.9 – Thesis Summary          40
 1.10 – References           42 
 
Chapter 2________________________________   ________ 
Polyproline – Amphipathy and the polyproline II helix in ice inhibitor design     
 2.1 – Chapter Abstract          51 
 2.2 – Chapter Introduction          53 
 2.3 – Results and Discussion            
  2.3i – Synthesis of oligo- and poly- prolines       56 
  2.3ii – The IRI activity of oligo- and poly- prolines      62 
  2.3iii – Cryopreservation with oligo- and poly-prolines     67 
  2.3iv – Preparation of poly(L-proline) via in-situ N-carboxyanhydrides and 
   ROP           71 
 2.4 – Conclusions           75
 2.5 – Experimental           76
 2.6 – References           88 
  
iv 
Chapter 3_______ __________________________________ 
Photo-activatable ice recrystallisation inhibitors           
 3.1 – Chapter Abstract          93 
 3.2 – Chapter Introduction          94 
 3.3 – Results and Discussion              
  3.3i – Rational design and synthesis of the photoconjugates     99 
  3.3ii – Characterisation and IRI activity of the photoconjugates  106 
  3.3iii – Synthesis, characterisation, and IRI analysis of poly(vinyl alcohol) 
   photoconjugates       118 
 3.4 – Conclusions         127
 3.5 – Experimental         129
 3.6 – References         143 
 
Chapter 4_______ __________________________________ 
Rationally designed amphipathic glycopolymers for ice growth inhibition       
 4.1 – Chapter Abstract        147 
 4.2 – Chapter Introduction        149 
 4.3 – Results and Discussion 
  4.3i – Synthesis of amphipathic homopolymers    152 
  4.3ii – The IRI activity of the amphipathic homopolymers   163 
  4.3iii – Synthesis and IRI activity of amphipathic copolymers  165 
 4.4 – Conclusions         176
 4.5 – Experimental         177




Chapter 5_______ __________________________________ 
Engineering ice inhibitory activity into new synthetic materials     
 5.1 – Chapter Abstract        208 
 5.2 – Chapter Introduction        209 
 5.3 – Results and Discussion              
  5.3i – Synthesis and IRI analysis of Simvastatin derivatives   211 
  5.3ii – Synthesis and IRI analysis of poly(bile acids)   214 
 5.4 – Conclusions         231
 5.5 – Experimental         232
 5.6 – References         247 
 
Chapter 6                                        _______ ______________ 
Conclusions             249 
 
Appendices_______________      ______________________ 
Appendix A – Supplementary Information       252 
Appendix B – Additional Experimental Data      273 
Appendix C – Publications          281 
  
vi 
List of Figures 
 
Chapter 1___________________________________ ______ 
 
Figure 1.1 Graphical representation of the effect of the freeze/thaw process on 
biological material 
Figure 1.2 Illustration depicting the Thermal Hysteresis effect of AF(G)P’s on 
ice crystal growth 
Figure 1.3 Structure of the AFGP repeat unit 
Figure 1.4 Illlustration depicting the A) Hydrophilic/phobic separation of 
AFGP and B) Polyproline II Helix and Circular Dichroism analysis 
of AFGP. 
Figure 1.5 Crystal Structures of A) AFP Type I, B) AFP Type II, C) AFP Type 
III, D) Spruce budworm AFP, and E) Perennial rye grass AFP 
Figure 1.6 Illustration of AFGP primsatic face binding, leading to dynamic ice 
shaping / growth along the unbound axis 
Figure 1.7 Graph depicting the Thermal Hysteresis effect of AFGP Fractions 
adapted from Zachariassen and co-workers’ 
Figure 1.8 ‘Splat’ micrograph of AFGP in PBS compared to PBS alone 
Figure 1.9 Illustration of AFP clathrate water ordering postulated by Davies and 
co-workers’ on surface of MpAFP 
Figure 1.10 Hydrogen bonding model postulated by Molinero and co-workers’ 
depicting the exploration by a single chain of PVA of the {101̅0} ice 
crystal face (primary prismatic plane) 
Figure 1.11 Reversible AFGP face binding model postulated by Molinero and 
co-workers’ 
Figure 1.12 Illustration depicting the Disordered Water Layer hypothesis 
Figure 1.13 Graph depicting the IRI potency of poly(vinyl alcohol) 
Figure 1.14 Structure of Ben and co-workers’ first generation C-linked AFGP 
mimetic probe 
Figure 1.15 Structure of Ben and co-workers’ second generation C-linked AFGP 
mimetic probe 
vii 
Figure 1.16 Graphical representation, reproduced from Ben and co-workers’, of 
IRI activity of a series of sugars correlated to their hydration 
potential as carbohydrates 
Figure 1.17 Structures of the flexible IRI glycopolymers prepared by Cameron 
and co-workers’ 
Figure 1.18 Graphical representation of the self-assembly of Safranine O 
Figure 1.19 Graphical representation, adapted from Gibson and Scott and co-
workers’, outlining their IRI active, enantiomerically pure 
metallohelix, featuring an amphipathic surface 
Figure 1.20 Structures of a series of IRI active small molecules designed by Ben 
and co-workers’ 
Figure 1.21 Structures of a series of IRI active ampholyte polymers prepared by 
Gibson and co-workers’ 
Figure 1.22 Structures of a series of IRI active amphipathic polymers prepared 
by Matsumura and co-workers’ 
Figure 1.23 Illustration of the IRI active substances prepared to date in the 
literature 
Figure 1.24 Examples of protein biomimetic polymers from Tew and co-
workers’ 
Figure 1.25 Structures of some select biomimetic adhesive polymers 
 
 
Chapter 2___________________________________ ______ 
 
Figure 2.1 Graphical representation of IRI active species; Sculpin Type I AFP, 
AFGP, Nisin A, and Metallohelices 
Figure 2.2 Proposed preparation of poly(L-proline) from the N-
carboxyanhydride of L-proline 
Figure 2.3 Graphical representation of the preparatory routes of N-
carboxyanhydrides 
Figure 2.4 Mass Spectrum of Pro-NCA (GC/MS) 
viii 
Figure 2.5 Graphical representation of the ring opening polymerization of 
proline-NCA through the Normal Amine Mechanism (NAM), 
contrasted to the Activated Monomer Mechanism (AMM) 
Figure 2.6 Graphical representation of the condensation polymerization of 
proline 
Figure 2.7 Graph showing the A) Circular dichroism spectra of poly(proline), 
the B) IRI activity of polyproline series, and C) the IRI activity of 
poly(proline) compared to other homo-polypeptides, and D) a 
cryomicrograph of a PBS negative control compared to, E) a 
cryomicrograph of 20 mg.mL-1 poly(proline) 
Figure 2.8 Hydrophobic surface mapping of A) Recombinant Type I Sculpin 
AFP, and homopeptides B) PPro10, and C) PGlu10 
Figure 2.9 Graphical representation of the experimental determination of 
dynamic ice shaping 
Figure 2.10 Graph showing extent of A549 cellular cryopreservation by 
poly(proline) 
Figure 2.11 Graph showing extent of red blood cell haemolysis by poly(proline) 
Figure 2.12 Graph showing cytotoxicity of poly(proline) as a function of time 
Figure 2.13 Graphical representation of the generation of a proline carbamate 
precursor and it’s in-situ N-carboxyanhydride generation and 
subsequent ROP 
Figure 2.14 Suggested mechanism for (undesirable) ester formation during 
proline-4-nitrophenoxy carbonyl synthesis 
 
 
Chapter 3___________________________________ ______ 
 
Figure 3.1 Illustration of the hypothesised protection of tissue through photo-
controlled IRI 
Figure 3.2 Illustration of A) the molecular orbital diagram showing the 
photolysis induced excitation of anthracene, resulting in; B) a 
concerted [4πs + 4πs] Diels-Alder cycloaddition of two anthracene 
units, forming a photodimer. C) Literature example of polymer 
cross-linking utilizing the anthracene/photodimer motif 
ix 
Figure 3.3 Graphical representation showing the photodimerisation of two 
anthracene rings under UV (365 nm) light, giving 2 potenital 
photoproducts 
Figure 3.4 Graphical representation depicting the proposed monomeric and 
photo-dimeric products arising from this work 
Figure 3.5 Graph showing the Anthracene-AFP22 HR/LCMS spectra 
Figure 3.6 Graphs showing the UV-Vis Spectra of unconjugated anthracene-
dilysine dihydrochloride in A) Water and B) MeOH 
Figure 3.7 Graph showing the irradiation trials of the PC-Ala photoconjugate 
Figure 3.8 Graph showing the irradiation effect upon the UV-Vis spectra of the 
Anthracene-AFP photoconjugates 
Figure 3.9 Graphs showing the HPLC Spectra of A) 9-ACA Control, and B) 
PC-AFP22 (6b) Dimer at 213 nm 
Figure 3.10 Graphs showing the CD Spectra of Anthracene-AFP Conjugates in 
Water 
Figure 3.11 Graphs showing the A) Effect upon PBS ice crystal size of AFP Type 
I, and B) the effect upon saline ice crystal size by the PC-Ala 
photoconjugates 
Figure 3.12 Graph showing the A) Effect upon saline ice crystal size of the native 
AFP11 and PC-AFP11 derivatives, and B) the effect upon saline ice 
crystal size of the native AFP22 and PC-AFP22 derivatives 
Figure 3.13 Graph showing the comparative % MGA of AFP Type I and the 
anthracene-AFP22 derivatives, relative to PVA 56. 
Figure 3.14 ‘Splat’ micrographs comparing between the undimerised and 
dimerized anthracene-AFP22 conjugates and free AFP22 
Figure 3.15 Graph showing the SAXS Data of the AFP22-PC irradiated and 
unirradiated samples, after background buffer subtraction 
Figure 3.16 Graph showing the low temperature WAXS X-Ray diffraction 
patterns between the frozen irradiated and unirradiated PC-AFP22 
species at the saturated concentration versus a saline control 
Figure 3.17 Graph showing the Anthracene-PVA HR/LCMS spectra 
Figure 3.18 Graph showing the Irradiated PC-PVA Photoconjugate 
x 
Figure 3.19 Graph showing the HPLC Trace of the dimerised PC-PVA 
photoconjugate 
Figure 3.20 Graph comparing the unirradiated PC-AFP22 and PC-PVA 
photoconjugates 




Chapter 4___________________________________ ______ 
 
Figure 4.1 Graphical representation of the (AFGP)n repeat architecture, 
showing structural features along a PPII helix 
Figure 4.2 Graphical representation comparing the structural flexibility of 
active and inactive glycopeptides 
Figure 4.3 Graphical representation of our proposed structural framework based 
upon the solution state structure of AFGP 
Figure 4.4 Structures of our rationally designed monomeric architectures 
Figure 4.5 Retrosynthetic analysis of our proposed candidates 
Figure 4.6 1H NMR (CDCl3) of diastereoisomerically pure exo,exo-
fulvonorborneneimide 
Figure 4.7 1H NMR (CDCl3) of M1 
Figure 4.8 Graph showing the A) IRI activity of the initial homopolymeric 
candidates, featuring a graphical representation B) of the difference 
in the surface amphipathy of poly(Oxo) and poly(Fulvo) 
Figure 4.9 Graphical representation of the library of monomers and 
(co)polymers produced herein 
Figure 4.10 Graph showing A) the IRI activity of the statistical copolymer versus 
the homopolymers. Graphical representations of B) a Splat wafer of 
PBS and C) poly(Fulvo-co-Oxo) for visual comparison. 
Figure 4.11 SEC/GPC Trace of poly(Fulvo-co-Oxo) in THF and DMF 
Figure 4.12 IR Spectra of poly(Fulvo-co-Oxo) indicating incomplete 
deacetylation 
xi 
Figure 4.13 Graph showing the IRI activities of the poly(Fulvo-co-Diol) 
molecular weight series 
Figure 4.14 Graph showing the IRI activities of the weak to inactive candidates 
Figure 4.15 Illustration of the inactive, modified, co(polymeric) species 
Figure 4.16 ‘Splat’ micrograph / ice morphology analysis of A) Water, B) 
AFGP-8, and C) poly(Fulvo-co-Diol)-17 
Figure 4.17 Graph showing the SANS data for poly(Fulvo-co-Diol)-11 and 
poly(Fulvo-co-Diol)-17 
Figure 4.18 Graphs containing Beer Lambert Plots and UV-Vis spectra of the 
poly(Fulvo), poly(Fulvo-co-Diol)-11 and -17 polymer series 
Figure 4.19 Graphs containing Beer Lambert Plots and UV-Vis spectra of 
poly(Fulvo-co-Diol)-35, poly(Fulvo-co-FPEG), and poly(Diol) 
polymer series 
Figure 4.20 Graphs containing Beer Lambert Plots and UV-Vis spectra of the 
poly(FPEG) and poly(Fulvo-co-Diol)-17 + H2 polymer series, and 
deacetylated Fulvo-Gal monomer series 
Figure 4.21 Graph showing the background UV/Vis spectrum of DMSO 
(background zeroed) and DMSO containing PBS salt 
 
 
Chapter 5___________________________________ ______ 
 
Figure 5.1 Panel of simvastatin derivatives prepared for IRI activity assessment 
Figure 5.2 Graph showing the IRI activities of the modified simvastatin series 
at their saturated solution concentrations 
Figure 5.3 Illustration comparing the structural motifs of AFGP and 
chenodeoxycholic acid 
Figure 5.4 Energy minimized model of the polymeric conjugate (featuring axes) 
Figure 5.5 Energy minimized model of the proposed poly(chenodeoxycholic 
acid) derivative at varying molecular weights. A) DP10 Simulation, 
and B) DP20 Simulations 
Figure 5.6 13C NMR (CDCl3) of (7/3)-ketolithic acid methyl ester (Crude) 
Figure 5.7 13C NMR (CDCl3) of 7-ketolithic acid methyl ester (Purified) 
xii 
Figure 5.8 SEC trace of poly(7-ketolithocholic acid) 
Figure 5.9 Graphical representation of the stereoselective reduction of 7-
ketolithocholic acid methyl ester to CDCA methyl ester 
Figure 5.10 13C NMR (CDCl3) of chenodeoxycholic acid methyl ester (Post 
NaBH4 Reduction) 
Figure 5.11 Graphs showing the A) Overlaid SEC RI traces of the polymeric bile 
acid series synthesised, and B) a comparison between poly(7-
ketolithocholic acid) and the reduced poly(CDCA) 
Figure 5.12 1H NMR (CDCl3) of poly(chenodeoxycholic acid-7-malonate 
galactose) 
Figure 5.13 Comparative 13C NMR (CDCl3) of poly(chenodeoxycholic acid-7-
malonate galactose) and chenodeoxycholic acid methyl ester 
Figure 5.14 Series of bile acid derivatives and polymers assayed for IRI activity 
Figure 5.15 Graph showing the IRI activities of the bile acid series 
 
Appendix A _________________________________ ______ 
 
Figure A2.1 Uncorrected CD Spectra of poly(proline) and controls 
Figure A2.2 Splat micrographs of L-proline and PBS 
Figure A2.3 ESI LC-MS Spectra of PPro10 (Peptide Protein Research Ltd) 
Figure A2.4 ESI LC-MS Spectra of PPro20 (Peptide Protein Research Ltd) 
Figure A2.5 IR Spectra of prepared Pro-NCA and literature comparison 
Figure A3.1 ESI LC-MS Spectra of AFP22 (Peptide Protein Research Ltd) 
Figure A3.2 Uncorrected CD Spectra of PC-PVA Dimer and Monomer 
Figure A3.3 SEC/GPC trace of provided PVAc-NHS 
Figure A4.1 1H NMR (CDCl3) of attempted anomeric deacetylation of Glc 
pentaacetate 
Figure A4.2 1H NMR (CDCl3) of attempted anomeric deacetylation of GalNAc 
peracetate 
Figure A4.3 1H NMR (CDCl3) of M1 with triphenylphosphine oxide by-product 
Figure A4.4 TLC plate of Mitsunobu coupling (inseparable mixture) 
xiii 
Figure A4.5 1H NMR (THF-d6) Kinetics Study (1 hr Waterfall Plot) of Catalyst 
and Monomer 
Figure A5.1 UV/Vis Traces and Beer-Lambert solubility determination of 
poly(chenodeoxycholic acid) 
Figure A5.2 UV/Vis Traces and Beer-Lambert solubility determination of 
poly(7-ketolithocholic acid) 
Figure A5.3 UV/Vis Trace of Simvastatin 
Figure A5.4 UV/Vis Trace and Beer-Lambert solubility determination of 
Hydrolysed Simvastatin 
Figure A5.5 UV/Vis Trace and Beer-Lambert solubility determination of Ring 
Opened and Hydrolysed Simvastatin 





List of Schemes 
 
Chapter 3___________________________________ ______ 
 
Scheme 3.1 Scheme depicting the A) attempted coupling of arginine derivatives. 
B) Intramolecular dehydrative reduction 
Scheme 3.2 Scheme outlining the optimised synthetic route for the synthesis of 
anthracene-AFP conjugates, and also showing the library of prepared 
candidates 
Scheme 3.3 Scheme showing the In-situ synthesis of poly(alanine) via N-
Carboxyanhydride ROP 
Scheme 3.4 Scheme outlining the attempted azide-alkyne ‘click’ coupling to 
prepare the anthracene-PVA derivative 
Scheme 3.5 Scheme outlining the revised synthetic route to the anthracene-PVA 
derivative 
 
Chapter 4___________________________________ ______ 
 
Scheme 4.1 Scheme detailing the initial synthetic route for the preparation of the 
devised monomers / M1 and M2 
Scheme 4.2 Scheme showing the attempted Mitsunobu synthesis of M1 
Scheme 4.3 Scheme detailing the revised synthetic route for the synthesis of M1 
and M2 
Scheme 4.4 Scheme showing the trialed carbohydrate conjugation strategies; via 
A) The preparation of the norborneneimide salt in-situ, B) silver 
carbonate promotion, and C) Iodine (Lewis-acid) promotion 
Scheme 4.5 Scheme detailing the optimised coupling route for the synthesis of 
M1 and M2 
Scheme 4.6 Scheme outlining the mechanism of ring-opening metathesis 
polymerisation (ROMP) 
Scheme 4.7 Scheme showing the polymerisation of a Norbornenediol 
xv 
Scheme 4.8 Scheme detailing the monomethylation and tosylation of PEG and 
its subsequent conjugation to the monomer unit 
Scheme 4.9 Scheme detailing the hydrogenation of the poly(Fulvo-co-Diol)-17 
species with palladium (II) hydroxide over carbon and triethyl silane 
 
Chapter 5___________________________________ ______ 
 
Scheme 5.1 Scheme detailing the initial synthetic route for the generation of a 
poly bile acid-carbohydrate conjugate 
Scheme 5.2 Scheme outlining the revised synthetic route for the production of 





List of Tables 
 
Chapter 1___________________________________ ______ 
 
Table 1.1 Table containing an overview of AFP species 
 
Chapter 2  __________________________________ ______ 
 
Table 2.1 Table outlining the attempted syntheses of Proline-NCA 
Table 2.2 Table detailing the analysis and characterisation of the 
poly(proline)’s prepared through condensation coupling 
Table 2.3 Table detailing the analysis and characterisation of the 
poly(proline)’s prepared through the in-situ NCA/ROP protocol 
 
Chapter 3  __________________________________ ______ 
 
Table 3.1 Table showing the Anthracene-AFP22 HR/LCMS major fragments 
Table 3.2 Table detailing the DLS Data for the PC-AFP22 photoconjugates 
Table 3.3 Table showing the Anthracene-PVA HR/LCMS major fragments 
Table 3.4 Table detailing the DLS Data for PC-PVA photoconjugates 
 
Chapter 4  __________________________________ ______ 
 
Table 4.1 Table detailing the SEC characterisation data for the prepared 
homopolymers 
Table 4.2 Table detailing the SEC characterisation data for the prepared 
(co)polymers 
Table 4.3 Table detailing the polymer preparation summary 




Chapter 5  __________________________________ ______ 
 





List of Equations 
 
Chapter 1___________________________________ ______ 
 




°C Degrees Centigrade 
μ Micro (× 10-6) 
Ac Acetate 
ACA Anthracene Carboxylic Acid 
AF(G)P Antifreeze (Glyco)protein 
AFP Antifreeze Protein 
Ala Alanine 
Asn Asparagine 
cm Centimetre (× 10-2 meters) 
Đ Dispersity Index = Mw/Mn 
Da Daltons 
DCM Dichloromethane 
DIS Dynamic Ice Shaping 
dm Decimetre (× 10-1 meters) 
DMAc Dimethyl acetamide 
DMF Dimethyl formamide 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DP Number average Degree of Polymerisation 
ESI-MS Electrospray Ionisation Mass Spectrometry 
FDA United States of America Food and Drug Administration 
g Gram 
GPC Gel Permeation Chromatography 
[I] Initiator concentration 
xx 
IBS Ice Binding Site 
IR Infrared Spectroscopy 
IRI Ice Recrystallisation Inhibition 
kDa kiloDaltons (× 103 Daltons) 
Lys Lysine 
m Metre 
[M] Monomer concentration 




MLGS Mean Largest Grain Size 
mm Millimetre (× 10-3 meters) 
Mn Number-Average Molecular Weight 
Mol Moles 
Mw Weight-Average Molecular Weight 
nm Nanometre (× 10-9 meters) 
NCA N-Carboxyanhydride 
NPC Nitrophenyl Chloroformate 
NMR Nuclear Magnetic Resonance 
OH Hydroxyl 
PBS Phosphate-Buffered Saline 
PEG Poly(ethylene glycol) 
Pro Proline 
PVA Poly(vinyl alcohol) 
xxi 
PVAc Poly(vinyl acetate) 
PVP Poly(vinyl pyrrolidone) 
RAFT 
Reversible Addition-Fragmentation Transfer (Radical 
Polymerisation) 
ROMP Ring Opening Metathesis Polymerisation 
ROP Ring Opening Polymerisation 
SAXS Small-Angle X-Ray Scattering 
SANS Small-Angle Neutron Scattering 
SEC Size Exclusion Chromatography 
TH Thermal Hysteresis 
THF Tetrahydrofuran 
Thr Threonine 
TPPO Triphenylphosphine oxide 
UV/Vis Ultraviolet/Visible 






First and foremost, my heartfelt thanks and appreciation go to Matt – for taking me on, for 
being an excellent supervisor (who was never short on encouragement or optimism), and for 
giving me the freedom to explore the field and to lead my own research. The past three and a 
half years have been a truly enjoyable experience and your support and mentorship, which will 
continue to make up the basis of my research career, has always been greatly received. The 
conference trips to Ghent, Tel Aviv, and Boston, amongst others, were fantastic experiences 
which won’t be easily forgotten and have undoubtedly helped my development. Thank you! 
Secondly, the Gibson Group. I couldn’t have asked for a better team to work in. It was great 
(and well resourced!) fun. Specific thanks go to Alice, Alex, Caroline, and (other) Ben. 
Next up, to the University of Warwick, the Department of Chemistry, and all the support, 
administrative, and technical staff. Thank you for the access to the resources, equipment, and 
services needed to get this far. Likewise, my thanks go to the European Research Council for 
my PhD funding, and to the Royal Society of Chemistry and the Society of Chemical Industry 
for their generous grants and career support/development over the years. Sincere thanks also 
go to my alma matter, the University of Reading – for an excellent undergraduate experience, 
for giving me the potential to succeed, and for making me who I am today. 
To all my friends – but particularly Krissi, John, and Charlotte – thanks for always being there. 
To Mum and Dad, for the financial and emotional support, for always believing in me, for 
spurring me forward, and for always telling me to ‘reach for the stars’. I love you both. To my 
grandparents, Rose and the late Francis, whose support helped to make many things a reality. 
Lastly – and by no means least – to Joe. The man to whom I owe everything, and who I’m 
nothing without. I love you. Your endless support, encouragement, and care over the years 













“We are all in the gutter, but some of us 
are looking at the stars” 







“I have broken the machine and 
touched the ghost of matter.” 





This thesis is hereby submitted to the University of Warwick in partial fulfilment of the 
requirements for the degree of Doctor of Philosophy. The work reported herein was carried out 
in the laboratories of the Department of Chemistry, University of Warwick between October 
2015 and March 2019. All reported work was carried out by the author alone unless otherwise 
stated, and no part of the reported work has been previously submitted in any shape or form 
for any other degree at any University. 
Particular sections of this thesis have been published or submitted for publication, as follows: 
• Chapter 2: B. Graham, T. L. Bailey, J. R. J. Healey, M. Marcellini, S. Deville, and M. 
I. Gibson, "Polyproline is a minimal antifreeze protein mimetic and enhances the 
cryopreservation of cell monolayers", Angewandte Chemie Int. Ed., 2017, 56, 15941 – 
15944 
• Chapter 3: B. Graham and M. I. Gibson, “Synthesis of anthracene-conjugates of 
truncated antifreeze protein sequences. Effect of end-group and photo-controlled 
dimerization on ice recrystallisation inhibition activity”, Submitted 
• Chapter 4: B. Graham, A. E. R. Fayter, J. E. Houston, R. C. Evans, and M. I. Gibson, 
"Facially amphipathic glycopolymers inhibit ice recrystallization", Journal of the 
American Chemical Society, 2018, 140, 5682 – 5685 
In line with the above declaration, the following sections contain contributions from 
colleagues: 
• Chapter 2: Trisha L. Bailey: Performed the cell cryopreservation and cell toxicity 
assays and conducted the consequent data analysis. 
Dr. Joseph R. J. Healey: Provided the data of the modelled protein structures. 
xxvii 
Dr. M. Marcellini and Dr. S. Deville: Performed the ice shaping experiments and 
conducted the consequent data analysis. 
• Chapter 3: Dr. Steven Huband and Alice E. R. Fayter: Performed the SAXS and 
WAXS experiments, respectively, and conducted the consequent data analysis. 
Dr. Muhammad Hassan: Provided the AFP type I antifreeze protein data. 
Christopher D. Stubbs: Provided the poly(vinyl)acetate-N-hydroxysuccinimide. 
• Chapter 4: Alice E. R. Fayter: Performed the sucrose sandwich/ice-shaping assay and 
provided the image files. 
Dr. Judith E. Houston/Dr. Rachel. C. Evans: Performed the SANS experiments and 
conducted the consequent data analysis. 
 




The cryopreservation and storage of biological materials essential to biomedicine – such as 
blood, stem cells, and tissues – is hampered by poor cellular recoveries and viabilities. This is 
largely due to the formation of ice crystals during the freeze/thaw process, causing catastrophic 
ice induced damage to cell-based material. Without a reliable, reproducible, and effective 
cryopreservation method, it is not possible to maintain an on-demand, high quality, and ready 
supply of vital, life-saving biological products – impacting upon both lives and biomedical 
research and development. Strategies to inhibit this ice induced damage would therefore have 
wide application in biomedicine. 
Many organisms inhabiting sub-zero environments are able to survive and thrive without issue. 
Shrubs, plants, insects, but particularly, marine life, have all demonstrated varying degrees of 
‘cold protection’. Antifreeze glycoproteins (AFGPs) found in cold water fish, are known to 
infer substantial protection on these cold-dwelling organisms, where surrounding water 
temperatures are typically –2 ºC, and yet, the fish don’t freeze solid. AFGPs have been shown 
to prevent ice crystal growth, and whilst cytotoxic, mimics of AFGPs may have translational 
application in the cryopreservation of biological materials. 
This thesis reports on a series of proof-of-concept studies, intending to replicate the 
fundamental cryoprotective properties of AFGPs on simple synthetic constructs, so that they 
may be applied to cryopreservation. This study intends to further elucidate the precise 
engineering required to incorporate potent ice growth inhibitory properties into a synthetic 
architecture. By establishing fundamental design rules, a ‘blueprint’ maybe prepared for the 
future development of potent ice recrystallisation inhibitors, with applications in improving 
biological storage. Chapter 1 provides a comprehensive literature study of the pre-existing 
field, whilst Chapter 2 reports on the development of poly(proline) as a potential ice growth 
inhibitor, mirroring the same solution structure and amphipathic balance as AFGP as core 
design motifs. Chapter 3 outlines the synthesis of a photo-activatable ice growth inhibitors 
with potential applications in cryosurgery, representing a tuneable AFGP mimetic. Drawing 
further on the apparent design features and properties of AFGP, Chapter 4 details the de novo 
design of a library of facially amphipathic and rigid AFGP mimetics, which are capable of 
potently inhibiting ice crystal growth. Chapter 5 reports on the attempted development of a 
series of bile acid derivatives, featuring the core design motifs associated with AFGPs; domain 





The state of humanity’s technological and scientific abilities can be best observed at the very 
forefront of biomedicine. From the first antibiotics of the early 20th Century to the CART-T 
treatments of the 21st, progress across medical science has in recent years exponentially soared 
above and beyond the capabilities of our predecessors. For the first time, we look to a future 
where the treatment of cancers, HIV/AIDS, and Alzheimer’s may be routine. The effective 
application of stem cell therapies in particular, a biopharmaceutical market reputed to be worth 
$16bn US Dollars by 2025,1 would mark a paradigm shift in modern medicine, allowing for 
the effective treatment of a myriad of currently untreatable conditions through the 
bioengineering of one’s own immune system. Similarly, immunotherapies such as CAR-T are 
highly promising and have been shown to allow for the specific treatment of particular blood 
cancers by ‘hijacking’ the human immune system,2,3,4 with a patient response rate of ~ 80% 
and a ~ 60% remission rate (12 months) for juvenile B-cell acute lymphoblastic leukaemia.5 
However, all these treatments fundamentally require, on demand, a ready and effective supply 
of medically important cell types or biological proteins. 
This represents a significant logistical challenge. Given that many therapeutically important 
biological materials (cells, tissues, proteins etc.) have both poor stability and an intolerance 
towards extremes in temperature, how do you ensure a rapid and uncompromised supply of 
biomaterials when required? For the above treatments to be effective in the long-term, it is 
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essential we have a reliable process, giving us an effective methodology to get these species 
from ‘petri-dish to patient’, every time. 
The natural assumption would be to freeze biological material in order to extend its shelf life. 
But whilst you can guard against exposure to heat (and its associated damage), freezing brings 
with it its own set of problems. Primarily, how do you ensure stability and viability of cell and 
tissue-based materials after being stored at low temperature? 
The ‘Raspberry Problem’ is a prime example of this. If you freeze a raspberry, and thaw it, you 
lose the texture and the structural integrity. You get mush – Figure 1.1. The same is true of 
carrots, freeze then thaw a carrot, and you end up with a sodden, wringable sponge. 
 
Figure 1.1 – Effect of the freeze/thaw process on biological material. 
How do we prevent this same level of damage to a cell line? Or a blood bag? 
Interestingly, many organisms (particularly extremophiles) are known to tolerate (and often 
thrive in) extremely cold temperatures. The atlantic cod survives in waters ~ 1.5 degrees 
Celsius below freezing, without freezing solid.6,7 Likewise, tardigrades have been jettisoned 
into the cold vacuum of space, only to be recaptured and thawed, and found to still exhibit 
normal growth and signs of life.8 Some insects have also been shown to have particular cold-
tolerance, whilst certain classes of amphibians and reptiles have been found to have evolved to 
contain high levels of carbohydrates in their blood and tissues, allowing them to effectively 
‘solidify’ without internal ice crystal formation, weathering their freezing winter environments 
Freeze Thaw
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before thawing back to life in the spring.9,10 In addition, numerous plants and shrubs have also 
been identified as possessing a disposition for severe climates.11,12 
In order to begin to address the problems associated with ensuring effective cryoprotection 
during freezing, an understanding of these unusual effects in the natural world would seemingly 
be advantageous. 
Once understood, we can then begin to ask the question – can we engineer our biological 
materials to withstand the harsh conditions of freezing?   
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1.1 – Antifreeze glycoproteins 
Scholander and co-workers’ first noted in 1957 the apparent ability of various arctic fish to 
thrive and survive in supercooled waters which were at least 0.7º C cooler than the freezing 
point of their blood serum (-0.9 to -1.0 ºC), without the fish freezing solid. This observation of 
an apparent freezing point depression – a thermal hysteresis effect – was claimed to be 
indicative of an inherent bloodborne ‘antifreeze’ quality, suggesting isotonicity with seawater 
and allowing the fish to survive in the ‘Thermal Hysteresis (TH) Gap’. Figure 1.2.13,7 
 
Figure 1.2 – Thermal Hysteresis effect of AF(G)Ps on ice crystal growth; In the presence of AFGP, the 
growth of the ice crystal is prevented (post nucleation) within the TH Gap due to inhibition of the primary 
prismatic plane by AFGP, with growth occuring only below the supressesed freezing point. Normal ice 
crystals in the absence of AFGP grow freely in all dimensions giving hexagonal ice, below the freezing 
point (0 ºC). 
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DeVries and Wohlschlang later reported (1969) on the isolation of a carbohydrate containing 
polypeptide from the blood of Trematomus borchgrevinki and Dissostichus mawsoni, which 
accounted for 30% of this observed freezing point depression. This represented a substantial 
freezing point depression, given the mix of low molecular weight amino acids, sugars, and salts 
contributing the remainder.14 Importantly, whilst these glycosylated peptides are known to 
exhibit a maximum thermal hysteresis effect of 1.2 degrees at 40 mg.mL-1,15 they are found in 
the blood serum at concentrations as low as 5 mg.mL-1,16 at which they demonstrate a 
comparable freezing point suppression on a weight basis to sodium chloride. This ultimately 
represents a minimum x180 fold thermal hysteresis capacity relative to NaCl.17 Subsequent 
studies by DeVries further elucidated the primary structure of this class of proteins, establishing 
them as freeze depressing (glyco)proteins or “FDGPs”, and were found to contain threonine 
(16%), alanine (23%), D-galactose (28%), and N-acetyl-D-galactosamine (29%), and existing 
as a polydisperse mixture (2.6 – 33 kDa).15 They were further identified as featuring an Ala-
Ala-Thr (and rarely, a Pro/Arg-Ala-Thr) tri-mer repeat unit conjugated to an O-linked β-1,3-
disaccharide (Gal/GalNAc) motif (Figure 1.3) and as having high water solubility.17,18,19 
 
Figure 1.3 – AFGP repeat unit. 
However, these FDGPs were quickly determined to possess two other potent cryogenic 
properties. The first of which was their ability to dynamically shape ice into spicular-like 
needles as a result of ice face binding, and the second, ice recrystallisation inhibition – the 
ability to retard ice crystal growth (Ostwald Ripening). The evolution of their initial 
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characterisation resulted in FDGPs being instead regarded as antifreeze glycoproteins or 
“AFGPs”.15 
Further analysis in recent years has enhanced our understanding of AFGP structure and 
function, although much remains unknown. Many isoforms of AFGP exist, with AFGP-8 as 
the shortest naturally occurring AFGP fraction found in extremophile fish, consisting of 4 
repeat units and with a molecular weight of approximately Mw 2700 g/mol-1.20,21 The nature 
of AFGP’s ice binding mechanism is contested, with some studies indicating it binds 
reversibly,22 whilst others suggest irreversible binding occurs.23 However, some key pieces of 
structural information which may shed light on these questions have been acquired. Due to its 
high degree of flexibility and the numerous conformers which AFGP is thought to be able to 
adopt in solution, no X-Ray crystal structure presently exists.24 However, work by Matsumara 
and co-workers’ has shown that AFGPs adopt a facially amphipathic structure by solution 
phase NMR (Figure 1.4A) – with the hydrophilic glycosyl units spatially segregated from the 
hydrophobic peptide backbone.25 
 
Figure 1.4 – A) Hydrophilic/phobic separation of AFGP.24 B) Polyproline II Helix and Circular 
Dichroism analysis of AFGP.21 
In addition, circular dichroism (Figure 1.4B) analysis has further indicated that this segregated 
domain structure occurs along a polyproline type II helix,21 and also corroborates other NMR 
and simulation data which suggests that AFGP exists in solution as extended three-fold 
helices.24  
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1.2 – Antifreeze proteins 
Whereas AFGPs are found only in Antarctic notothenioids and northern cods, antifreeze 
proteins – unglycosylated antifreeze proteins (AFPs) with similarly potent ‘antifreeze’ 
properties – are more widely spread in nature. Like AFGPs, AFPs developed in isolated species 
through convergent evolution.26 However, whilst AFGPs exist as a highly conserved structure 
differing only by molecular weight and occasional amino acid substitution, AFPs possess 
substantially different structures and primary sequences depending upon their species of origin, 
and several ‘classes’ of AFPs exist. Table 1.1 and Figure 1.5.27 
Table 1.1 – AFP Summary * One example of a myriad of plant AFPs.24,28,29,30 
 Molecular Weight Structure Origin 
Type I AFP 3.3 – 4.5 kDa α-Helix, >70% Ala 
Right eyed 
flounders, sculpins 
Type II AFP 11 – 24 kDa 
Disulphide Bonded 
Globule 
Sea raven, herring, 
smelt 
Type III AFP 6.5 kDa β-Sandwich 
Eel/ocean pout, 
wolfish 
Type IV AFP 12.3 kDa Helical Bundle Longhorn sculpin 
Insect AFP 50.2 kDa β-Helical Bundle 
Darkling beetle, 
spruce budworm 
moth, midge, fly 
Plant AFP 27.6 kDa β-Helical Bundle Rye grass * 
 
Antifreeze proteins are by and large better characterised than their AFGP counterpart. They are 
known to irreversibly bind to ice, and many X-Ray crystal structures exist, Figure 1.5. Similar 
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to AFGP, AFPs have been found to be intrinsically amphipathic with defined regions of 
hydrophobicity,27 and exist as alpha helixes, beta-sheets, globules, and helical bundles. 
Unusually, many AFPs (such as Type I) contain high proportions of alanine in their structure, 
and yet are wholly water soluble.30 Some AFPs – particularly plant AFPs, such as those 
extracted from the leaves of Ammopiptanthus mongolicus or the shoots of hippophae 
rhamnoides – are glycosylated,29,30 but represent a fundamentally different class of species and 
are not synonymous with AFGPs. 
 
Figure 1.5 – Crystal Structures of A) AFP Type I – WFB1. B) AFP Type II – 2PY2. C) AFP Type III – 
1HG7. D) Spruce budworm AFP – 1M8N. E) Perennial rye grass AFP – 3ULT.31–35 
 
Whilst the thermal hysteresis effect is generally stronger for AFPs than AFGPs, this is further 
pronounced in the case of “Hyperactive AFPs” which have been reported in both cryophilic 
insects and bacteria. These species show substantially enhanced thermal hysteresis capacity 
relative to other AFPs, potentially due to basal face binding.27 
  
A                          B                                   C 
D                                 E 
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1.3 – Mechanisms of action 
The mechanism by which AF(G)Ps prevent ice crystal formation and growth, preventing ice 
induced cryoinjury, is fundamentally unknown. However numerous studies and hypotheses 
have been proposed in recent years. 
Three properties are exhibited by AF(G)Ps: 
I) Dynamic Ice Shaping (DIS) 
II) Thermal Hysteresis (TH) 
III) Ice Recrystallisation Inhibition (IRI) 
Dynamic Ice Shaping 
DIS is the most understood property of AF(G)Ps. It is thought that AF(G)Ps bind to specific 
planes of ice – usually the primary prismatic plane – preventing the addition of further water 
molecules to the ice crystal face, and so inhibiting the growth of the crystal along the bound 
axis. Figure 1.6.36 
 
Figure 1.6 – AFGP primsatic face binding, leading to dynamic ice shaping / growth along the 
unbound axis. 
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Growth along the unbound axis results in the formation of long, spicular needles, which are 
able to cause catastrophic damage to biological matter on a cellular level – bursting and 
popping cells through effective ‘puncturing’.37 Dynamic ice shaping will however only occur 
below the TH Gap during ice crystal growth, and so this property is not detrimental to the 
marine life which utilise AFGPs for survival.36,38 
Thermal Hysteresis 
A non-colligative freezing point depression effect, thermal hysteresis (TH) acts to lower the 
freezing point of a solution whilst leaving the melting point fixed into place.39 The addition of 
a solute (such as sodium chloride to water) will generally result in a colligative depression of 
the freezing and melting point of a solution – in the case of water, from 0 ºC to -6 ºC at 10% 
w/v NaCl.40 This is proportionate to concentration and in-accordance with Gibbs’ law of free 
energy.39 
(Tm = Tf)Solution >  (Tm = Tf)Solution+Solute. 
Equation 1.1 – Thermal Hysteresis Gap. 
 
However, the TH phenomenon results in the suppression of the freezing point of the solute 
containing solution further: Tm > Tf, – resulting in a ‘TH Gap’ between melting and freezing 
points, Figures 1.2 and 1.7.39 
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Figure 1.7 – Thermal Hysteresis effect of multiple AFGP molecular weight fractions. Adapted from 39. 
 
Whilst the precise mechanism is unknown, and has been speculated on, TH is thought to occur 
through the binding of AF(G)P to the face of a seeded ice crystal which has spontaneously 
formed in supercooled solution, and then prevents it from expanding (or melting) within the 
TH Gap, with growth only occurring when the temperature drops below it. It is hypothesised 
that antifreeze proteins are capable of equilibrating vapour pressure at the concentrations within 
the TH range, so that ‘molecular escape’ is zero and the net on/off rate of water molecules to 
the ice crystal is equal. Crystal surfaces which are not bound to an AF(G)P however will exhibit 
‘budding’ and slight growth along unhindered/uninhibited axis, a precursor to DIS. The TH 
effect is concentration dependent, with the greatest TH effect observed at higher 
concentrations.39 Whilst some extremophile insect and plant AFPs are known to be 
‘hyperactive’ – and able to supress freezing point to -30C – TH is problematic in the context 
of cryopreservation. Recent attempts to utilise the AFP MpdAFP to preserve horse sperm 























Ice Recrystallisation Inhibition 
Ice recrystallisation inhibition (IRI) is the observed effect by which the growth of ice crystals 
is impacted, slowed, or halted when solution freezing occurs in the presence of an AF(G)P or 
other synthetic mimic.42 This is in comparison to an unadulterated solution, which will by 
comparison yield substantially and significantly larger crystals. Figure 1.8. 
 
Figure 1.8 – ‘Splat’ Assay of AFGP in PBS (Left) and of PBS Alone (Right). 
This phenomenon is a particular problem in the storage of biological samples (blood, tissues, 
cells of all types, organs etc.)43 as Ostwald Ripening dictates that larger crystals will grow at 
the expense of smaller ones, especially during thawing.44 As a result, large crystals are able to 
cause catastrophic ice induced cellular damage – squeezing and rupturing cells from the 
outside.36,38,43 The smaller that ice crystals are allowed to grow, the less damage can result – 
which is of particular concern during thawing. A recent study by Gibson and co-workers’ 
confirmed that cell recovery is directly linked to the restriction of ice crystal growth.43 
The mechanism by which ice recrystallisation inhibition operates is unclear. Several competing 
arguments exist, and it is possible that different solutes function and infer IRI through different 
processes. It may even be the case that there is no ‘one’ unified or common mechanism of IRI. 
AF(G)Ps are all however thought to function through an adsorption-inhibition mechanism. 
Jia and co-workers’ have reported that many AFPs feature an “Ice Binding Site” (IBS) which 
is flat, rigid, and amphipathic, but with predominantly hydrophobic character.45,46 An 
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established and accepted theory was subsequently postulated by Davies and co-workers’, 
detailing how the IBS of a bacterial AFP (MpAFP – 1.5 MDa) derived from Marinomonas 
primoryensis and displaying Ca2+ dependent hyperactivity, does not itself bind to ice, but 
instead orders local waters along the IBS which are a good 3D conformational match for the 
primary prismatic plane of ice.47 These ordered waters then bind to the ice crystal face, co-
ordinated in to place by the AFP to which they are hydrogen bonded, blocking bulk water 
addition and preventing crystal growth. Figure 1.9. 
 
Figure 1.9 – AFP Clathrate water ordering postulated by Davies and co-workers’ 47 on surface of 
MpAFP. Figure Adapted. 
Recent fluorescence/microfluidic studies have further indicated that this binding is irreversible 
in the case of AFPs.48–50,51 Conversely, similar studies have indicated that some AFP binding 
is seemingly reversible,52,53 whilst others have assumed reversibility of binding as a 
prerequisite for AFP function.54,55 The phenomena is therefore not very well understood. 
On the other hand, poly(vinyl) alcohol (PVA) has long been recognised as a potent IRI species 
and represents the most active synthetic mimetic of AF(G)P discovered to date. Koop and co-
workers’ – along with Molinero and co-workers’ – have postulated that PVA binds to the ice 





3D match to ice crystal faces
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operates in a ‘zipper-mechanism’ like fashion. The precise spacing between PVA’s alternating 
hydroxyl groups of 2.92Å and 7.46Å between every 2 groups, in addition to PVA’s intrinsic 
flexibility, is believed to allow the polymer chain to ‘explore’ the ice crystal face, binding 
through every other 2 hydroxyl groups in a ‘2-on-1-off’ approach. This is a good 
conformational match to the water molecules in the primary prismatic plane of ice at distances 
of 2.76Å and 7.35Å respectively. This site occupation again physically blocks-off the ice 
crystal from water addition, preventing growth, Figure 1.10.44,56 
 
Figure 1.10 – Hydrogen bonding model postulated by Molinero and co-workers’ 50 depicting the 
exploration by a single chain of PVA of the {101̅0} ice crystal face (primary prismatic plane). 
The mechanism of AFGP’s IRI activity is poorly understood and contested,57 but is believed 
to be very different to that of AFP – described previously. A recent computational study by 
Molinero and co-workers’ has suggested that the domain segregation AFGP is critical to IRI 
activity. It was hypothesised that the hydrophilic glycosyl units of the protein chain extend out 
into the non-frozen aqueous solution immediately surrounding the ice crystal and disrupt water 
ordering. Meanwhile, the hydrophobic units reversibly bind to the ice crystal face.22 Given that 
the surface of ice has appreciable hydrophobic character (and has a reported water contact angle 
of 12 degrees)58, the authors reported that the fatty methyl groups of the amino acids (Ala and 
Thr) in the backbone of the protein chain bind and ‘rest’ in the defects of the hydrophobic 
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crystal surface. The equilibrial occupation of these cracks, nooks, and cavities by AFGP then 
prevents crystal expansion. Figure 1.11. 
 
Figure 1.11 – Reversible AFGP face binding model postulated by Molinero and co-workers’.22 
However, alternative theories have also been proposed. A further recent study by Drori and co-
workers’ has indicated that AFGPs in fact function through irreversible ice face binding, 
suggesting that their primary mechanism of action is via an adsorption-inhibition process, 
validating this hypothesis through microfluidic/AFGP fluorescence tagging experiments.23 
These studies corroborate the work of DeVries and co-workers’, who has published extensively 
on the binding of glycans to ice.59–61 
A recent model has also evolved in an effort to explain the ice recrystallisation inhibitory effect 
of synthetic mimics which display IRI properties in the absence of TH or DIS. It has been 
hypothesised that the presence of some AFGP mimetic solutes can disrupt bulk water ordering 
in the surrounding unfrozen solution.62–64 This therefore energetically inhibits water transfer 
across a disordered water layer – an interstitial phase (~ 10Å thick) of neither frozen nor liquid 
water between the bulk water and an ice crystal face.65 Whilst the mechanism has not been 
elucidated,39,66 it is thought that this effect ultimately prevents/disrupts water molecule addition 





Figure 1.12 – Disordered Water Layer Hypothesis.  
Ice Crystal  Interface   Bulk H2O   Interface Ice Crystal
IRI Active Solutes
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1.4 – Applications of AF(G)Ps 
Tissue engineering, gene therapy, drug screening and emerging regenerative medicine 
therapies are fundamentally reliant on high-quality cell culture,67 but current methods to 
cryopreserve cells typically result in extensive cell death, giving low yields and recoveries, 
especially in the case of adherent cell culture.68,69 A similar problem is encountered with blood 
stocks and blood products, which are well known to suffer from a short shelf life. In conjunction 
with a shortage of donors, supplies are often stretched in some geographical areas, whilst 
discarded unused in others.70 These issues are particularly pronounced when ensuring sufficient 
blood supplies of rare or essential blood groups, such as O Negative (the Universal Donor). 
The biobanking and storage of stem cells – which themselves represent a paradigm shift in 
biomedicine – and tissues is also a key problem, with low viabilities and recoveries again 
observed.71 
A contributor to cell death during cryopreservation is ice recrystallisation. Ice recrystallisation 
occurs as a result of extracellular ice crystal formation (i.e. ice formation outside the cell) 
during freezing, which leads to mechanical damage and lysis as a result of repeat freeze-thaw 
cycles; where larger ice crystals grow at the expense of smaller ones through slow 
recrystallisation. This effect cannot be circumvented by rapid thawing, which is often difficult 
to achieve homogeneously. 
However damage can also occurring during freezing and so the rate of freezing is significant. 
Very slow freezing results in the formation of extracellular ice, which no longer being liquid 
water, results in the flow of water out of the cell across the osmotic gradient to redress the 
equilibrium. As a result, the cell slowly dehydrates and dies. On the other hand, fast freezing 
at below -40 ºC hastens the formation of intracellular ice crystals, which can lead to cell lysis 
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by the expansion of trapped intracellular water and further cause catastrophic damage on 
thawing due to Ostwald Ripening.72 
As such, an intermediate freezing rate is optimum, but extracellular ice crystal formation 
remains a problem – especially during thawing. Existing strategies to circumvent the damage 
induced by ice recrystallisation during the cryopreservation of cell and tissue biomaterials often 
involve the infusion of unsustainably large quantities of (typically cytotoxic) organic solvents 
such as DMSO, or alternatively, glycerol.73 
Whilst IRI inactive – these penetrating cellular cryoprotectants act to prevent ice crystal growth 
in a colligative manner by freezing point suppression, and further modulate the 
concentration/increase in intracellular solutes during freezing.74–76 
However, these techniques are non-ideal, and in the case of DMSO, often results in as little as 
5% cellular recovery post-thaw in the case of adhered embryonic stem cells.68,69 Furthermore, 
recent studies have indicated that despite common perception, DMSO’s cytotoxicity profile 77 
is a cause for concern and can lead to phenotypic changes and mutations in cell lines 78,79 – a 
fundamental problem in biomedicine where identical cell lines are required. 
Clearly, engineering medically important cell and tissue types towards cold tolerance is key to 
pioneering new treatments and enhancing cellular storage, and by the elucidation of the 
mechanism of cold-tolerance exhibited by extremophile organisms, we may be able to 
incorporate freeze-tolerance properties, enhancing and facilitating cryopreservative 
techniques. 
As such, additives which can inhibit recrystallisation have the potential to redefine cell storage 
and hence biomedicine, and antifreeze (glyco)proteins would seemingly have application 
herein. The total synthesis of AFGP and some modified derivatives has been reported several 
times – notably by Payne and co-workers’ and Nishimura and co-workers’80–82,83 Aside from 
19 
their suspected immunogenicity, the dynamic ice shaping effect of AFGPs in particular would 
pose a problem in cellular cryostorage.84 As most biological samples are stored at -20, -80, or 
more commonly at -196 ºC – significantly below the TH gap – ice crystal growth (while IRI 
inhibited) would still result in the formation of spicular/needle like crystals, which are able to 
cause catastrophic mechanical damage and pierce cell membranes. 
It is therefore clear that research towards a synthetic AF(G)P mimetic, which is capable of 
preventing ice induced damage above-and-without the use of organic solvents, would have 
clear application in biomedicine and cryostorage – and numerous studies have been reported 
in recent years.  
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1.5 – Synthetic AF(G)P Mimetics 
Early attempts at preparing and identifying synthetic AF(G)P mimics were often unsystematic 
and disconnected, with individual studies investigating Thermal Hysteresis or Ice 
Recrystallisation Inhibition alone. Knight and co-workers’ first identified the potential of 
synthetic polymers to act as potent ice recrystallisation inhibitors, emerging as a new paradigm 
for controlling ice crystal growth.85 
Knight further developed the ‘Splat’ assay – a method of determining IRI activity by dropping 
a 10 µL sample (dissolved in PBS buffer – pH 7.4) onto a chilled glass coverslip. Upon hitting 
the coverslip, a frozen wafer forms instantaneously, the glass coverslip is then transferred to a 
cryostage and held at -6 to -8 ºC. Photographs are then obtained after a discreet interval and 
compared to a PBS negative control, allowing the size difference to be assessed and the IRI 
potency of the sample to be determined. The appropriate method for the reporting of data has 
become an arguable issue in recent years – initial experiments such as those performed by 
Knight (and perturbated in some recent studies) often presented micrographs of the ice crystal 
wafers in lieu of any mathematical or statistical analysis, and so acting as a simple visual 
comparison. More often, IRI activity has since been expressed as Mean Largest Grain Size 
(MLGS) – where the length of the ‘n’ largest crystals in the field of view are measured over 
three replicates and the average taken and given as a % relative to PBS. Similarly, Mean Grain 
Area or Size (MGA / MGS) has also been used, and has established its self as the predominant 
metric in recent literature. This measurement counts the number of crystals in the field of view, 
over three replicates, and is again expressed as a % of PBS. It is arguable that MLGS may 
represent a more appropriate figure, given that it would be the largest crystals that would induce 
the most damage upon biological material. However, it does not take into account that the 
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largest crystals in the sample may not be representative of the remaining field (where many 
small crystals may exist) – and so MGS is considered a better approximation. 
In 1995, Knight first reported on the activities of poly(vinyl alcohol) (PVA) and 
poly(hydroxyproline), both demonstrating significant potency at 1 mg.mL-1. On the other hand, 
a series of poly(histidine), poly(aspartic acid), poly(asparagine), poly(acryl acid), and 
poly(vinylpyrrolidone) all displayed weak-to-no activity.85 These observations contributed to 
a long standing school of thought which suggested that hydroxyl group presence was ultimately 
required to incorporate IRI potency into synthetic architectures. 
Poly(vinyl alcohol) is of particular interest and is the most studied (and potent) synthetic 
AF(G)P mimetic reported/identified to date. PVA is able to inhibit ice crystal growth to 10% 
of its original size (MLGS) at less than 0.1 mg.mL—1, Figure 1.13,86 and is notable for its ability 
to enhance the cryopreservation of cells in suspension.86 Uniquely, PVA is IRI active over a 
large molecular weight range, and has recently been found by Gibson and co-workers’ to 
‘become’ IRI active at DP 14.87 
 
Figure 1.13 – IRI potency of poly(vinyl alcohol).86 
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However, in spite of PVAs IRI potency and biocompatibility/non-toxicity,88,89 it’s activity 
cannot be fine-tuned/optimised. It has been shown to dramatically lose activity when subjected 
to even slight structural modifications,86,90 and consequently we do not know how it works. 
PVA may therefore not be applicable as a ‘universal’ ice recrystallisation inhibitor. 
Ben and co-workers’ first reported in 1999 on the development of a synthetic protocol for the 
preparation of a C-linked AFGP mimetic species, to act as probes in AFGP mechanistic studies. 
Figure 1.14.91 
 
Figure 1.14 – Ben and co-workers’ first generation C-linked AFGP mimetic probe.91 
This low molecular weight, simplified species, featuring a monosaccharide motif attached to a 
lysine-glycine tri-repeat unit, eventually led to Ben’s 2005 development of a series of 
galactosyl serine AFGP analogues (Figure 1.15),92 following several precursor studies.93–95 
 
Figure 1.15 – Ben and co-workers’ second generation C-linked AFGP mimetic probe.92 
This study of the structure-activity relationship indicated the superior activity of the candidate 
where the number of carbon atom spacers between the sugar and peptide backbones was n=1. 
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Amazingly, this candidate was able to inhibit ice crystal growth to approximately 16% of their 
original size (MLGS) at 8.36 mg.mL-1, relative to 14% of AFGP-8 at 14.3 mg.mL-1, 
representing a new dimension of synthetic IRI potency. On the other hand, the longer side chain 
derivatives of n=2 and 3 rapidly lost activity – indicating that IRI activity is a highly tuned, 
sensitive property, and clearly intolerant to minor structural modification (as is also observed 
with PVA). 
Similarly, Ben further reported that substitution of the galactose motif for other sugar residues 
impacted upon IRI potency.64 A galactose derivative of the first generation probe – featuring 
an additional repeat unit to give a tetramer and one fewer carbon in the linker – had statistically 
similar activity at 27% MLGS at mg.mL-1. A glucose derivative, however, exhibited just ~ 80% 
MLGS whilst substitution with mannose or talose reduced activity to effectively zero.  Given 
that these derivatives are epimers and differ only by the stereochemical orientation of the 
hydroxyl group at the sugar C-4, Ben further speculated that molar hydration capacity 
influences IRI activity. Figure 1.16. 
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Figure 1.16 – IRI activity correlated to hydration potential of carbohydrates. Reproduced from Ben 
and co-workers’.96,97 
This clear trend in IRI potency dependent upon the extent of sugar hydration would seemingly 
lend credence to the disordered water layer hypothesis – suggesting (as the authors claim) that 
the individual glycosyl’s affinity towards and differing interactions with the hydrogen bonded 
network of supercooled water at the bulk/disordered water interface directly impacts upon the 
energetic transfer of water to the ice crystal face. Galactose clearly has a greater proclivity 
towards hydration, and therefore has a greater disruptive force on local hydrogen bonding, 
disrupting water transfer and imparting IRI activity.62,64 This fundamentally disagrees with the 
mantra that ‘hydroxyl groups = IRI activity’. 
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In addition, this observation would seemingly indicate the preference/selection for galactose 
and N-acetyl-galactosamine over other carbohydrate units in the natural product. 
Further assessment of the primary candidate through in vitro cell assays indicated that whilst 
AFGP-8 exhibited intrinsic cytotoxicity to human liver (WRL 68) and kidney cells (HEK 293) 
– hypothesised to be as a result of rapid endocytosis promoting 3/7-capase activity – the 
synthetic analogue did not induce cell death and apoptosis. This was attributed to the ability of 
the mimic to on the other hand supress the 3/7-capase pathway when taken into the cell. 
Crucially, and unlike AFGP, the mimic exhibited no detrimental effect on cell viabilities after 
incubation (37 ºC) for 20 hrs at 5 mg.mL-1.98 
Interestingly, the first generation probe devised by Ben did not have any thermal hysteresis 
activity, despite being highly IRI active. Nishimura and co-workers’ first reported the ability 
to separate out two of the three key effects of AF(G)Ps into discreet qualities, showing that it 
was possible to have a TH effect in the absence of DIS.99 This is ultimately important, as this 
allows for the rational design of potent IRI inhibitors with the detrimental properties dispensed 
with. 
Further studies by Ben and co-workers’ have covered the synthesis of a sequentially modified 
derivative of the second generation probe, featuring a triazole linker in place of the C-linked 
amide, and was found to possess poor activity. This study again reinforces the structural 
sensitivity of AF(G)P mimetics, ultimately indicating the necessity of the amide unit.100 
Specifically, this may indicate that the comparatively increased structural rigidity of the triazole 
has impacted upon solution confirmation, affecting the ability of the candidate to disrupt water 
ordering. 
Numerous studies investigating the preparation of AF(G)P mimetics with IRI potency have 
continued to focus on the development of polymers. This is however a non-trivial task and is 
26 
highly challenging, as it is often necessary to precisely engineer structures given that many 
polymers (such as PEG) show no IRI activity whatsoever, and minor modifications of potent 
species generally lead to a loss of activity. Whilst the design rules are unclear, it has been 
hypothesised that – due to the hydrophobic nature of ice – that the presence of hydrophobic 
groups in synthetic mimics is essential for IRI. 
Cameron and co-workers’ reported on the IRI inactivity of a series of glycopolymers and 
polypeptides derived through RAFT polymerisation and the ring opening of N-
carboxyanhydrides. The polypeptides – including poly(lysine) and poly(glutamic acid) – did 
not show any meaningful activity.101 However (and unusually) the range of flexible 
glycopolymers assayed showed next-to-no IRI activity at all molecular weights, despite the 
chain possessing carbohydrate motifs and a simplified polymer backbone, representative of 
AFGP. Figure 1.17. 
 
Figure 1.17 – Flexible glycopolymers prepared by Cameron and co-workers’.101  
This disparity of non-hydroxylic polyampholytes showing potency, whereas hydroxylic 
glycopolymers are wholly inactive, has begun to suggest that the presence of hydroxyl groups 
in IRI inhibitors are not actually responsible for the incorporation of IRI activity. In association 
with this, Gibson and co-workers’ have assayed a large range of small molecule mono, di, and 
polysaccharides, with none displaying any significant IRI properties at elevated 
concentration.102 Ben and co-workers’ have also assayed a number of synthetic mono and 
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disaccharides, again, observing little-to-no activity.103 Given that Safranine O – a non-
hydroxylic synthetic dyestuff – has been reported by Drori and co-workers’ to be a potent ice 
recrystallisation inhibitor, this would indicate that hydroxyl groups in-and-of themselves are 
not essential for IRI.104 Safranine O is believed to self-assemble in solution, forming an 
amphipathic, supramolecular structure, with defined regions of hydrophobicity and 
hydrophilicity – akin to AFGP. Figure 1.18. 
 
Figure 1.18 – Self-assembly of Safranine O, a potent IRI. Adapted from Drori and coworkers’.104 
Likewise, a similar species – zirconium acetate – has been shown to adopt an amphipathic and 
polymer-like supramolecular architecture in solution, again showing particular potency.105 
Unusually – Nisin A – a naturally occurring protein which is added to milk products as a 
preservative, has also been shown to be IRI active at low pH (~ 5) only (where it adopts an 
amphipathic structure in acetate buffer).106  
Other small molecules have also shown unprecedented levels of activity. A water soluble 
synthetic metallorganic framework or ‘metallohelix’ reported by Scott and Gibson and co-
workers’, featuring an Fe2+ centre in the core of a stereochemical pure helix, has supressed ice 
crystal growth to approx. 15% MLGS at ~ 32 mg.mL-1. Intriguingly, modelling of the surface 




Figure 1.19 – Enantiomerically pure metallohelix reported by Gibson and Scott and co-workers’ 
featuring an amphipathic surface.107 
These combined studies begin to suggest that amphipathy maybe a core design motif, as 
opposed to hydroxyl group presentation. Specifically, this asks a greater mechanistic question 
too, as to whether ice face binding is actually required for ‘isolated’ IRI activity (in the absence 
of TH or DIS effects) or whether simple disruption of the supercooled water at the 
bulk/disordered water interface by an amphipath is sufficient to impart inhibition. Gibson 
previously surmised that long-range order was deemed to be inessential for IRI activity, whilst 
necessary for thermal hysteresis effects.108 In terms of a mechanistic mode of action, disruption 
to give a bulk/disordered water interface would not require long range order, only efficient & 
effective local disruption to impart a long range effect.109 
Ben and co-workers’ have also reported on the development of small molecule mimetics of 
AF(G)P. Whilst it has been demonstrated that monosaccharides lack IRI potency, Ben has 
recently shown how a series of modified glycosides are however able to potently inhibit ice 




Figure 1.20 – Small molecule library of IRI active AFGP mimetics designed by Ben and co-
workers’.110-113 
Unexpectedly, an octyl galactose derivative (Figure 1.20A) is capable of potent inhibition of 
the order of < 10% MGA at 12.86 mg.mL-1, signifying the importance of hydrophobic domain 
incorporation.110 Unusually, aryl functionalisation of the galactose motif in place of the octyl 
chain (Figure 1.20F) inferred greater activity upon the unit. This is potentially due to the 
aromatic ring acting as a ‘tighter’ and more defined hydrophobic unit (with less intrinsic 
flexibility, and with fewer solution conformations available to it). Exceptional activity was 
however only present when the ring was halogenated in the para position with specifically 
bromine (5% MGA at 7.4 mg.mL-1) and chlorine (20% MGA at 6.4 mg.mL-1), with other 
derivatives displaying moderate-to-little activity.111 Curiously, a glucose equivalent (Figures 
1.20D and E) showed stronger activity with fluorine or methoxy in the same position (20% 
MGA in both instances versus 80% for Gal), in addition to bromine and chlorine (with very 
slight reductions in activity observed).111,112 This is highly unusual, given Ben’s earlier report 
that glucose derived species had no activity and were hypothesised to be IRI inactive due to 
weak hydration effects. The brominated glucose derivative was further found to be a highly 
effective cryoprotectant in red blood cell cryopreservation, with significant protective capacity 
above and beyond the rest of the series. A 15% glycerol solution (acting as a conventional 
cryoprotective mix, but lower than the industrially ‘standard’ 40%), supplemented with 30 mM 
A                                      B                                       C
D                                      E                                       F
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(10 mg.mL-1) of this agent increased RBC integrity post-thaw by 40% and 20% (relative to no 
adulteration) for slow and fast freezing protocols, respectively. The equivalent bromo-
galactose derivative exhibited comparable effects at 30 mM (fast freezing) and 55 mM (slow 
freezing).111 The ability to lower the requisite concentration of glycerol is undoubtedly 
beneficial, reducing the complexity of protracted glycerol removal procedures. 
The rationale for the substantially different activity profiles of this series is unclear. The authors 
note that electronic effects of the ring substituents seemingly have no correlation in terms of 
IRI activity, whilst the introduction of alpha-linkages (in place of beta) cause a substantive loss 
in potency. In the case of the glucose anisole derivative (representing the most potent IRI of 
this class), it was clear that the ‘methoxy’ group in particular was essential for activity, with 
substitution for a hydroxyl or methyl group leading to an immediate loss of activity. Likewise, 
other structural substitutions (such as for bromine) yielded a weaker IRI candidate. Further 
studies on synthetic disaccharides in this report again show the sensitivity and significance of 
the carbohydrate hydroxyl groups and epimeric confirmations upon IRI.111 Collectively, these 
observations indicate that the ability to disrupt the ordering of water by small molecules is 
ultimately dependent upon very specific structural properties, conformations, and overall net 
polarity – with minor changes vastly impacting IRI ability. 
Aldonamide species derived from sorbitol have also shown hyper potency, with a similar octyl 
functionalised derivative inhibiting ice growth to ~10% MGA at 0.15 mg.mL-1 (Figure 1.20B). 
Whilst no hydration parameters are available, this derivative is however known for its ability 
form micelles and increasing the solution concentration eventually led to the neutralisation of 
activity (> 10 mM).110 This may be ultimately problematic in cryopreservative applications, 
where higher concentrations (above and beyond the candidates IRI potency range) maybe 
required. However, this observation has shown that micelle formation is not a structural factor 
in IRI activity. Interestingly, the amide group was found to be critical for IRI (as observed in 
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Ben’s previous work where the amide was substituted for a triazole), with removal and 
substitution causing an unrecoverable loss of activity.110 Functionalisation of this aldonamide 
with an aryl group in place of the octyl unit (Figure 1.20C), specifically either 2-F, 4-OMe, or 
2,6-difluoro, displayed comparable IRI activity, but at elevated concentration (6.4 – 6.8 
mg.mL-1).113 This is unusual, as other permutations of this structure (such as 2-Cl or 4-F), failed 
to infer any IRI properties. However, this study further confirmed that hydrogelation of these 
candidates had no bearing on IRI activity. Furthermore, when employed as a cellular 
cryoprotectant, the 2-F derivative at 1.45 mg.mL-1 enhanced the total number of 
UCB/Progenitor CD34+ cell colonies post-thaw, up by approximately 10% - further showing 
that an IRI active compound has cryoprotective ability.113 
As further discussed vide infra (Chapter 3), Ben and co-workers’ have further detailed the 
development of ‘photoswitchable’ carbohydrate derived surfactants, which by virtue of an azo-
benzene linker, are able to weakly modulate IRI activity upon irradiation.114,115 Other stimuli-
response IRI active species have also been reported, with Gibson and co-workers’ detailing the 
development of a catechol-PVA system, which ‘engaged’ IRI activity in the presence of Fe3+ 
cations via aggregation, resulting in an increase in PVA molecular weight.116 
Gibson and co-workers’ have reported on the development of polyampholytes for IRI,117 
recently detailing the development of a zwitterionic alternating polymer which increased red 
blood cell recovery by around 40% post-thaw (with 100% cell viability up to 60 mg.mL-1).118 
Another recent polymer study by Gibson and co-workers’ detailed the preparation of a panel 
of polyampholytes prepared via isopropyl acetate/maleic anhydride RAFT polymerisation – 
giving an expanded series of candidates at a range of molecular weights. Figure 1.21. One 
particular candidate, featuring an N,N-dimethylethylamine motif was found to possess superior 
activity (16% MGA or 55% MLGS) over the rest of the range at 20 mg.mL-1 and DP 92. The 
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remaining candidates possessed comparable activity in the ~ 50% MGA range at the same 
concentration.119 
 
Figure 1.21 – Ampholyte polymer series prepared by Gibson and co-workers’.119 
This data supports the concept that precise engineering of the hydrophilic/hydrophobic balance 
is essential for IRI, and that whilst itself essential, over-introducing ‘hydrophobicity’ does not 
necessarily infer greater activity. Similarly, this study also serves to demonstrate the perils of 
minor structural modification upon activity. As the prepared candidates did not feature any 
obvious ice binding motif or engineered ice binding face (and so have no inherent 3D ‘match’ 
for an ice crystal plane),119 they potentially lend support to the hypothesised disordered water 
layer mechanism of inhibition. 
Matsumura et al. have developed several libraries of polyampholytes which have shown 
cryoprotective qualities despite having only moderate IRI activity.120 Two particular 
copolymeric species were able to inhibit crystal growth to around 5 – 10% MGA but only at 
very high concentration (100 mg.mL-1).121 A similar species lacking a third ‘bloc’ inhibited 
growth to 48% MGA.120 This again effectively demonstrates the importance of precise 
engineering, and further shows that the introduction of a more pronounced hydrophobe (octyl 
vs methyl) does not enhance activity. Figure 1.22. 
33 
 
Figure 1.22 – Amphipathic polymer series prepared by Matsumura and co-workers’.120 
These species effectively enhanced the cryopreservation of L929 cells, demonstrating (on 
average) > 50% cell viability with a polymer loading of 7.5%.121 However, 100 mg.mL-1 is a 
prohibitively concentrated solution, and a cryoprotectant requiring such a large infusion would 
not normally be applicable for biomedical translation, equating to 10% w/v of the total volume. 
It does however show remarkable inhibitory properties, as colligative effects alone would not 
account for this extent of potency at this concentration. 
Other species have also been shown to possess significant IRI potency. Wang et al. have 
demonstrated the significant IRI and cryoprotective activity of graphene oxide (GO), reducing 
ice crystal growth to around 20% MLGS at 5 mg.mL-1.41 The authors hypothesise that GO 
possesses such IRI potency due to the preference for the hydroxy groups on the GO basal plane 
to form hydrogen bonds with the ice crystal face over surrounding water, facilitated by the 
graphitic ‘honeycomb’ lattice. This preferred adsorption leads to a curved ice crystal surface, 
lowering the freezing point. The authors further demonstrate graphene oxide’s application in 
the cryopreservation of horse sperm, increasing spermatozoa motility by nearly 50% in the 
presence of 0.01 wt % of graphene oxide, post-thaw. 
Of the many IRI active species detailed herein, a major setback is that many are not necessarily 
biocompatible, biodegradable, nor bioresorbable and have not been applied to the significant 
challenge of cell monolayer storage. As per Figure 1.23, it is further apparent that – whilst a 
wide range of IRI active compounds exist – they all possess wildly different activities and have 
34 
disparate structures and functional properties. Furthermore, many may not be applicable to 
biomedical translation due to their intolerance to functional modification. Given the disparity 
between IRI active structures, it is entirely possible that there are multiple distinct mechanisms 
responsible for IRI activity. As such, it is necessary to probe the boundaries of the IRI structure-
activity relationship, so that a blue-print for the rational design of better mimics maybe 
developed, which have real translatable application in biomedicine. 
 





C-Linked     
Glycopeptides
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1.6 – Protein Mimics in Biomedicine 
Numerous examples exist in the biochemical and pharmaceutical sciences of ‘synthetically 
engineered’ species capable of mimicking the effect and action of naturally occurring proteins 
and peptides.122,123,124,125 
In particular, Tew and co-workers’ have done extensive work on the development of 
antimicrobial polymers known as “SMAMPs” (Synthetic Mimics of Antimicrobial Peptides), 
which mimic the naturally occurring Antimicrobial Peptides (AMPS) used by bacterial species 
as a defence mechanism. Figure 1.24. AMPs are often highly potent and are of vital importance 
given the increasing rates of antimicrobial resistance in the modern world, potentially offering 
therapeutic benefits. However, they often possess poor biocompatibility and significant 
cytotoxicity towards mammalian cells, necessitating the development of mimetics.126,127 
The ROMP methodology used in the development of SMAMPs by Tew has also been applied 
to the development of similar polymeric architectures for the purposes of controlled drug 
delivery. Figure 1.24. These derivatives are capable of mimicking protein transduction domains 
(PTDMs), acting as protein transporter molecules. Inspired by amphipathic peptides known to 
transport biologically active/functional proteins into cells (which usually possess poor 
membrane permeability – thereby limiting their biomedical applicability), the PTDMs 
developed were capable of transporting the EGFP protein into Jurkat T Cells.128 This concept 
is of significant importance, as the shift in contemporary medicine moves towards 
biopharmaceuticals, effective therapeutic protein delivery is a primary concern in the viability 
of treatments. 
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Figure 1.24 – Examples of protein biomimetic polymers from Tew and co-workers’.128 
Examples of synthetic protein mimetics also exist in marine science. The biofouling of surfaces 
represents a major problem, and efforts have been deployed in the development of polymeric 
species which are capable of inhibiting attachment of species, debris, and the formation of 
biofilms on submerged surfaces.129 
Similarly, zwitterionic polymers and small molecules inspired by this technology have also 
been developed to prevent the adhesion of bacteria, proteins, and other cellular and biological 
debris on implantable medical devices (such as arterial stents and catheters).129,130 
Some marine species – such as mussels and barnacles – are known for their ability to produce 
a natural protein with pronounced adhesive qualities, allowing them to ‘stick’ to surfaces. 
These proteins would have particular application a number of heavy industries, but can not be 
isolated in significant quantities or easily synthesised. Synthetic mimics of these proteins have 
therefore been investigated and reported, with many replicating the naturally occurring DOPA 
unit, but on a simplified polymer chain, Figure 1.25.131,132 
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Figure 1.25 – Biomimetic adhesive polymers inspired by a molusc natural product (catechols and 
cations).131,132 
The development of antifreeze glycoprotein mimetics therefore represents an exciting 
expansion to this field, and inspiration maybe drawn from the established literature in order to 
best facilitate the development of potent, IRI active, biomimetics. 
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1.7 – Summary 
It is clear from the prevailing literature that the development of new, potent, IRI inhibitors with 
potential applications in cryostorage and biomedicine is slowed by the poor understanding of 
the root cause of IRI activity. The mechanism of action is unknown and the structural design 
rules governing the incorporation of IRI activity in to synthetic inhibitors are fundamentally 
unclear, and in some cases contradictory. This is further complicated by the probability of there 
being multiple mechanisms of action. At present, serendipitous discovery / trial-and-error is 
the beacon by which the field advances, but this is unsustainable, and it is essential that we 
have a defined series of design criteria to guide the development of adaptable, clinically useful 
and applicable ice recrystallisation inhibitors. 
PVA represents the most potent synthetic AF(G)P mimic to date, but it is not wholly applicable 
for biomedical translation. Many synthetic mimics also suffer from this problem, generally due 
to suspected toxicity or intolerance to functionalisation. Natural AF(G)P products also have 
detrimental ice shaping and immunogenic properties.  
Whilst a definitive structure-activity relationship does not yet exist, a number of recent studies 
have provided convincing evidence which may guide the rational design of IRI active AF(G)P 
mimics. Amphipathy (in conjunction with prominent hydrophobicity), over hydroxyl group 
presentation, may be the preeminent structural motif required for IRI potency. This warrants 
further investigation in the pursuit of a blueprint for the design of highly active materials with 




1.8 – Project Aims and Overview 
Various small molecule, polymer, peptide, and protein-conjugates, containing specific 
structural motifs and chemical properties as observed in AFGPs, will be prepared through 
synthetic organic, carbohydrate, amino acid, and ROMP chemistries. Using these species (and 
some sequentially modified derivatives), we will probe the boundaries of IRI activity in order 
to enhance our understanding of the mechanistic mode of action of AF(G)P mimetics. It is 
envisioned that this improved understanding will represent a ‘blueprint’ for the better (and 





1.9 – Thesis Summary 
Chapter 2 details the synthesis and activity assessment of poly(proline) – specifically, 
oligomeric stretches of homo-proline – which is known (and shown herein) to adopt a 
polyproline type II helix, akin to AFGP. The poly(proline) was shown to inhibit ice crystal 
growth to a significantly greater extent than poly(hydroxyproline), a previously identified IRI 
which is prepared from poly(proline) via a non-quantitative biotransformation. Poly(proline) 
(at as short as 20 residues) is therefore IRI active – in the absence of hydroxyl groups – due to 
its amphipathic domain presentation along a PPII helix, therefore demonstrating the 
unequivocal importance of amphipathy in IRI design. Cell recovery assays further indicated its 
potential as a synthetic cryoprotectant, increasing cellular recovery by over 30% post-thaw, 
without dynamic ice shaping. 
Chapter 3 reports on the development of a stimuli-responsive, photo-activatable, small 
molecule IRI inhibitor prepared from anthracene and a short (IRI inactive) peptide stretch, but 
which was derived from a potent antifreeze protein primary sequence. Inactive as a monomeric 
unit in solution, this anthracene-peptide conjugate was capable of enhanced IRI inhibition when 
photo-irradiated, triggering covalent dimerisation through an on-water Diels-Alder 
cycloaddition, increasing the effective molecular weight (from a 22-mer to a 44-mer). This 
species possessed a ‘reversed’ sequence as a photodimer, indicating that a specific peptide 
sequence may not be required, and that activity is more ‘functionally centred’ around the 
presence of a ‘good’ hydrophobic/hydrophilic domain structure. This conjugate may represent 
a blueprint for the design of ice recrystallisation inhibitors with potential applications in 
cryosurgery. A panel of small molecule Simvastatin analogues were also assayed and found to 
have no activity. 
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Chapter 4 builds upon the work of Chapter 2 and deals with the de novo rational design of a 
potent AFGP mimetic. In order to replicate the structural rigidity observed in AFGP whilst 
maintaining hydrophobic/hydrophilic domain balance, a panel of monomers were prepared – 
featuring disparate head and tail groups (some hydrophobic, some uniformly hydrophilic) – 
and a series of (co)polymers derived from them via Grubbs’ Metathesis (ROMP). These 
sequentially modified architectures were assayed and an optimum candidate identified – 
indicating that a rationally designed, structurally rigid, amphipathic candidate of a particular 
molecular weight could demonstrate IRI potency at the µg.mL-1 level. This provides further 
evidence that amphipathy is a core design motif, and why some structurally flexible polymers 
– which can adopt many different conformations – do not have the same levels of IRI potency, 
due to their poorly segregated, domain structure. 
Chapter 5 discusses the attempted preparation of an IRI mimic with the same fundamental 
structural properties as AFGP. Namely; polydispersity, structural rigidity, helicity, and 
amphipathy. These species, prepared from bile acids, did not display any IRI potency, despite 
meeting the hypothesised design criteria. This work may indicate an element of (essential) ice 
face binding in the IRI mechanism. 
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Polyproline – Amphipathy and the polyproline II helix in 
ice inhibitor design 
__________________________________________________ 
2.1 – Chapter Abstract 
This chapter describes a study in to the core structural motifs responsible for incorporating ice 
recrystallisation inhibition (IRI) activity into synthetic proteins, as a means to guide rational 
AF(G)P mimetic design. A brief review of the literature is presented, which highlights facial 
amphipathy as a necessary structural motif. Like, poly(vinyl alcohol) (PVA)1,2,3, the IRI 
activity of poly(L-hydroxy proline) has previously been considered to stem from the presence 
of hydroxyl groups directly binding to ice (hydrogen bonding)4,5; Indeed, it has been proposed 
that AF(G)Ps themselves may function the same way.6 Recently however, there have been 
many literature assertions of structural amphipathy as a driver for IRI activity in synthetic 
AF(G)P mimetics, with hydrophobic binding dominating.7,8 In order to resolve this 
contradiction and clearly establish a structure-activity relationship for IRI, we aimed to prepare 
the structural analogue poly(L-proline) at a series of molecular weights, and to investigate its 
IRI activity. An optimised synthetic route – using in situ N-carboxyanhydride chemistry – for 
the preparation of low molecular weight poly(proline) is also discussed. The IRI activities of 
the prepared poly(L-proline) molecular weight series were subsequently determined by ‘Splat’ 
assay, the results of which indicate that poly(L-proline) is a superior IRI inhibitor to poly(L-
hydroxy proline), exhibiting a 30% increase in IRI at 20 mg.mL-1. This suggests that the 
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presence of repetitive hydroxyl units are not essential for IRI activity, and that an amphipathic 
surface structure is a key factor in synthetic (non-PVA) species exhibiting ice recrystallisation 
inhibition. Poly(L-hydroxy proline)’s biotransformative preparation from poly(L-proline), 
which is often incomplete,9 distorts the potency of poly(L-proline) whilst leaving some 
stretches intact, therefore explaining its residual (albeit weaker) activity. Poly(proline) is shown 
to be an excellent additive for the cryopreservation of adherent cell culture. It is accessible by 
both solution and recombinant methods, it does not dynamically shape ice, and is 




2.2 – Chapter Introduction 
In recent years, the number of studies concerning the IRI activity of synthetic macromolecules 
has steadily increased.10 Poly(vinyl alcohol) (PVA) in particular has been the core focus of a 
number of research projects, representing the most potent synthetic IRI inhibitor discovered to 
date.11,12 Its potential mechanisms of action have been explored and is widely believed to 
function through hydrogen bonding by binding to the prismatic ice crystal face.1 Molinero and 
co-workers have computationally hypothesised that PVA binds in this way to the prismatic 
faces of ice via a ‘zipper’-like mechanism,2 whilst Koop and co-workers has suggested PVA’s 
attuned repeat spacing allow it to engage in a ‘2-on-1-off’ binding strategy, preventing ice 
crystal growth.1 The mechanism of PVA’s activity may well be unique among IR inhibitors, 
however, and considerable effort has also been applied to elucidating the mode of action for 
the naturally occurring IRI active species – AFPs and AFGPs. The lack of a crystal structure 
naturally makes assessment of the AFGP mechanism of action difficult, but many hypotheses 
have still been offered (Chapter 1). 
Davies and co-workers in conjunction with Sonnischen, have however extensively analysed 
the “ice binding site” (IBS) of numerous AFPs, of which several crystal structures have been 
obtained. As is hypothesised for AFGPs, AFPs are known to be intrinsically amphipathic, and 
these ice binding sites are not thought to directly bind to ice, but are thought to order local 
clathrate waters, which themselves providing a good 3D conformational match to the primary 
prismatic ice crystal face.13 Binding through these ordered waters then impedes ice crystal 
growth. The ice binding site itself is believed to be relatively flat and rigid, and largely 
hydrophobic, but with a degree of amphipathic character.13,14 This common structural property 
of AF(G)Ps is of particular importance and interest, as many species which exhibit IRI activity 
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other than the natural AF(G)Ps also appear to have surface amphipathy as a core structural 
motif (Figure 2.1). 
 
Figure 2.1 – Structural comparisons of Sculpin Type I AFP, AFGP, Nisin A, and Metallohelices. 
Nisin A, a natural product and antimicrobial protein often added to milk products, has been 
shown to possess IRI activity when protonated at pH ~4, where it adopts an amphipathic 
structure.8 Interestingly, enantiomerically pure amphipathic metallohelices, featuring a Fe3+ 
centre in a metal-organic framework, have also been shown to possess highly potent IRI 
activity at micromolar concentrations.7 This particular class of species is however unusual, in 
that they do not possess any obvious H-bond donors, nor do they possess hydroxyl groups, 
which have previously been held responsible for the inference of IRI activity. In addition, some 
structurally simplified glycopolymers (representative of the more complex AFGP) have been 
shown to have little to no activity whatsoever, despite possessing high degrees of structural 
similarity.5 It is apparent from this that simply possessing a high proportion/density of hydroxyl 
groups may not be sufficient (or they key) to instilling potency in IRI species other than (the 
structurally unique) PVA. 
Furthermore, many of the IRI active species reported to date often have limited potencies, and 
few examples exist amongst them of biomedically translatable materials – with cytotoxicity 
15,16 and intolerance to functionalisation 17 preventing application. 
What is clear, is that in order to access new highly potent IRI active species which have real 
biomedical application, a rational design blueprint is required to highlight the key structural 
motifs necessary to engineer in IRI potency into synthetic architectures which may be 
functionalised as necessary for biocompatibility, and biomedical translation. 
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In pursuit of this, we were interested in establishing the role of amphipathy in IRI design. AFGP 
is thought to adopt a polyproline type II like-helix, as confirmed by CD spectroscopy,18 which 
is believed to be fundamental in the presentation of the amphipathic surface structure.19 
Curiously, poly(L-hydroxy proline) has been observed to have IRI activity and was first 
reported by Knight and co-workers in 1995.11 This activity has long been attributed to the 
presence of a hydroxyl group in the 3’ position of the cyclic proline ring. However, poly(L-
proline), like poly(L-hydroxy proline), also adopts a polyproline type II helix in aqueous 
solution. Poly(L-proline), however, has not been previously investigated. It contains a spatially 
separated secondary amide (hydrophilic and only H-bond accepting, preventing intramolecular 
H-bonding) distinct from a hydrophobic ring, giving a relatively open and solvent accessible 
structure, resulting in significant water solubility (similar to AFPI, which is 70% alanine – a 
hydrophobic amino acid). We therefore hypothesised that poly(proline) could be a minimal 
AF(G)P mimic and may possess sufficient surface amphipathy that it can act as an effective IR 
inhibitor. Homo-polypeptides are appealing targets compared to vinyl polymers as they can be 
prepared via solid phase synthesis,20 solution phase polymerization21 or by recombinant 
methods,22 proving vast (bio)synthetic space. If correct, this would facilitate the synthesis of 
and provide a new, versatile and easy to access IRI active polymer. As such, we aimed to 
investigate as to the necessity of this ring hydroxyl in poly(L-hydroxy proline) and determine 
the IRI activity of poly(L-proline) through the preparation of a molecular weight series. 
Crucially, this study will indicate as to the supremacy of amphipathy over hydroxyl group 





2.3 – Results and Discussion 
2.3i – Synthesis of oligo- and poly-prolines 
Initial attempts to prepare poly-L-proline for IRI activity assessment were made through the 
attempted synthesis of the N-carboxyanhydride (NCA) of proline, which was to be 
subsequently polymerised through Ring Opening Polymerisation (ROP), Figure 2.2. 
 
Figure 2.2 – Proposed preparation of poly(L-proline) from the N-carboxyanhydride of L-proline. 
However whilst many literature examples exist describing the preparation of N-
carboxyanhydrides from amino acids in general,23 which are widely exploited in polypeptide 
chemistry, the preparation of polyproline and the synthesis of its Proline-NCA precursor is 
often a non-trivial task. 24,25,26 The classical ‘Leuchs Method’ for the synthesis of amino acid 
derived N-carboxyanhydrides involves a one-pot reaction of phosgene or triphosgene and the 
relevant amino acid in THF at elevated temperature (50 – 60ºC), Figure 2.3A. Boc protection 
of the starting amino acid (Figure 2.3B) often improves yield and supresses the formation of 
Diketopiperazine (DKP) by-products, although DKP product formation is generally of limited 
issue for non-proline amino acids. Boc protection is the preferred methodology for preparing 
proline-NCA. Specifically, due to prolines unique status amongst the canonical amino acids, 
featuring a cyclic secondary amine at its α-carbon, exploitation of the classical Leuchs Method 
is often not possible, as the carbamoyl chloride intermediate does not spontaneously cyclise (in 
the absence of a tertiary base) due to its restricted conformation (Figure 2.3C). However, the 
presence of bases such as triethylamine often exacerbate the production of the DKP by-
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products (by increasing the nucleophilicity of the carboxylic acid). Even if successfully 
prepared, removal of residual quantities of base, salts, and DKP have been previously reported 
as problematic. Proline-NCA is particular sensitivity to heat, moisture (and therefore, air) as a 
result of its unfavourable conformational strain promoting rapid hydrolysis, complicating 
isolation. 
 
Figure 2.3 – Preparatory routes of N-carboxyanhydrides. 
In light of this, initial inspiration was taken from work previously conducted by Giralt and co-
workers,24 who pioneered the use of a polymer-bound tertiary amine (N,N-
diethanolaminomethyl polystyrene – DEAM-PS) in the Leuchs method (Figure 2.3C), in place 
of TEA, in 3x excess. This route reportedly overcame the noted problems of triethyl ammonium 
salt and Pro-Pro DKP by-product contamination, in the absence of Boc protection, Table 2.1. 
However this initial attempt to prepare Pro-NCA was not fruitful, with 1H NMR indicating the 
absence of the anticipated NCA triplet at 4.34 ppm. As ethyl acetate was used as the solvent in 
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place of the THF due to its properties as a non-hygroscopic dry medium, we hypothesised that 
it likely failed to swell the DEAM-PS resin to a sufficient extent. A dry atmosphere (nitrogen) 
was introduced in conjunction with dry THF, and N-Boc-protected proline was substituted for 
the free amino acid. 
 Starting Material Base (Excess) % Yield 
Free Amino Acid Method L-Proline * PS-DEAM (3 eqv) 0% 
N-Boc Protected Method N-Boc-L-Proline PS-DEAM (3 eqv) 53% 
Modified N-Boc Protected 
Method 
N-Boc-L-Proline Triethylamine (1 eqv) 0% 
Table 2.1 – Attempted syntheses of Proline-NCA in the presence of Triphosgene, Base, at 0ºC in dry 
THF under N2. * Solvated in dry EtOAc, in air. 
Pro-NCA was successfully obtained in reasonable yield via this revised route and confirmed 
as present by GC/MS (Figure 2.4), with peaks observed at 70 and 114 m/z – characteristic of 
Pro-NCA fragmentation products. Likewise, IR signals in the C=O region followed the general 





Figure 2.4 – Mass Spectrum of Pro-NCA (GC/MS). Corroborative of Gkikas and co-workers.25 
The use of PS-DEAM resin was more efficient, as attempts to prepare Pro-NCA utilising 
triethylamine (as per Figure 2.3B), showed no success. Ring opening polymerisation (ROP) of 
the NCA would be expected to proceed through the normal amine mechanism (NAM), initiated 
by a primary amine (Figure 2.5). Usually, an amino acid NCA is capable of proceeding through 
both NAM and the activated monomer mechanism (AMM), with both mechanisms actively 
competing with one another to give the polypeptide. Proline’s unique status as containing a 
secondary α-amine, however, prevents the AMM pathway from being pursued, due to the lack 




Figure 2.5 – Ring Opening Polymerization of Proline-NCA proceeding through the Normal Amine 
Mechanism (NAM) only, facilitated by a primary amine base. 
Isolation of the NCA proved complex, however, and attempts to polymerise the obtained Pro-
NCA gave no polymer product. This likely indicates degradation, supported by the presence of 
carboxylic acid proton signals in the 1H NMR of the crude – suggesting hydrolysis of the 
anhydride ring due to the poor stability of Pro-NCA towards heat and principally, water. Being 
highly hygroscopic, the moisture content of anhydrous THF is likely a significant factor 
promoting hydrolysis, despite the use of air-free techniques, with literature precedents 
suggesting that Pro-NCA synthesis may be better suited to a glove box. 
Due to the difficulty encountered in preparing polyproline by NCA methods, condensation 
polymerisation was used. 
A molecular weight series of L, D, and D/L (racemic) polyproline were synthesized by 
condensation polymerization using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, EDCI, 
Figure 2.6 (alongside several commercial samples). Following dialysis, unexpected narrow 
dispersity was observed (due to fractionation), the polymers were characterized by SEC (size 




Figure 2.6 – Condensation polymerization of proline. Materials are stereo-pure, but both L and D 
isomers used, hence no stereo centre shown. 
 Mn, 
(g.mol-1) 






[a] 1.03 11 
PPII PPro15 1700 
[a] 2.12 15 
PPro19 2100 
[a] 1.50 19 
P(D)Pro15 1700
 [a] 1.01 15 Enantiomeric PPII 
P(DL)Pro21 2400
 [a] 1.01 21 - 
PPro10-100 1 – 10000 
[b] - 10-100 PPII [e] 
PPro10 900 
[c] [d] 10 PPII [e] 
PPro20 2000 
[c] [d] 20 PPII [e] 
Table 2.2 – Polyproline Characterisation [a] Determined by SEC; [b] Value from supplier; [c] Mass 
Spectrometry provided by commercial supplier; [d] Single species [e] From Literature.27,28,29 
 
Circular dichroism spectroscopy (CD) further confirmed that PPro15 adopted a PPII helix 
(Figure 2.7A and Appendix)30 with characteristic signals present at 207 and 228 nm, whilst a 
random coil would exhibit slight peak shifting, with signals absent in the 220 nm region.31 





2.3ii – The IRI activity of oligo- and poly-prolines 
This series of peptides were subsequently tested for IRI activity using a SPLAT assay.12 This 
involves seeding a large number of small ice crystals, which are annealed for 30 minutes at –8 
ºC, before being photographed. The average crystal size is measured, relative to a PBS control, 
with smaller values indicating more IRI activity, Figure 2.7B/C. 
All polyprolines were found to display dose-dependent IRI activity but weak molecular weight 
dependence in the range tested. The shortest peptide (PPro10) lost activity below 10 mg.mL
-1, 
but the longer species retained activity at 5 mg.mL-1. The magnitude of activity is significantly 






Figure 2.7 – A) Circular dichroism spectra; B) IRI activity of polyproline series, measured as a function 
of solute concentration; C) IRI activity compared to other homo-polypeptides; D) Cryomicrograph of a 
PBS negative control; E) Cryomicrograph of 20 mg.mL-1 poly(proline). Photos taken after 30 mins at –
8 C. Error bars represent the ± standard deviation from three independent measurements. Images 
shown are 1.2 mm across. MLGS = Mean largest grain size relative to a PBS control, expressed as %. 
Knight has observed that poly(hydroxy-L-proline) has IRI activity, which was assumed to be 
due to the regularly spaced hydroxyl groups along the backbone.11 However, the observations 
made here suggest that the PPII helix, rather than hydroxyl groups, are what gives rise to the 
observed activity. Figure 2.7C compares IRI activity of poly(hydroxyl proline) with PPro15 
and, two α-helical poly(amino acids).35 Poly(lysine) (PLys50) and poly(glutamic acid) 
(PGlu110), show no IRI, similar to the negative control. PPro15 was found to be more active 
than poly(hydroxyl proline) of higher molecular weight. This confirms that hydroxyl groups 
are not essential for activity in IRI active compounds. P(D)Pro15 and P(DL)Pro21 had 
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statistically identical activity to PPro15 suggesting local rather than long range order is crucial 
for activity. Specifically, we hypothesise that IRI activity requires segregated hydrophilic and 
hydrophobic domains (amphipathy).8,36 As per Figure 2.8, PPro10 was compared to a non-
glycosylated Type I sculpin AFP37 and also against PGlu10, by mapping their 
hydrophobic/hydrophilic domains. Type I sculpin AFP (Figure 2.8A) possess ‘patches’ of 
hydrophobic/hydrophilic groups, and likewise, PPro10 (Figure 2.8B) also possesses this facial 
amphiphilicity. The intrinsically amphipathic nature of poly(proline) and therefore, of the 
polyproline type II helix, in the absence of hydroxyl groups – can be attributed to as responsible 
for the observed IRI activity. In comparison, PGlu10 (no IRI activity) has charged groups 
around the core of the helix, which prevents the presentation of the central hydrophobic 
domains. This agrees with a previous study by Gibson and co-workers on Nisin A, which has 
IRI activity associated with segregated domains8 and also of amphiphiles developed by Ben et 
al., which only function below the critical micelle concentration.36 
 
Figure 2.8 – Hydrophobic surface mapping of A) Recombinant Type I Sculpin AFP; B) PPro10; C) PGlu10 




In addition to IRI activity, AF(G)Ps display unwanted ice shaping which promotes the 
formation of needle-like ice crystals which damage cell membranes.38 This is one of the 
overriding factors preventing their application to cell cryopreservation, and the source of their 
cytotoxicity. Cryo-confocal microcapillary microscopy has emerged as a tool for monitoring 
ice crystal shaping,39 and was employed here (experimental performed by M. Marcellini and 
S. Deville), Figure 2.9. A non-IRI active dye, sulforhodamine B, provided contrast against the 
ice (which appears dark). A control using pure PBS showed no shaping whilst zirconium 
acetate (ZrAc), which is a strong ice shaping, produced hexagonal crystals.39 PPro19 did not 
induce shaping supporting the concept that polyproline inhibits ice crystal growth without 
inhibiting or binding to a specific plane of ice. Specifically, unlike PVA which is thought to 
bind ice, and AFGP which is known to, it is possible that this study provides a degree of 
substantiation for a specific mechanism of IR inhibition which – through the disordering of 
local waters – may inhibit ice crystal growth by preventing the energetic transfer of water 





Figure 2.9 – Cross-section of ice crystals perpendicular to temperature gradient. A) ZrAc (positive 
control); B) PPro19; C) PBS (negative control). The ice crystals expel the dye while growing, appearing 




2.3iii – Cryopreservation with oligo- and poly- prolines 
This apparent inability to dynamically shape ice and polyproline’s intrinsic IRI activity 
suggested its wider application as a potential cellular cryoprotectant. Numerous biomedical 
procedures and practices (such as tissue engineering, gene therapy, and the manufacture of 
therapeutic proteins) depend upon the storage and transport of donor cells.40 Principally, in 
order to access the full potential offered by stem cell therapy treatments, a ready, available, and 
on-demand supply of cellular material is essential. A reliable, replicable methodology for the 
cryopreservation of cell lines (preferably in the simpler monolayer format – providing 
phenotypically identical cells) is therefore highly desirable. In comparison, in vitro cell cultures 
are less favourable, as they undergo phenotypic and genetotypic changes when propagated over 
long periods of time41,42 It is therefore necessary to freeze these cell lines in the presence of 
large volumes (of typically cytotoxic) cryoprotective organic solvents such as DMSO, which 
acts to limit the effective rise in extracellular solute concentration during freezing, lowering 
cryo-induced cellular damage. Repeated DMSO exposure, however, can result in the mutation 
of DNA methylation profiles and induces phenotypic drift.43,44,45 Low cellular recoveries are 
also a factor, with embryonic stem cells generally giving only 5% cellular recovery when 
exposed to commercial formulations containing between just 5 – 10% DMSO. 46–48,49,50 
Of the IRI species developed to date, several have been subject to cell freezing studies. 
Matsumura et al. have developed polyampholytes51 which are cryoprotective in spite of their 
moderate IRI activity.33,34 Wang et al. have demonstrated the significant IRI activity of 
graphene oxide.52 Ben et al. have developed low molecular weight surfactants which also 
inhibit ice growth.36 A major setback is that the above synthetic IRIs are not biodegradable nor 
bioresorbable and have not been applied to significant challenge of cell monolayer storage. 
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To explore polyproline as a biocompatible, biodegradable and bioresorbable macromolecular 
cryopreservative A549 cells were employed as prototypical adherent cell line.53 
Performed by Trisha L. Bailey, the protective osmolyte proline (which has no intrinsic IRI 
activity, see Appendix) was used as a secondary cryoprotectant to protect against osmotic 
stress. A549 cells were incubated with 200 mM proline or media alone for 24 hours. The 
solution was then removed and replaced with 10% DMSO with PPro11, and after 10 minutes 
exposure, all excess solvent was removed followed by controlled freezing to –80°C and 
storage. Cells were subsequently thawed and the total number of viable cells assessed by trypan 
blue staining. 
 
Figure 2.10 – A549 Cryopreservation. Error bars ± S.E.M from n= 3 with two nested replicates.  
# P < 0.05 compared to 10% DMSO treatment; * P < 0.05 compared to 200 mM proline exposure with 
10% DMSO treatment. Performed and Graphed by T. L. Bailey. 
Figure 2.10 shows that the industrial ‘gold standard’ (DMSO) which gives just 27% cellular 
recovery under the employed conditions. Addition of polyproline to 10% DMSO failed to give 
any additional protection. However, cells which had been pre-conditioned with 200 mM 
proline for 24 hrs before exposure to 5 mg.mL-1 PPro11/10% DMSO dramatically increased 
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recovery of viable cells to 53%. Increasing the concentration of polyproline beyond  
10 mg.mL-1 did not increase recovery further.54 This is a significant improvement in cell 
recovery and demonstrates the successful application of a simplistic, yet potent, antifreeze 
protein mimic. 
Red blood cells haemolysis assays were also carried out, which indicated that polyproline was 
effectively non-haemolytic and biocompatible across the concentration range, Figure 2.11, 



























Figure 2.11 – Red blood cell hemolysis assay for poly(proline) (PPro15) at 37 ºC. 
 
Over a 24 hour period, significant cytotoxicity (signified by reduced cellular viability) with 
respect to poly(proline) is observed at concentrations in excess of 5 mg.mL-1. Figure 2.12. 
However, these results are substantially better than what is observed for DMSO alone. 
Additionally, toxicity is only observed over extended periods, and given that the 
cryopreservation strategy employed requires only fleeting exposure to poly(proline) – no 
greater than 10 minutes – before removal of both DMSO/poly(proline) and subsequent freezing 
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as a monolayer, this is of little concern. Furthermore, the thawing of cells by addition of warm 
media will further dilute any residual poly(proline), minimising any long term cytotoxic effect. 
 
Figure 2.12 – Long Exposure (24 hrs) of A549 Cells to PPro. % Cell Recovery determined by alamar 
blue (resazurin) reduction. Error bars ± S.E.M from n= 3; * P < 0.05 compared to PPro-free control. 
Performed and Graphed by T. L. Bailey. 
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2.3iv – Preparation of poly(L-proline) via in-situ N-
Carboxyanhydrides and ROP 
The ability to produce poly(proline) on a large scale maybe an attractive proposition, given that 
we have demonstrated that it is a potent additive for cell-monolayer cryopreservation. 
However, production through Steglich coupling is not a practical method for anything other 
than small quantities, particularly due to its low efficiency and invariably low yield (1-10%). 
It is therefore not economically scaleable, requiring unrealistically large quantities of reagent 
to give very little product. The effective step-growth process is also self-limiting, with steric 
hindrance of the proline ring preventing chain growth. As already discussed, preparation of 
poly(proline) through N-carboxyanhydride synthesis and subsequent polymerisation has 
proved challenging, due to the instability of the NCA. Recent literature work by Schlaad et 
al.55 and Endo and co-workers56–62,63 has shown the ability to prepare N-carboxyanhydrides in-
situ, subsequently generating the polypeptide of interest in high yield, through an effective 
transition state. Furthermore, Endo and co-workers has shown – to a very limited extent – the 
ability to prepare poly(proline) through this method,64 and is the only example of its kind to 
date. However, this preparation was sparse in detail, low yielding, and gave no molecular 
weight or dispersity characterisation. Additionally, the poly(proline) prepared was insoluble in 
water and numerous organic solvents (including DMF and DMSO) – implying poly(proline) 
had only been produced in very high molecular weights by this method. In spite of this, as this 
approach does not require NCA isolation, it may have adapted application here for the mass, 




Figure 2.13 – Generation of Carbamate Precursor and in-situ NCA Generation/ROP 
Attempts to prepare the carbamate as per the literature precedent were inconsistent, however. 
Use of a non-nucleophilic base (TEA) to scavenge HCl and improve yield relative to the 
literature (33%), resulted in the generation of 4-nitrophenoxide. Able to attack an otherwise 
transient intermediate (1, Figure 2.14), this competitive side reaction led to the production of 
the inactive ester product (Crude LCMS Fragment at 277 m/z = Ester + ACN), Figure 2.14. 
Column chromatography (9:1 chloroform:acetone) allowed isolation of the carbamate, but in 
less than expected yield (20%). As the ester is unable to undergo the cyclisation process to the 
NCA, it is a dead-end product, with any nucleophilic step growth to the polypeptide by 
intramolecular nucleophilic attack of the amine ultimately restricted by its own steric bulk. 
 
Figure 2.14 – Likely mechanism of ester formation during proline-4-nitrophenoxy carbonyl synthesis 
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However, once isolated, in-situ cyclisation of the carbamate to the NCA and subsequent ROP 
was found to be effective Table 2.3 – Entry 1, giving well defined oligo(proline) in substantially 












1 28.8 : 1 720 1.08 6 27.1% (Crude) 







Table 2.3 – Characterisation of polyprolines prepared through in-situ NCA/ROP protocol. [a] Determined 
by SEC (DMF) 
Unlike Endo’s previous work, poly(proline) was obtained in low molecular weight and low 
dispersity. Importantly, the Mw’s of the poly(proline) acquired was similar to the oligomers 
previously prepared by Steglich coupling, suggesting that this method is applicable for 
scaleable production of poly(proline) as a macromolecular cellular cryoprotectant. 
In the interests of improving yield further, attempts were made to prevent ester formation 
outright during carbamate preparation. Taking inspiration from Endo’s later work on 
sarcosine,62 we later substituted the use of free proline for the tert-butoxy protected equivalent, 
deactivating the α-carboxylic acid. When reacted with the 4-nitrophenol chloroformate, this 
selectively led to the tBu-carbamate product in 84% yield before brief exposure to 50% TFA 
in DCM, cleaving the protecting group to reveal the free acid/carbamate derivative. In-situ 
polymerisation followed – Table 2.3, Entry 2 – with a lower excess (12 : 1 vs 29 : 1) of 
benzylamine used in order to produce longer poly(proline) chains, of the same order as those 
produced in the Steglich coupling (DP ~ 15). Despite the significantly reduced mass loss in the 
new procedure, the in-situ NCA/ROP protocol led to the formation of trace quantities of very 
long poly(proline) chains, of approximately 18 kDa molecular weight. The desired shorter 
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chains of approximately 1.7 kDa were also produced (and were significantly more pronounced 
by GPC), however, the mass of all fractions recovered was negligible (< 0.1 mg). This indicates 
that a large proportion of the proline carbamate was converted to very short oligomers (below 
the molecular weight cut-off of the dialysis tubing) or failed to polymerise at all. Given the 
steric hindrance of poly(proline), it is probable that the prolines have a propensity to form short 
stretches, with longer sequences disfavoured, rendering the synthesis of defined lengths 
problematic to achieve in practice. Further work is required in order to optimise this method 
and realise its potential to provide large quantities of poly(proline), economically.   
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2.4 – Conclusions 
In summary, here we have introduced poly(proline) as a minimum (bio)synthetic antifreeze 
protein mimic. We have demonstrated polyproline has ice recrystallization inhibition activity, 
hypothesised to be due to its ‘patchy’ amphipathic PPII helical structure. This assertion has an 
important impact upon the understanding of IRI mechanistic action, disproving the necessity 
for hydroxyl groups and potentially supporting a theory of activity dependent upon the 
disruption of local water ordering in the absence of ice binding. Crucially, having elucidated 
some key structural motifs and asserted the supremacy of amphipathy, the observations made 
here may now allow for the enhanced rational design of potent AF(G)P mimetics, expanding 
the synthetic space which may be explored. 
Poly(proline) was further found to significantly improve the cryopreservation of cell 
monolayers/adherent cell culture, with a remarkable increase from 20% (DMSO alone) to > 
50% in total cell recovery post cryopreservation, thought to be a result of ice recrystallisation 
inhibition. This ultimately demonstrates a new macromolecular approach for the storage of 
complex cells to enable next generation therapies. 
Transient exposure of poly(proline)/DMSO, followed by the removal of the excess solvent, 
limits the cytotoxicity associated with long-term exposure to poly(proline). As such, this may 
impart biomedical benefits in comparison to existing high-solvent-concentration vitrification 
techniques, making poly(proline) an appealing candidate to other cryoprotective species. 
Furthermore, being comprised only of native amino acids, poly(proline) is an ideal motif in the 
emerging field of macromolecular cryoprotectants. Unlike some synthetic polymers, 
poly(proline) may be accessed by both chemical and biochemical methods, making it a 
versatile new tool in cell biology and biomedicine.  
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2.5 – Experimental 
Materials 
L and D-proline, poly-L-proline mol wt 1,000-10,000 (PPro10-100), ethyl (hydroxyimino) 
cyanoacetate (OxymaPureTM), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDCI), dichloromethane (DCM), phosphate-buffered saline preformulated 
tablets, and hydrochloric acid (37%) were purchased from Sigma Aldrich Co Ltd (Gillingham, 
UK) and used without further purification. Dialysis Membrane Spectra/Por 7 Flexible 38mm 
FWT 1000 MWCO 4.6 mL/cm was purchased from Fischer Scientific (Loughborough, UK) 
and used directly. Phosphate-buffered saline (PBS) solution was prepared using preformulated 
tablets in 200 mL of Milli-Q water (>18.2 Ω mean resistivity) to give [NaCl] = 0.138 M, [KCl] 
= 0.0027 M, and pH 7.4. PPro10 and PPro20 (>90%) were purchased bespoke from Peptide 
Protein Research Ltd (Fareham, UK) and were used without further purification.  PPro10: m/z 





Physical and analytical methods 
1H and 13C NMR Spectra (300 – 400 MHz and 75 – 100 MHz, respectively) were recorded 
using one of a Bruker DPX-300/400 Spectrometer under standard NMR conditions. Chemical 
shifts were recorded in ppm and referenced to solvent residual peaks, using ACD Labs NMR 
Spectroscopy software. 
ESI MS experiments were performed on an Agilent 6130B Single QUAD ESI-LC MS 
spectrometer in either positive or negative mode with an H2O/MeOH (80:20) eluent feed, with 
samples dissolved in water, methanol or ethanol, unless otherwise stated. 
IR experiments were carried out on a Bruker Vector 22 (ATR) FTIR Spectrometer in either the 
solid or thin film (volatile organic solvent) phase, with background subtraction. 
SEC (size exclusion chromatography) was acquired a DMF Agilent 390-LC MDS instrument 
equipped with differential refractive index (DRI), viscometry (VS), dual angle light scatter 
(LS) and dual wavelength UV detectors. The system was equipped with 2 x PLgel Mixed D 
columns (300 x 7.5 mm) and a PLgel 5 µm guard column. The eluent is DMF with 5 mmol 
NH4BF4 additive. Samples were run at 1 mL/min at 50’C. Poly(methyl methacrylate) standards 
(Agilent EasyVials) were used for calibration. Analyte samples were filtered through a nylon 
membrane with 0.22 μm pore size before injection. Respectively, experimental molar mass 
(Mn,SEC) and dispersity (Đ) values of synthesized polymers were determined by conventional 
calibration (relative to poly(methyl methacrylate) standards) using Agilent GPC/SEC software. 





Ice recrystallization inhibition (splat) assay 
Ice recrystallisation inhibition was measured using a modified splat assay. 1 A 10 µL sample 
of polymer dissolved in PBS buffer (pH 7.4) was dropped 1.40 m onto a chilled glass coverslip, 
resting on a thin aluminium block placed on dry ice. Upon hitting the coverslip, a wafer with 
diameter of approximately 10 mm and thickness 10 µm was formed instantaneously. The glass 
coverslip was transferred onto the Linkam cryostage and held at -8oC under N2 for 30 minutes. 
Photographs were obtained using an Olympus CX 41 microscope with a UIS-2 20x/0.45/∞/0-
2/FN22 lens and crossed polarizers (Olympus Ltd, Southend-on-Sea, UK), equipped with a 
Canon DSLR 500D digital camera. Images were taken of the initial wafer (to ensure that a 
polycrystalline sample had been obtained) and again after 30 minutes. Image processing was 
conducting using Image J, which is freely available. In brief, five of the largest ice crystals in 
the field of view were measured and the single largest length in any axis recorded. The average 
(mean) of these five measurements was then calculated to find the largest grain dimension 
along any axis. This was repeated for three individual wafers, and the average (mean) of these 
three values was calculated to give the mean largest grain size (MLGS). The average value was 
compared to that of a PBS buffer negative control. 
Surface hydrophobicity mapping of proteins 
NMR solution phase (AFP Sculpin) and X-Ray crystal structures of proteins and peptides of 
interest were acquired from the Protein Data Bank and other publicly accessible sources, or 
computationally modelled in-house (PPro10 and PGlu10) by Dr. Joseph J. R. Healey. Structures 
were rendered in PyMOL (Schrödinger LLC, Cambridge, MA), which is freely available for 
educational use, and surfaces on the structures were displayed. An open source script “color_h” 
was used to colour the protein surface according to the Eisenberg hydrophobicity scale of its 
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constituent amino acids, from red (hydrophobic) to white (hydrophilic). For the homo-
polypeptides where scaling is not possible, aliphatic hydrogen and carbon were defined as 
hydrophobic whilst oxygen, hydrogen and nitrogen as hydrophilic, utilising the same colour 
scheme. Due to the lack of hydrogen bond donors in a PPro10 PPII helix, this was considered 
representative. 
Cell culture 
Performed by Trisha L. Bailey. Human Caucasian lung carcinoma cells (A549) were obtained 
from the European Collection of Authenticated Cell Cultures (Salisbury, UK) and grown in 
175 cm2 cell culture Nunc flasks (Corning Incorporated, Corning, NY). Standard cell culture 
medium was composed of Ham's F-12K (Kaighn's) Medium (F-12K) (Gibco, Paisley, UK) 
supplemented with 10 % USA-origin foetal bovine serum (FBS) purchased from Sigma 
Aldrich Co Ltd (Gillingham, UK), 100 units/mL penicillin, 100 µg/mL streptomycin, and 250 
ng/mL amphotericin B (PSA) (HyClone, Cramlington, UK). A549 cells were maintained in a 
humidified atmosphere of 5 % CO2 and 95% air at 37 °C and the culture medium was renewed 
every 3–4 days. The cells were S4 subcultured every 7 days or before reaching 90 % 
confluency. To subculture, cells were dissociated using 0.25 % trypsin plus 1 mM EDTA in 
balanced salt solution (Gibco) and reseeded at 1.87x105 cells per 175 cm2 cell culture flasks. 
Cell solution preparation 
Performed by Trisha L. Bailey. Solutions for cell incubation experiments were prepared by 
dissolving the individual compounds in F-12K supplemented with 10 % FBS and 1X PSA 
(solutions used as freezing buffers did not contain PSA) and sterile filtered prior to use. 
Cytotoxicity Measurements 
Performed by Trisha L. Bailey. Cells were seeded at 6·104 cells per well in 200 µL of cell 
culture medium with indicated concentrations of polyproline in 96-well plates (ThermoFisher). 
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Cells were incubated for 24 h in a humidified atmosphere of 5% CO2 and 95% air at 37 °C. 
Following the incubation period, resazurin sodium salt (Sigma Aldrich) was dissolved in 
phosphate buffered saline (Sigma Aldrich) and added to wells in an amount of 1/10th initial 
well volume. Absorbance was measured at 570/600 nm every 60 minutes until control cells 
reached ~ 70 % reduction, and the viability reported relative to the control cells. 
Haemolysis assay 
Samples containing 250 µL ovine red blood cells (RBCs) and 250 µL of PPro solution (at twice 
the indicated concentration) were incubated at 37 °C for 1 hour. After centrifugation, 10 µL of 
the supernatant was added to 90 µL of PBS buffer in a 96 well plate. The absorbance was 
measured at 450 nm and compared against a PBS buffer and deionised water (to lyse cells) 
controls to determine the % haemolysis relative to the controls. 
Statistical analyses 
Performed by Trisha L. Bailey. Data were analysed with a one-way analysis of variance 
(ANOVA) on ranks followed by comparison of experimental groups with the appropriate 
control group (Holm–Sidak method) followed by Tukey’s post hoc test. Excel 2013 (Microsoft, 
Redmond, WA) and R (R Foundation for Statistical Computing, Vienna, Austria) were used 
for the analyses. Data sets are presented as mean ± (SEM). 
Cryopreservation of A549 cell monolayers  
Performed by Trisha L. Bailey. Cells to be frozen in the monolayer format were seeded at 
0.4X106 cells per well in 500 µL of cell culture medium in 24-well plates (Corning 
Incorporated, Corning, NY). Plates had a total available volume of 3.4 mL with an approximate 
growth area of 1.9 cm2, no coverslips were used and plates were used with the accompanying 
lid.  Cells were allowed to attach to the entire free surface of the bottom of the well and formed 
a confluent layer not greater in height than one cell. Before experimental treatments, cells were 
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allowed to attach for 2 h to the plates in a humidified atmosphere of 5% CO2 and 95% air at 
37°C. The medium was exchanged against medium that was or was not supplemented with 
solutes as indicated in the figure. Control cells received no additional solutes and experimental 
cells were incubated with 23.1 mg/mL L-proline for 24 h in a humidified atmosphere of 5% 
CO2 and 95% air at 37 °C. Following the incubation period, the culture medium was removed 
and cells were exposed for 10 min at room temperature to different concentrations of solutes 
dissolved in F-12K supplemented with 10% FBS and 10% DMSO.  After 10 min, the freezing 
solutions were removed and the plates placed inside a CoolCell® MP plate (BioCision, LLC, 
Larkspur, CA), transferred to a -80 °C freezer and frozen at a rate of 1 °C/min. After 24 h at -
80 °C, cells were rapidly thawed by addition of 500 µL cell culture medium warmed to 37 °C.  
Cells were placed in a humidified atmosphere for 24 h and then dissociated using 0.25% trypsin 
plus 1 mM EDTA in balanced salt solution. The number of viable cells was then determined 
by counting with a haemocytometer (Sigma Aldrich Co Ltd) at room temperature after 1:1 
dilution of the sample with 0.4% trypan blue solution (Sigma Aldrich Co Ltd). The initial cell 
medium was discarded such that any non-attached cells were not included in the assessment.  
The percentage of recovered cells was calculated by dividing the number of cells with intact 
membranes after freezing and thawing by the number of cells present prior to freezing (i.e. 
after application of pre-treatments), multiplied by 100. 
Confocal Microscopy sample preparation and measurements 
Performed by Moreno Marcellini/Sylvian Deville. The solution of 20 mg/mL of poly(proline) 
in PBS was prepared as previously reported. This solution was stained with 60 µL/mL of 1 mM 
solution of Sulphorhodamine B in deionized water. The fluorophore absorbs the 552 nm 
wavelength laser light and emits in a wide band: The fluorescent light was integrated in the 
575-625 nm range. Water at the liquid/solid phase transition expels all ions, such that the ice 
crystals will be constituted by pure water. In this way, we can highlight the ice crystals that 
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upon freezing will grow in the solution as black bodies in the fluorescent liquid. The 
experimental setup for a similar experiment has been described elsewhere.3 A thin Hale-Shaw 
cell was built as follows: on a squared thin glass slide (20 x 20 mm2, thickness λ ≈ 170 µm, 
VWR) a 10 µl drop was deposited by using a pre-calibrated pipette. The sessile drop was 
carefully covered with a circular thin glass slide (Ø=15 mm, λ ≈ 170 µm, VWR). The circular 
contour of such Hale-Shaw cell was sealed with nail polish (L'Oreal). With time, the solvent 
of the seal eventually evaporates, making the seal porous. The sample was therefore rapidly 
mounted on the cryostage and frozen only once, while the seal was still effective. The sample 
was discarded after the experiment. 
Confocal Microscopy Measurement: To simulate – to a first approximation – the protocol of 
splat experiments reported elsewhere, 4 the sample was brought as quickly as possible (a few 
minutes) at the minimum temperature Tmin ≈ –22°C that the cryostage can sustain. 
Nevertheless, this protocol is largely unable to provide the same crystallization feature of the 
splat experiments owing to the ice crystallization in a fraction of a second being more feasible 
with the latter. At a temperature below –15°C ice crystals burst from the cold side towards the 
hot side. The rapid imaging rate of the microscope is able to capture the growing ice crystal 





General procedure for the synthesis of polyproline peptides PPron 
EDCI (0.50 g, 2.60 mmol) was dissolved in dry DCM (20 mL) and stirred at room temperature 
under a flow of dry nitrogen for 20 minutes, followed by cooling to 0 ºC. Within 5 minutes of 
cooling, L- or D-proline (0.30 g, 2.60 mmol, 1 eqv) and OxymaPureTM (0.37 g, 2.60 mmol, 1 
eqv) were added together to the reaction mixture, resulting in an instantaneous colour change 
to yellow. The mixture was stirred on ice under nitrogen for 1 further hour, and then warmed 
to RT with stirring overnight. The dark yellow solution was condensed in vacuo, dissolved in 
Milli-Q water (10 mL) acidified to pH 3-4 with 3M HCl, and a minimum volume of methanol 
added until residual solids dissolved. Dialysis (> 1 kDa) for 48 hours was subsequently 
performed with regular water changes. The resulting solution was freeze dried, yielding an off-
white solid. 31.4 mg (10.4%). The DL racemate, P(DL)Pron, utilised a 1:1 ratio of L- and D-
proline (2.60 mmol prolines). 
Attempted synthesis of poly-L-proline from in-situ N-carboxyanhydride (NCA) 
generation and ring-opening polymerisation (via Free α-amine) 
 
L-Proline (7.6 g, 66.0 mmol) was dissolved in ethyl acetate (50 mL) containing acetonitrile (20 
mL) and 4-nitrophenylchloroformate (15.83 g, 78.55 mmol, 1.2 eqv) added. Triethylamine (12 
mL, 86.10 mmol, 1.3 eqv) was then introduced dropwise, and the mixture stirred overnight at 
room temperature. The solution was then reduced in vacuo to a thick oil and loaded onto silica 
gel for purification by column chromatography (9:1 chloroform/acetone), Rf = 0.73, Fractions 
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6 – 10, yielding an off-white solid. 3.69 g (20.0 %). m/z (ESI, -ve) Expected 376.1, Observed 
376.1 [100%, M + Proline – H2O – H
+]. 
This solid was subsequently dissolved into dry DMAc, under N2, and then sparged with 
nitrogen for 20 minutes. Benzylamine was then added (50 µL) and the mix was heated at 60ºC 
for 3 days with stirring. The mixture was then exposed to air, condensed to a thick oil in vacuo 
and subjected to SEC analysis. 1 g (27.1%). 
Attempted synthesis of poly-L-proline from in-situ N-carboxyanhydride (NCA) 
generation and ring-opening polymerisation (via Protected α-amine) 
 
Preparation of 1: L-Proline tert-butyl ester (600 mg, 3.50 mmol) was dissolved in THF (30 
mL) and 4-nitrophenylchloroformate (1.06 g, 5.26 mmol, 1.5 eqv) added, in conjunction with 
triethylamine (0.75 mL, 5.38 mmol, 1.53 eqv), and the mixture stirred overnight at room 
temperature. After 18 hours the solution was reduced in vacuo to a thick oil and then 
precipitated from ice cold water (~ 45 mL), to give a white solid which was filtered, rinsed 
with acetone, and then condensed in vacuo. The solid residue was then desiccated overnight, 
to give the arylated product. 1.03 g (87.4 %). m/z (ESI, +ve) Expected 359.3, Observed 359.2 
[100%, M+Na+]. 
Preparation of 2 and in-situ Polymerisation: 1 (910 mg, 2.71 mmol) was exposed to 50% 
trifluoroacetic acid in DCM for 1 hour on ice, and condensed in vacuo, yielding a brown oil. 
m/z (ESI, –ve) Expected 393.3, Observed 393.1 [100%, M+TFA-]. 
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The oil was rapidly dissolved into dry DMAc, under N2, and sparged with nitrogen for 20 
minutes. Excess acidity was removed with triethyl amine (13 µL) – until pH 7 – and then 
benzylamine added (25 µL). The mix was heated at 60ºC for 4 days with stirring. The mixture 
was then exposed to air, condensed to a thick oil in vacuo, and dissolved up into water (~ 40 
mL) and dialysed (MWCO 1 kDa), with regular water changes until the loss of the yellow p-
nitrophenol by-product. The contents of the dialysis bag were then freeze dried to give a very 
thin translucent film of negligible mass. 
Failed and redundant syntheses of (S)-tetrahydro-1H,3H-pyrrolo[1,2-c]oxazole-1,3-dione 
(L-Proline NCA) 
 
Free Amino Acid Method: L-proline (0.1 g, 100 mg, 0.87 mmol) was suspended in dry EtOAc 
(50 mL) with stirring, and heated to 50°C. Triphosgene (0.5 eqv, 0.13 g, 0.43 mmol) was added 
in whole, and the reaction mixture stirred for one hour (until dissolved). The intermediate was 
subsequently condensed in vacuo and the yellow oily residue redissolved in dry EtOAc (60 
mL), added to pre-swollen DEAM-PS (3 eqv, 0.82g, 2.61 mmol) in dry EtOAc (20 mL), and 
stirred at RT for 2 hours. The filtrate was recovered and condensed in vacuo, the solid having 
been washed with further dry EtOAc (20 mL) at the pump. The off-white crude residue 
obtained was redissolved in dry EtOAc (5 mL) and crystallised from pentane (20 mL), with 
cooling to –20°C overnight, yielding yellow crystals. Recrystallisation from EtOAc (5 mL) and 
cold pentane (30 mL) at –20°C yielded an off-white solid. 25 mg. (Product Absent by 1H and 
13C NMR – 0%). Compound previously reported.25 
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N-Boc Protected Method: N-Boc-L-Pro-OH (0.1 g, 100 mg, 0.46 mmol) was suspended in dry 
THF (15 mL) with stirring under nitrogen. DEAM-PS (3 eqv, 0.44 g, 1.39 mmol) was added 
and allowed to equilibrate for 1hr 30 minutes, followed by the slow addition of Triphosgene 
(0.37 eqv, 51.00 mg, 0.17 mmol) in THF (5 mL), drop wise, at –7°C. The reaction mixture was 
stirred for a further 30 minutes on ice, and then quickly warmed to 40°C for 5 minutes, with 
stirring at RT overnight. The mixture was then filtered, washed with dry THF (100 mL), and 
condensed in vacuo, yielding the crude mixture which was subsequently dried under reduced 
pressure (4 hrs). The crude was then dissolved in EtOAc/Pentane (15 mL, 1:2), chilled at –5°C 
and then extracted once with ice cold water (50 mL). The organic phase was subsequently dried 
over MgSO4, filtered and condensed in vacuo, yielding a clear oil featuring an off-white solid. 
32 mg (53 %). IR (ATR): 2961 cm-1 (-OH); 1744, 1720, 1700, 1650 cm-1 (C=O). GC-MS 
(360°C): 12.67 min, m/z = 57.1 (309924, Unknown) 70.1 (1551485,-H+N=CHCH2CH2CH2-), 
114.0 (1188295, -HN-CH(CO2
+)-CH2CH2CH2-). Compound previously reported.
24 
Modified N-Boc Protected Method: N-Boc-L-Pro-OH (0.5 g, 2.32 mmol) was dissolved in 
dry THF (20 mL) under nitrogen. Triphosgene (0.37 equiv, 0.25 g, 0.65 mmol) was added 
under vigorous stirring and after 10 minutes, triethylamine (1.1 equiv, 0.35 mL, 2.55 mmol) 
added dropwise over 15 minutes at –15°C, and the reaction mixture stirred for 1.5 hrs at RT 
under nitrogen. The reaction mixture was then cooled to 0°C to allow for complete precipitation 
of the triethylammonium salt and was removed by filtration. The filtrate was subsequently 
condensed in vacuo and dried under reduced pressure. The crude was dissolved in dry ethyl 
acetate (10 mL), chilled, and then extracted once with ice-cold water (30 mL). The organic 
phase was died over MgSO4, filtered, and condensed in vacuo. The oily residue was 
subsequently chilled to – 20°C overnight under nitrogen, yielding white crystals. 0.301 g. 
(Product Absent – 0%). IR (ATR): 2967, 2985, 2716 (CH), 1828, 1779, 1736, 1701, 1632 
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(C=O), 1478, 1423 (CH), 1257, 1211 cm-1 (CO). GC-MS (360°C): Uninformative. Compound 
previously reported.25 
 
Attempted Syntheses of Poly-L-Proline 
The crude material from the N-Boc Protected Method (0.301 g) was dissolved in dry THF (5 
mL), under nitrogen with benzylamine (0.1 mL), and stirred vigorously for 24 hours. A large 
excess of diethyl ether (50 mL) was added and the mixture centrifuged (10k RPM 10 minutes). 
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Photo-activatable ice recrystallisation inhibitors 
__________________________________________________ 
3.1 – Chapter Abstract 
Antifreeze proteins (AFP) are capable of binding to specific planes of ice and are potent ice 
recrystallisation inhibitors (IRIs). Their activity is controlled though modulation of protein 
expression via light regulated expression systems, whereas when used in application areas the 
activity is ‘always on’. This chapter outlines the development of a series of photo-activatable 
IRI inhibitors, and is the first reported method for such external control over AFP activity using 
a photo switch based on the photo-reversible dimerization of anthracene. Truncated peptide 
sequences based on the consensus repeat sequence from Type I AFPs (TAANAAAAAAA) 
were conjugated to an anthracene unit featuring a dilysine solubilising linker, and the 
conjugates dimerised with exposure to UV-light. Dimerization (causing a head to head 
coupling and hence breaking the peptide sequence, giving a mirrored stretch) reduced activity 
compared to the non-dimerized derivative. This proof of concept study shows a new route 
towards providing spatio-temporal control over antifreeze protein function, potentially 
providing a blueprint for the design of advanced materials with applications in cryosurgery and 
biomedicine.   
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3.2 – Chapter Introduction 
Antifreeze proteins (AFPs) exist in the blood serum of a number of marine and insectoid 
species, in addition to plants, which inhabit extremely cold climates. Their presence has the 
remarkable effect of restricting ice crystal growth,1 allowing species like the right-eyed 
flounder to survive without freezing solid in icy waters.  
During the summer months (when the oceans are warmer), a gene circuit inhibits the synthesis 
of AFPs by the liver. As temperatures begin to fall in the autumn (and the ocean grows colder), 
the fish begin to require protection, and a drop in available sunlight results in the pituitary gland 
inhibiting the production of the growth hormone which prevents AFP gene transcription, 
facilitating AFP biosynthesis.2 There is no simple way to gain localised, spatiotemporal control 
over AFP function in therapeutic applications, and providing ‘on-demand’ protection against 
ice crystal growth is inherently complex, but would be particularly desirable in numerous 
fields, such as cryosurgery. 
The use of cryogens – such as liquid nitrogen and carbon dioxide – in biomedical procedures 
has long been established as a viable method for the localised destruction of diseased tissue, 
and ‘Cryosurgery’ is often used for the removal of unwanted growths; particularly moles, 
warts, and benign/malignant melanomas.3 Cryotherapy also finds use in invasive medical 
procedures, specifically in the treatment of tumours and cancerous growths on organs such as 
the lungs, kidneys, and liver. In this context ‘Cryoablation’ destroys the malignant tissue 
through the induction of cell apoptosis, ice crystal growth (causing catastrophic cell damage), 
and the effects of freezing ultimately cutting shutting off the tissues blood supply resulting in 
tissue ischemia.4,5 However, extensive damage to surrounding healthy tissues in both 
Cryosurgery and Cryoablation is a fundamental problem with the cryogenic approach. Many 
patients suffer varying levels of pain post-surgery and are prone to the formation of blisters and 
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scarring.6 The ability to restrict or inhibit this surrounding tissue damage, however, would 
ultimately alleviate pain, limit the formation of unsightly scarring or skin defects, improve 
recovery time, and enhance patient compliance. Therefore, there is clear potential to develop 
an ice recrystallisation inhibitor which is capable of being selectively activated by an external, 
non-invasive, photo-stimulus to ensure that the surrounding tissues are protected from cold 
damage, restricting cryodamage to the diseased region, Figure 3.1. Light is a desirable trigger, 
as it has high spatial resolution and is easy to apply, and the wavelengths can be tuned as 
required. Such photo triggers have found wide application in areas such as hydrogels,7,8 light 
triggered polymerizatinon9–11 and even to gain control over gene level expression.12,13 
 
Figure 3.1 – Hypothesised protection of tissue through photo-controlled IRI. 
There are very few examples of photo (or any stimulus) control of IRI activity, with Ben and 
co-workers reporting on the development of azobenzene derived carbohydrate 
(fluoro)surfactants which showed moderate, but significantly different, IRI activities between 
the isomerized derivatives.14,15 Sonnischen and co-workers have demonstrated the use of 
azobenzene linkages to deform antifreeze proteins upon exposure to light, modulating their IRI 
activity.16 Gibson and co-workers have used catechols to reversibly assemble polymeric IRIs 
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through co-ordination of Fe3+ ions, leading to pseudo-star polymers with increased activity.17 
However, this method does not enable remote control. Other than these isolated examples, there 
are no reports, to the best of our knowledge, of dynamically controllable IRIs. In contrast, there 
is vast literate on the use of photo-reactive units to control materials properties. Azobenzene 
has featured heavily in the literature as a biological photoswitch, Woolley and co-workers have 
comprehensively reviewed its deployment in this context.18 Importantly, the ability to ‘red-’ or 
‘blue-shift’ the photodimerization wavelengths of azobenzene’s through aromatic functional 
group substitution is particularly important, allowing for application in sensitive biological 
systems where UV exposure would otherwise cause harm. 
Most notably, azobenzene has found use in the photocontrol of the helical conformations and 
solution structures of several proteins and DNA, and has been applied to controlling protein 
cross-linking, DNA transcription, and protein activity.16,19,20 Azobenzene incorporation into 
peptides has also provided for the artificial introduction of a β-like turn in normally a-helical 
structures through the application of a light stimulus.18 This ability to order, and disorder, a 
protein was exploited by Aemissegger and co-workers, who demonstrated that the 
incorporation of an azobenzene motif could solicit the formation of a well defined β-hairpin 
solution structure of a peptide when in the trans conformation, whilst the protein-photoswitch 
conjugate promoted peptide oligomerization when cis.21 Furthermore, azobenzene derived 
tethered ligands have also been applied to the selective activation and deactivation of biological 
receptors and ion channels, such as nicotinic acetylcholine,22 potentially providing a 
therapeutic effect. 
Similarly, anthracene derived species represent a second class of photo-triggers in biological 
molecules, as individual Anthracene units are capable of ‘dimerizing’ into a cycloaddition 
product upon exposure to UV light. Some previous applications have included the 
incorporation of anthracene into DNA binding proteins,23 increasing protein binding affinity 
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when dimerized, whilst glycosylated anthracene derivatives have also shown promise as 
protein cleaving agents when irradiated.24 More recently, anthracene modified DNA has 
demonstrated dissimilar binding towards complementary DNA strands when dimerized, 
illustrating the potential role of DNA duplex formation in the control of a photochromic 
system.25 Intriguingly, despite anthracene chemistry being well established, the conjugation of 
anthracene to biological molecules is however heavily underexplored. To effect a similar 
molecular weight increase, anthracene’s ability to undergo an on-water Diels-Alder [4+4] 
cycloaddition under UV irradiation represents an attractive mechanism,26–28 resulting in a 
doubling of molecular weight for the AFP-conjugate species by the amalgamation of two 
distinct chains in solution. Similarly, the ability of some Safranine dyes to demonstrate IRI 
activity29 – presumably through pi-pi stacking interactions – suggests that a small molecule 
with a conjugated aromatic system would likewise allow for supramolecular assembly in 
solution, and the induction of IRI activity. In addition, the ‘on-water’ effect – whereby certain 
reactions proceed at an accelerated rate in water – which is observed for Diels-Alder 
cycloadditions, would potentially allow for a reversible transformation in aqueous solution. 
This would provide for a tuneable, activatable/deactivatable photoswitch, allowing us to 
control in-situ IRI activity with exposure to UV light. Figure 3.2 As such, this chapter outlines 
the development of photo-switchable IRI inhibitors derived from truncated type I AFP peptides 
based on the consensus repeat sequence, which undergo photo-reversible dimerization by 




Figure 3.2 – A) Molecular orbital diagram showing the photolysis induced excitation of anthracene, 
resulting in; B) a concerted [4πs + 4πs] Diels-Alder cycloaddition of two anthracene units, forming a 



















3.3 – Results and Discussion 
3.3i – Rational design and synthesis of the photoconjugates 
A symmetrically functionalized anthracene derivative with peptide conjugation in the 9- 
position was devised (Figure 3.3), restricting the total number of possible photodimers to 2 and 
favouring the ht isomer, due to the steric hindrance of the protein chains disfavouring hh. Figure 
3.3. In addition, this would allow for a ‘linear’ peptide sequence, running from end-to-end. 
Truncated 11 or 22-residue peptides based on the consensus 11-mer repeat sequence of a Type 
I AFP were obtained from solid phase peptide synthesis; TAANAAAAAAA.31 
 
Figure 3.3 – Photodimerisation of anthracene rings under UV (365 nm) light, giving 2 photoproducts, 
where R is the peptide stretch (N-termini conjugated). 
However, the high proportion of alanine in the Type I antifreeze protein (> 81 %) would, when 
conjugated to the hydrophobic anthracene framework, give poor aqueous solubility. 
Aggregation/micellization of the AFP would likely result in polar solvents, and could be 
expected to precipitate when dimerized in aqueous solution. 
In order to avoid neutralization of activity and hydrophilic/phobic domain obfuscation, a polar 
di-amino acid spacing linker was introduced, to aid solubilisation. Figure 3.4. This would also 
act to prevent the steric bulk of the anthracene rings hindering the proximal threonine hydroxyl 




Figure 3.4 – Proposed monomeric and photo-dimeric products with asparagine (Asn) linkers. 
Asparagine – as one of the most polar amino acids – was initially selected for its enhanced 
solubility, and a synthetic route to the monomeric photoresponsive unit designed, Scheme 3.1. 
Due to the presence of arginine in the ‘variable’ positions of some AFP Type I strains 
(*TAA*AAAAAAA),31 including the species employed here, it was assumed that the 
introduction of this di-amino acid arginine linker directly before the protein would have no 
effect on AFP activity, and would be well tolerated. 
However, as per Scheme 3.1, attempts to prepare the initial arginine-arginine dipeptide 
(Product A) failed. Mass spectrometry of the coupling product indicated a mass fragment of 
466.7 m/z (Product B + H3O
+ + 2 x Acetonitrile), with no observable fragments associated with 
the anticipated product and its mass of 402.21 g/mol-1. Whilst the primary amide side chain of 
arginine is generally stable (including those internalised arginines present within the AFP 




Scheme 3.1 – A) Attempted coupling of arginine derivatives. B) Intramolecular dehydration. 
As such, the absence of the product by mass spectrometry made clear that unforeseen 
dehydration of the amide groups to nitriles had occurred, which upon acid exposure may have 
further oxidised to carboxylic acids and thereby complicated protein coupling. This warranted 
the substitution of arginine for a similarly polar amino acid, lysine, Scheme 3.2. 
 
Scheme 3.2 – Optimised synthetic route for the synthesis of the anthracene-AFP conjugates, and 
prepared candidates (blue box). EDCI - 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide. TEA – 
Triethylamine. MAA – Mercaptoacetic acid. ACN – Acetonitrile. DMF – Dimethyl formamide. THF – 
Tetrahydrofuran. NHS – N-Hydroxysuccinimide. AFP-Antifreeze peptide. TFA – Trifluoroacetic acid. 
Preparation of product 4 was expedient and simple. Removal of the Fmoc protecting group in 
the presence of a methyl ester to give intermediate 2 was achieved through the combinative use 
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of mercaptoacetic acid (MAA) and sodium methoxide (DBU is a viable non-nucleophilic 
alternative). The avoidance of secondary amines (usually used for Fmoc deprotection) 
prevented the inadvertent cleavage or amidation of the methyl ester, with the mercaptoacetic 
acid effectively scavenging the dibenzofulvene (DBF) by-product produced. The use of heat 
(50 ºC) is however essential, as this step will fail to proceed at room temperature (as observed 
by LCMS). Similarly, the conjugation of anthracene and lysine to give 3 fails to proceed in 
dichloromethane at both room temperature and at 60 ºC; and so DMF is required. 
Prior to conjugating the antifreeze peptide to the photoresponsive unit, it was necessary to first 
estimate the overall solubility of the final AFP-photoconjugate. An alanine probe was therefore 
prepared. Although AFP Type I is water soluble, it has a defined secondary structure and is α-
helical, despite being comprised of >70% alanine. Poly(alanine), however, is notoriously water 
insoluble, and has the propensity to form β-sheets. As such, it was necessary to ensure that the 
AFP-(Lysine)2-Anthracene species would remain soluble when conjugated, despite the high 
proportion of alanine in the 11 and 22 residue stretches of AFP (>81%). By synthesising and 
conjugating poly(alanine), it would be possible to determine to model the solubility of the final 
conjugates. Scheme 3.3. 
 
Scheme 3.3 – In-situ synthesis of poly(alanine) via N-Carboxyanhydride ROP. 
Oligo alanine was obtained by the in situ ring opening polymerization of L-alanine N-carboxy 
anhydride (NCA). To enable NCA formation, the method of Endo et al.32 was used whereby 
the carboxylic acid was activated by functionalisation with para-nitrophenyl chloroformate. 
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Subsequent addition of benzyl amine (as the initiator) in a [M]:[I] ratio of 0.4:1 led to the 
formation of the NCA, inducing ring opening polymerization. Poly(alanine) was isolated with 
a DP of 8, Mn of 790 g.mol-1 and a low dispersity of 1.1 (likely resulting from fractionation 
during dialysis). This molecular weight was close to that of AFP11 and hence was suitable for 
initial studies. 
Attachment of the poly(alanine) stretch to 4 was achieved by condensation coupling and the 
conjugate was observed by mass spectrometry at 1613.8 m/z (Experimental), and when 
deprotected, was soluble in aqueous solution at a concentration of 3.5 mg.mL-1. This indicated 
that the similarly hydrophobic and alanine rich antifreeze peptides would likely have good 
solubility when conjugated.  However, the conjugate was visibly aggregative in phosphate 
buffered saline, seemingly demonstrating better solubility when in saline alone (0.137 M 
NaCl), and hence saline was used for all subsequent IRI activity studies. 
Attachment of the truncated antifreeze protein (e.g. AFP22) to 4 was then performed, typically 
by the preparation of the N-hydroxysuccinimide ester, followed by NHS displacement by the 
N-terminus of the peptides. Due to the presence of threonine in the AFP peptide stretch, 
subsequent hydrolysis by sodium methoxide followed, as despite the unreactivity of 
threonine’s α-alcohol group, it was necessary to ensure that it had not formed any unwanted 
ester linkages. The Boc groups were subsequently removed with hydrochloric acid to give the 
final products (6a; AFP11 / 6b; AFP22) as the dihydrochloride salt, which were dialysed to 
remove low molecular weight contaminants, reacidified, and isolated as a solid salt. Mass 
spectrometry of the final AFP-22 conjugate indicated an absence of unconjugated protein 
(which possesses a high molecular weight, above the MWCO of the dialysis tubing), therefore 
indicating complete conversion. 
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Importantly, it was found that the dialysis bags continued to fluoresce under UV light (265 nm) 
after 72 hours, indicating retention of a high-molecular weight anthracene motif and thus 
indicative of successful conjugation. High resolution mass spectrometry of 6b indicated the 
successful attachment of the peptide stretch, exhibiting several indicative fragments (Table 
3.1), notably at 556.3 m/z (Mass + 4H+ + 2H2O). Furthermore, the free AFP22 peptide starting 
material (Appendix, 864.74 m/z) was no longer visible, Figure 3.5. High degrees of 
fragmentation were observed, given the many possible ions produced during the mass 
spectrometry of a protein. 
 
Figure 3.5 – Anthracene-AFP22 HR/LCMS spectra. Annotated signals in Table 3.1. 
The low intensity / minor signals (< 0.2 Normalised Arb) in the 300 – 1100 m/z range are 
attributable to numerous γ and b fragments in numerous charge states, and are typical of a 
charged protein sample. 
  












































# Proposed ion fragment/charge m/z(OBS) m/z(EXPECTED) % Intensity 
1 XKK2+ 231.0 231.2 20 
2 XKKT2+ (K Sidechains: =NH2+) 279.2 280.1 48 
3 a5
+2 – H 301.1 302.7 52 
4 b5-H2O
+2 307.3 307.7 81 
5 XKKTA+2 317.3 317.3 100 
6 b9
+3 321.3 320.5 32 
7 b11-H2O
+3 361.2 361.9 58 
8 a11
+2 – H2 539.3 537.3 22 
9 TAANAAA-H2O 553.5 553.3 35 
10 Anthracene-AFP22 + 4H
+ + 2H2O 556.3 556.8 64 
11 b18
+3 557.3 558.0 27 
12 b12
+2 586.3 586.8 20 
13 b6-H2O 685.4 685.4 39 















Table 3.1 – Anthracene-AFP22 HR/LCMS major fragments. X = Anthracene unit. 
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3.3ii – Characterisation and IRI activity of the 
photoconjugates 
With the anthracene conjugates to hand, their photo-responsive behaviour could be explored. 
Figure 3.6 shows the UV-Vis absorption spectra of the unconjugated anthracene-dilysine 
dihydrochloride salt in both water and methanol. As per literature precedent, the classical 
anthracene multiplet in the UV-Visible 340 – 390 nm region, with λmax ≈ 365 nm, in both H2O 
and MeOH. 
 
Figure 3.6 – UV-Vis Spectra of unconjugated anthracene-dilysine dihydrochloride in A) H2O and B) 
MeOH. 
In order to establish the extent of dimerisation upon irradiation and ensure complete formation 
of the photoproduct, UV exposure trials were then conducted, Figure 3.7. The anthracene-
dilysine-poly(alanine) photoconjugate, 6c, hereafter referred to as PC-Ala, was initially used 
to trial the photo dimerization processes. After 24 hour exposure of the PC-Ala in aqueous 
solution, to both a High Powered UV-CrossLinker and a Fibre Optic UV lamp (both at 365 
nm), a complete loss of the multiplet in addition to the loss of the satellite peak at 255 nm was 
observed. This is consistent with cycloaddition induced dimerization of the anthracene motifs 
and provided proof of principle that the peptide conjugation does not inhibit this process due 
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λmax 366 nm (~ hv)
1 mg.mL-1
λmax 364 nm (~ hv)
1 mg.mL-1
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to steric hindrance. This ultimately corroborates the concept and viability of the on-water 
photoswitch for IRI. 
 
Figure 3.7 – Irradiation trials of the PC-Ala photoconjugate. 
The two peptide candidates; 6a (PC-AFP11) and 6b (PC-AFP22) were subsequently irradiated 
in pure water under UV 365 nm light, and after 1 hour, complete conversion to the dimerised 
product was observed by UV-Vis spectroscopy, Figure 3.8. Complete loss of the triplet was 
again observed, in conjunction with a shift in the satellite peak. Importantly, when irradiated, 
no visible solution change occurred – ruling out inadvertent precipitation of the photo product 
dimer, which would otherwise impact upon concentration. 
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Figure 3.8 – Irradiation effect upon the UV-Vis spectra of the Anthracene-AFP photoconjugates. 
Fluorescence analysis of the PC-AFP22 species further exhibited a 72% decrease in 360/40 nm 
emission post irradiation, further indicating successful dimerisation. Mass spectrometry 
monitoring of the photo-dimerization process showed complete removal of the undimerised 
monomers, but no peaks associated with the dimer products were observed. Therefore, HPLC 
was used. HPLC analysis of the PC-AFP22 in its dimerised state relative to an undimerised 9-
ACA control, Figure 3.9, indicated the presence of the dimeric form only (without prominent 
secondary signals), as corroborated by literature confirming that a photo-driven process can be 
used to control the size of the AFP conjugates.33,34 
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Figure 3.9 – HPLC Spectra of A) 9-ACA Control; and B) PC-AFP22 (6b) Dimer at 213 nm. 
Circular dichroism (CD) spectroscopy was employed to further investigate the dimerization 
process. Figure 3.10. Free AFP11 showed a small degree of β-sheet character, as suggested by 
fitting analysis (ESI) and corroborated by literature,35 as would be expected for a short alanine-
rich stretch. Free AFP22 was closer in nature to an α-helix (peak at 222 nm) which is seen for 
full length Type I AFP. These differences in secondary structure are crucial to understanding 
the observed IRI activity (discussed below). When conjugated to the anthracene-dilysine, the 
PC-AFP22 monomer had similar features to the free peptide but showed slight shifting and a 
stronger inclination in the second band at ~ 235 nm, implying some deviation in the secondary 
structure as a result of the attachment of the anthracene unit. This is possibly a result of helical 
seeding by the lysine residues and/or contributions from the aromatics in the 190 – 200 nm 
region. When irradiated with UV light (to induce dimerization), the same PC-AFP22 species 
lost its CD signature but retained a slight inclination of its former (unirradiated) signal 
morphology. Given the system possesses a central chromophore which is geometrically achiral, 
it is possible that it only has a small electronic chirality arising from coupling with the peptide 
chromophores, as a result, the induced CD could be expected to be comparatively small – 
further corroborating dimerisation.36 
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 PC-AFP22 (6b) Dimer
 
Figure 3.10 – CD Spectra of Anthracene-AFP Conjugates in H2O. 
With the photo-controlled dimerization process confirmed, the peptides were then evaluated 
for IRI activity. IRI activity was determined by the ‘splat’ assay, whereby a polynucleated ice 
wafer is annealed at – 8 °C, and the average crystal size determined after 30 minutes. Smaller 




Figure 3.11 – A) Effect upon PBS ice crystal size of AFP Type I (2 µg.mL-1). B) Effect upon saline ice 
crystal size by the PC-Ala photoconjugates (both at 3.5 mg.mL-1). IRI activity measured as a function 
of solute concentration. MGA = Mean grain area relative to a PBS or saline control, expressed as %. 
Error bars represent the ± standard deviation from three independent measurements. 
In comparison to type I antifreeze protein (Figure 3.11A) – a naturally occurring AFP with 
significant potency at very low concentration (9% MGA at 2 µg.mL-1) – it was found that the 
negative control – PC-Ala – had essentially no activity (and was statistically similar) in both 
the monomeric and dimerised states at 3.5 mg.mL-1, exhibiting > 80 % MGA at its upper limit 
(Figure 3.11B). This confirmed that the anthracene-dilysine motif conjugated to a homopeptide 
had no intrinsic IRI activity (in spite of its amphipathy)37,38,39, and this alanine conjugate was 
therefore employed as a negative control. In contrast to AFP type I, which is comprised of 40 
residues (sequence; DTASD(A)7T(A)10TAKAAAEAAAATAAAAR), the simplified free 
antifreeze peptides of 22 and 11 residues (repeat sequence; TAANAAAAAAA) were both 
found to have no activity in solution at their solubility limits of 0.9 and 1 mg.mL-1, respectively. 
Figure 3.12. 
Similarly, when conjugated to the anthracene-dilysine photounit, the PC-AFP11 species showed 
no activity in either the monomeric or dimeric state (solubility limit 1 mg.mL-1), and was 
statistically worse than PC-Ala control. This is ultimately unsurprising, given that it has been 
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previously reported that simply attaching (supposedly IRI active) proteins to nanoparticles or 
other central cores does not increase IRI activity.40,41–43 
 
Figure 3.12 – A) Effect upon saline ice crystal size of the native AFP11 and PC-AFP11 derivatives (both 
at 1 mg.mL-1). B) Effect upon saline ice crystal size of the native AFP22 (0.9 mg.mL-1 – giving very large 
crystals) and PC-AFP22 derivatives (at 0.6 mg.mL-1). IRI activity measured as a function of solute 
concentration. MGA = Mean grain area relative to a PBS or saline control, expressed as %. Error bars 
represent the ± standard deviation from three independent measurements. 
Intriguingly, despite the clear lack of IRI activity for PC-AFP11 and PC-Ala – and free AFP22 
in and of its self – conjugation to give PC-AFP22 resulted in appreciable IRI activity being 
observed. At its solubility maximum of 0.6 mg.mL-1 the monomeric candidate exhibited 35% 
MGA, this potentially represents the first example of an AFP having its activity regulated by 
the addition of an end group. As for full length AFPs, addition of fusion proteins (e.g. as a large 
end-group) results in no change in activity,44 and the same is observed for double hydrophilic 
blocks of poly(vinyl alcohol).45 This potency eclipses the observed activity reported for the 
optimised poly(Fulvo-co-Diol) 17 kDa species previously reported by us,46 representing a 
highly potent IRI inhibitor at sub-milligram concentrations, and is comparable with the activity 
of shorter chains of PVA (n=56) – Figures 3.13 and 3.14 (Data set provided by Congdon and 























































































free AFP22 in-particular, which when coupled with the large bulky anthracene hydrophobic 
domain – and the associated lysine units – has seeded a particularly amphipathic conformation 
and a stabilised secondary structure (optimised for ice face interaction). 





























 AFPI in PBS
 PC-AFP22 Monomer in Saline
 PC-AFP22 Dimer in Saline
 PVA 56
 
Figure 3.13 – Comparative % MGA of AFP Type I and the anthracene-AFP22 derivatives, relative to 
PVA 56. IRI activity measured as a function of Log solute concentration. MGA = Mean grain area relative 




  Figure 3.14 – Comparison between the undimerised and dimerized anthracene-AFP22 conjugates 
and free AFP22. 
Photodimerisation however, leading to a head-to-head peptide orientation, had a very weak 
effect on the IRI activity of the PC-AFP22 candidate. Despite dropping to 52 % MGA post-
irradiation, the data was statistically identical to the monomer, with both candidates losing their 
effect completely below 0.3 mg.mL-1 – indicating a very narrow activity window. 
In order to determine the structural phenomenon responsible for inferring IRI activity upon the 
PC-AFP22 series, attempts were made to elucidate solution structures of the candidates. 
Due to the perceived ability of the monomeric candidates to undergo pi-pi stacking interactions, 
potentially forming a supramolecular architecture in solution, dynamic light scattering (DLS) 
experiments were employed. Table 3.2. 
Sample (Saturated in H2O) Averaged Z-Avg (d.nm) Averaged Counts 
PC-AFP22 Undimerised (0.6 mg.mL
-1) 1352.0 8454.2 
PC-AFP22 Dimerised (0.6 mg.mL
-1) 1680.7 267.6 
Native AFP22 (0.9 mg.mL
-1) 1259.0 132.4 
Native AFP11 (1.0 mg.mL
-1) 392.6 229.2 
Table 3.2 – DLS Data for the PC-AFP22 photoconjugates. 
The free AFP22 peptide was found to have a larger diameter in comparison to the free AFP11, 











β-sheet. Both PC-AFP22 species had proximal Z-averages, with the dimerised derivative 
showing a slight increase which would be expected of the larger unit. However, interestingly, 
the undimerised equivalent shows a very large counts recording of around 8500 versus 270 for 
the dimer. As a fit of the number of objects ‘hit’ by the laser, this may indicate that there are a 
very large number of monomer units in close proximity in solution. This may indicate the 
formation of fibres in solution as a result of pi-pi stacking interactions, which would be 
impacted in the photodimer. In order to further investigate the possibility of fibre formation in 
solution, attempts to analyse the solution structure of the PC-AFP22 species by Small-angle X-
Ray Scattering (SAXS) were ultimately unsuccessful. The low saturated solution concentration 
of the photoconjugate fell below the detection limit of the instrument (Figure 3.15). 
 
Figure 3.15 – SAXS Data of the AFP22-PC irradiated and unirradiated samples, after background 
buffer subtraction. Performed and Graphed by Dr. Steven Huband. 
Similarly, low temperature wide-angle x-ray scattering (WAXS) studies further failed to 
signify any difference between the two samples (Figure 3.16). Hexagonal ice was formed 
during the freezing of our control sample (saline) and this was compared to the ice formed 
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when the irradiated and non-irradiated samples were frozen, potentially indicating differences 
in the structures of the ice produced. This would have allowed us to infer information on 
potential supramolecular ordering of the photoconjugates. 






























Figure 3.16 – Low temperature WAXS X-Ray diffraction patterns between the frozen irradiated and 
unirradiated PC-AFP22 species at the saturated concentration versus a saline control. Performed and 
Graphed by Alice E. R. Fayter. 
However, the diffraction patterns of the two samples are effectively identical, and both 
resemble hexagonal ice, similar to the control. Peaks are present at the same (characteristic) 
angles for each sample (22.75 °, 24.6 °, and 26 °, corresponding to ice faces 100, 002, 101, 
respectively). As such, differences between the samples could not be determined by X-ray 
117 
scattering. The differences in intensity between the samples can be attributed to a percentage 
of the crystallites orienting to diffract the X-ray beam.  
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3.3iii – Synthesis, characterisation, and IRI analysis of 
poly(vinyl alcohol) photoconjugates 
Preparation of poly(vinyl)alcohol derived candidates was also pursued. It was hypothesised 
that, as the most potent synthetic IRI species discovered to date, incorporating PVA into the 
photoconjugate architecture may provide another exploitable avenue for activatable IRI 
activity, and may permit tuning of PVAs potency. 
Due to the similarity in IRI activity with PVA56, and in order to compare the activity of these 
protein-conjugates with a polymer-conjugate, a ~ DP11 stretch of poly(vinyl)alcohol was to be 
conjugated to the photoconjugate motif in the same manner. It is well established that a DP20 
stretch of PVA is IRI active, with activity ‘off’ below DP14.48 As such, we hypothesised that 
the formation of a dimer through photoirradiation would result in the formation of a contiguous 
DP22-stretch of PVA from 2 x (inactive) DP11 units, and would potentially result in 
activatable, potent, IRI activity with a greater on/off activity gap. 
Initially, PVAc11-NHS was acquired and the NHS group displaced by 1-amino-3-azido-
propane, to give a reactive azide tether. 4 was functionalised with a complementary alkyne 
unit. Despite literature precedent, attempts to prepare candidate 8 were however hindered by 
the failure of the alkyne-azide click reaction between PVAc11-NH2(CH2)3N3 and 7 to proceed, 
Scheme 3.4, and no product was observed, with 7 remaining visible by LCMS. 
119 
 
Scheme 3.4 – Attempted azide-alkyne ‘click’ to prepare the Anthracene-PVA Derivative. 
A revised synthetic route was subsequently devised, Scheme 3.5. PVAc11-NHS was instead 
functionalised with tert-butyl (2-aminoethyl)carbamate, and the Boc group subsequently 
removed, yielding a free primary amine. This allowed for direct conjugation to the 
photoconjugate motif in the same manner as the AFP candidates. 
 
Scheme 3.5 – Revised synthetic route to the Anthracene-PVA Derivative. 
As previous, 9 (PC-PVA) was subsequently dialysed, reacidified, and reduced to a solid salt, 
in 25% yield. It was again found that the dialysis bags continued to fluoresce under UV light 
(265 nm) after 72 hours, indicating retention of a high-molecular weight anthracene motif and 
thus indicative of successful conjugation. High resolution mass spectrometry of PC-PVA again 
indicated the successful attachment of the PVA stretch, exhibiting numerous fragment ions 
(Figure 3.17 and Table 3.3). Furthermore, the free PVAc11-NH2 starting material was no longer 
visible, with loss of the characteristic Gaussian Distribution of PVAc fragments.  
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The mass of broad, low intensity / minor signals (< 0.2 Normalised Arb) in the 200 – 2000 m/z 
range are attributable to the unprotected PVA fragments which fly poorly. 
 
Figure 3.17 – Anthracene-PVA HR/LCMS spectra. Annotated signals in Table 3.3. 
  







































# Proposed ion fragment/charge m/z(OBS) m/z(EXPECTED) % Intensity 
1 HSHCOH(PVA)5
+ - H2O 266.2 266.1 79 
2 XKK(Z)+2 (Na) 282.2 282.6 43 
3 HSHCOH(PVA)5
+ (K) 321.2 322.1 32 
4 XKK(Z)(PVA)1
+2 – H2O (K) 339.2 339.6 39 
5 XKK(Z)(PVA)2
+2 – H2O (K) 361.2 361.6 40 
6 XKK(Z)(PVA)4
+2 (K) 413.3 414.7 100 
7 XKK(Z)(PVA)6
+2 (H3O
+) 429.2 429.8 68 
8 HSHCOH(PVA)7
+ (H+) – H2O 441.3 442.2 56 
9 HSHCOH(PVA)10
+ (H+) – H2O 485.3 486.2 24 
10 XKK(Z)(PVA)3
+ (Na) – H2O 669.4 668.4 52 
11 XKK(Z)(PVA)2
+ (Na) 685.3 686.4 30 
Table 3.3 – Anthracene-PVA HR/LCMS major fragments. X = Anthracene unit, Z = Linker. 
As per previous, PC-PVA was irradiated in pure water under UV 365 nm light, and after 1 
hour, complete conversion to the dimerised product was observed by UV-Vis Spectroscopy, 
Figure 3.18. Again, no visible solution change occurred. 
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Figure 3.18 – Irradiated PC-PVA Photoconjugate. 
Dimerisation was further confirmed by HPLC (Figure 3.19), as above, with only the dimeric 
species observed. 
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Figure 3.19 – HPLC Trace of Dimerised PC-PVA Photoconjugate at 213 nm. Control in Figure 3.9A. 
The dimerised PC-PVA demonstrated a less significant 36% decrease in 360/40 fluorescence 
after irradiation, but had markedly lower initial fluorescence intensity as the monomer. When 
also coupled with the weaker intensity of the anthracene ‘triplet’ banding of the PC-PVA 
candidate (compared to the PC-AFP22) by UV spectroscopy, Figure 3.20, this points towards 
the well-established phenomenon of fluorescence quenching, which is associated with PVA. 
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Figure 3.20 – Comparison of Unirradiated PC-AFP22 and PC-PVA Photoconjugates. 
However, activity was ultimately disappointing. It was clear that whilst possessing greater 
solubility (of the order of 5.7 mg.mL-1), these species did not hold any meaningful IRI activity, 
with crystals in the presence of the undimerised candidate consistently ~ 70 – 80% of their 
original size across the concentration range. Dimerisation resulted in generally weaker activity, 
and at lower concentration, seemingly resulted in the growth of ice crystals above and beyond 
PBS alone. Figure 3.21. 
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Figure 3.21 – ‘Splat’ Assay of the dimerised and undimerised PC-PVA photoconjugate. IRI activity 
measured as a function of solute concentration. MGA = Mean grain area relative to a saline control, 
expressed as %. Error bars represent the ± standard deviation from three independent measurements. 
PVA is however well recognised as being intolerant to functionalisation, with often minor 
structural modifications resulting in the sudden loss of IRI activity.47 The incorporation of a 
large hydrophobic central ‘core’ – the anthracene unit – restricting the rotational freedom of 
the PVA to explore the ice crystal face, and thereby also acting as modification preventing the 
formation of a truly contiguous PVA stretch, is likely a key problem. 
Circular dichroism analysis of both the dimerised and undimerised poly(vinyl)alcohol 
derivatives failed to demonstrate any appreciable CD Spectra (Appendix A), whilst DLS 




Sample (~ 1 mg.mL-1 in H2O) Averaged Z-Avg (d.nm) Averaged Counts 
PC-PVA Undimerised 638.2 148.2 
PC-PVA Dimerised 565.2 292.6 
Table 3.4 – DLS Data for PC-PVA photoconjugates. 
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3.4 – Conclusions 
Four IRI inactive species; poly(alanine)8, poly(vinyl alcohol)11, and two truncated antifreeze 
peptides of 11 and 22 residues – and comprised of the same repeat sequence as observed in the 
native AFP type I protein – were each conjugated to a rationally designed anthracene 
photoresponsive unit featuring a solubilising di-lysine linker. 
Conjugation of these species did not introduce any IRI activity upon the poly(alanine), PVA, 
or AFP11 candidates, and irradiation of the conjugates with 365 nm light leading to the 
formation of photodimers also failed to induce IRI. The free poly(alanine), AFP11 and AFP22 
peptides were also found to be IRI inactive. PVA being intolerant to functionalisation and AFP-
11 being β-sheet like would account for this. However, functionalisation of the AFP22 stretch 
with the anthracene-di-lysine unit successfully introduced IRI activity to the conjugate, of 
similar order and potency to short PVA chains (n=56) at low concentration (35% MGA at 0.6 
mg.mL-1). Activity of this order is previously unreported for synthetic candidates and may 
represent an exploitable avenue of synthetic space in the preparation of future, hyper-potent 
AF(G)P mimetics. This result further shows that it may be possible to reduce antifreeze proteins 
to their basic repeat unit, so that they are accessible by solid phase peptide synthesis rather than 
recombinant expression, with modulable activity by the addition of end-group units. We 
hypothesise that this enhancement was due to the anthracene stabilising the secondary structure 
in the short peptide, supported by circular dichroism measurements. 
However, irradiation of the conjugate led to an 18% drop in IRI activity upon photodimer 
formation, which was confirmed by UV-Vis and HPLC. As suggested by dynamic light 
scattering experiments, this activity drop may be attributed to the impaired ability to form a 
supramolecular solution structure (as observed in Safranine O), due to less efficient pi-pi 
stacking as a result of disrupted aromaticity in the photodimer product, resulting in a weaker 
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ice face interaction. However, whilst the ‘activity gap’ between the photodimer and monomer 
candidates were statistically within error, the clear difference in ice crystal size suggests that 
this candidate ultimately represents the first species devised to date with an appreciable IRI 
disparity when irradiated, relative to the nearest literature precedent. This species may serve as 
the future basis for a highly potent switchable inhibitor with an enhanced activity gap, with 
applications in cryosurgery.  
129 
3.5 – Experimental 
Materials 
NHFmoc-Lys-ε-(NHBoc)-OH, N-α-Boc-L-asparagine, L-asparagine tert-butyl ester 
hydrochloride were purchased from Fisher Scientific UK Limited (Loughborough, UK) and 
NH3Cl-Lys-ε-(NHBoc)-OMe was purchased from Fluorochem Limited (Glossop, UK). 
Dichloromethane, EDCI, OxymaPure™, triethylamine, hydrochloric acid solution (12M), 
sodium chloride, sodium hydroxide, sodium hydrogen carbonate, sodium carbonate, 
magnesium sulphate, sodium sulphate, acetonitrile, mercaptoacetic acid, 25% sodium 
methoxide in methanol, methanol, acetone, hexane, 9-anthracene carboxylic acid, dimethyl 
formamide, dimethyl acetamide, diethyl ether, alanine, ethyl acetate, 4-nitrophenyl 
chloroformate, benzylamine, N-Boc-ethylenediamine, 1,4-dioxane, N-hydroxysuccinimide, 
Amberlyst IR120 resin (hydrogen form), DMAP, propargyl alcohol, sodium ascorbate, CuSO4, 
tert-butanol, Amberlyst(R) A26 hydroxide form were purchased from Sigma Aldrich Co Ltd 
(Gillingham, UK). AFP11 and AFP22 were purchased from Peptide Protein Research Limited 
(Bishops Waltham, UK). Celite 545 was purchased from VWR Limited (Lutterworth, UK). 
PVAc was provided by Christopher Stubbs in the Gibson Group (University of Warwick, UK). 
All were used without further purification. Phosphate-buffered saline (PBS) solution was 
prepared using preformulated tablets in 200 mL of Milli-Q water (>18.2 Ω mean resistivity) to 
give [NaCl] = 0.138 M, [KCl] = 0.0027 M, and pH 7.4. 
Antifreeze protein type I was provided by Dr. Muhammad Hasan, 
Sequence: DTASDAAAAAAATAAAAAAAAATAKAAAEAAAATAAAAR;  
Mw: 3285.53 g/mol-1. 
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Physical and analytical methods 
1H and 13C NMR Spectra (300 – 400 MHz and 75 MHz, respectively) were recorded using a 
Bruker DPX-300/400 Spectrometer under standard NMR conditions. Chemical shifts were 
recorded in ppm and referenced to solvent residual peaks, using MestReNova NMR 
Spectroscopy software. 
ESI MS experiments were performed on an Agilent 6130B Single QUAD ESI-LC MS 
spectrometer in either positive or negative mode with an H2O/MeOH (80:20) eluent feed, with 
samples dissolved in water, methanol or acetonitrile, unless otherwise stated. 
Absorption UV/Vis (Ultra-violet/visible spectroscopy) spectra were acquired on an Agilent 
Technologies Cary 60 Variable Temperature UV-Vis spectrophotometer at room temperature 
fitted with Holographic Grating (27.5 × 35 mm, 1200 lines/mm, blaze angle 8.6° at 240 nm), a 
double beam, Czerny-Turner monochromator, 1.5 nm fixed spectral bandwidth, full spectrum 
Xenon pulse lamp single source, dual silicon diode detectors, quartz overcoated optics, non-
measurement phase stepping wavelength drive, room light immunity. Analysis undertaken 
using Agilent CaryWin UV Scan software. All sample spectra were acquired in Hellma 
Analytics High Precision Quartz UV Cuvettes. Machine was zeroed and solvent background 
subtracted. 
Irradiation experiments were carried out in a Vilber Lourmat™ Biolink™ BLX UV Crosslinker 
(Vilber, Germany) containing 5 x 8 W tubes (365 nm). 
HPLC experiments were conducted on an Agilent 1260 Infinity II LC System (Bioinert) fitted 
with a quaternary pump and C18 reverse phase column. Detection was carried out with the UV 
module, and the UV lamp set at 213 nm. All samples were dissolved in methanol with an 
injection volume of 100 µL, flow rate of 1 ml/min, and gradient solvent system (Initial: 100% 
MeOH to 50:50% MeOH/H2O), at room temperature, over a 30-minute run time. 
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Circular Dichroism experiments were conducted on a standard Jasco J-1500 CD Spectrometer 
utilising 1 mm quartz cuvettes containing 200 µL of appropriately diluted aqueous sample, 
with measurements taken in the 260 – 180 nm range at a voltage not exceeding 600. Solvent 
(water) backgrounds were subtracted. 
Fluorescence measurements were made using a BioTek Synergy HT multi-detection 
microplate reader and Gen5 software (BioTek Instruments, Winooski, VT). 
Dynamic light scattering was conducted using a NanoZs (Malvern Instruments, UK). Scattered 
light was detected at 173º and the observed count rates recorded. Hydrodynamic radii (where 
appropriate) were determined using the manufacturer's software. Diameters are an average of 
3 measurements using at least 10 scans. 
SAXS and WAXS experiments (performed by Dr. Steven Huband and Alice E. R. Fayter, 
respectively)  were carried out on a 5m Xenocs Xeuss 2.0 SAXS instrument equipped with 
dual microfocus (Cu/Mo) sources and a Pilatus 300K hybrid photon counting detector. A 




Solubilization of insoluble samples for analysis 
Insoluble samples for splat and instrument analyses were made up in a pure water solution (1 
mL) and centrifuged (10K RPM, 10 minutes). The supernatant was then wholly removed and 
reduced to dryness in a glass phial. The net weight difference of the phial was then calculated 
– giving the mass of material soluble in pure water (1 mL) at a saturated concentration. Either 
saline or PBS (as applicable, 1 mL) was then added, vortexed (and complete re-suspension 
confirmed), to give a wholly soluble solution of known concentration in saline/PBS. 
Ice recrystallization inhibition (splat) assay 
Ice recrystallization inhibition was measured using a modified splat assay.1 A 10 µL sample of 
the species of interest, dissolved in PBS or saline buffer (pH 7.4 or 7, respectively), was 
dropped 1.40 m onto a chilled glass coverslip, resting on a thin aluminium block placed on dry 
ice. Upon hitting the coverslip, a wafer with diameter of approximately 10 mm and thickness 
10 µm was formed instantaneously. The glass coverslip was transferred onto the Linkam 
cryostage and held at -8oC under N2 for 30 minutes. Photographs were obtained using an 
Olympus CX 41 microscope with a UIS-2 20x/0.45/∞/0-2/FN22 lens and crossed polarizers 
(Olympus Ltd, Southend-on-Sea, UK), equipped with a Canon DSLR 500D digital camera. 
Images were taken of the initial wafer (to ensure that a polycrystalline sample had been 
obtained) and again after 30 minutes. Image processing was conducted using Image J, which 
is freely available (National Institutes of Health, Bethesda, MD). In brief, the number of ice 
crystals in the field of view was measured, and the measurement repeated for three independent 
wafers. The average (mean) of these three measurements was then calculated to find the mean 
grain area (MGA). The average value and error was compared to that of a PBS or saline buffer, 




Synthesis of methyl N2-(N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N6-(tert-
butoxycarbonyl)-L-lysyl)-N6-(tert-butoxycarbonyl)-L-lysinate (1) 
 
NHFmoc-Lys-ε-(NHBoc)-OH (0.5 g, 1.07 mmol) was dissolved in DCM (20 mL) with stirring, 
to which EDCI (0.246 g, 1.2 eqv, 1.28 mmol), OxymaPure™ (0.182 mg, 1.2 eqv, 1.28 mmol), 
and TEA (0.18 mL, 1.2 eqv, 1.28 mmol) were added. NH3Cl-Lys-ε-(NHBoc)-OMe (0.348 g, 
1.1 eqv, 1.17 mmol) was subsequently added, and the reaction mixture stirred at RT for 18 
hours. The crude mix was subsequently extracted with dilute hydrochloric acid solution (x2 , 
25 mL, pH 5 – 6), then saturated sodium hydrogen carbonate solution (x2, 30 mL), and finally 
brine (x1, 30 mL). The organic phase was dried over MgSO4, filtered, and condensed in vacuo. 
The white solid was then crystallised from diethyl ether (30 mL), washed, filtered, and 
condensed in vacuo, yielding a colourless solid. 520 mg (68.6%). 1H NMR (400 MHz, CDCl3) 
δ = 7.82 – 7.21 (m, 8H), 6.82 (s, 1H), 5.71 (s, 1H), 4.75 (s, 2H), 4.56 (s, 1H), 4.38 (d, J = 5.7 
Hz, 2H), 4.21 (t, J = 6.7 Hz, 2H), 3.73 (s, 3H), 3.22 – 2.98 (m, 4H), 1.86 (s, 2H), 1.71 (s, 2H), 
1.58 – 1.24 (m, 26H). 13C NMR (100 MHz, CDCl3) δ = 172.71 (MeOC=O), 171.89 (NHC=O), 
156.32 (2 x Boc C=O + Fmoc NHC=O), 143.95 (Fmoc), 141.37 (Fmoc), 127.83 (Fmoc), 
127.21 (Fmoc), 125.22 (Fmoc), 120.08 (Fmoc), 79.27 (C-tert) 67.27 (COC=ONH), 54.73 
(alpha-C), 52.53 (OMe), 52.21 (alpha-C), 47.21 (CH-Pent-Fmoc), 40.05, 32.23, 31.59, 29.56, 
29.51, 28.54 (6 x CH3), 22.52, 22.37. m/z (ESI, +ve) Observed 733.5 [100%, Na
+]. 
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Synthesis of methyl N6-(tert-butoxycarbonyl)-N2-(N6-(tert-butoxycarbonyl)-L-lysyl)-L-
lysinate (2) 
 
1 (1.4 g, 1.97 mmol) was dissolved in acetonitrile (10 mL), whilst mercaptoacetic acid (700 
µL, 0.928 g, 10.07 mmol, 5.1 eqv) was added dropwise to a 25% solution of sodium methoxide 
in methanol (900 µL, 0.852 g, 15.76 mmol, 8 eqv) at 0ºC. To this pre-stirred solution, the 
solution of 1 in acetonitrile was added, and the combined mixture stirred for 12 hours, with 
heating at 50ºC. The mixture was then acidified to pH 5 – 6 with hydrochloric acid solution 
(1M) added dropwise, and the precipitated salts were filtered. The filtrate was subsequently 
condensed in vacuo, redissolved in methanol (5 mL), and the mercaptoacetic acid-
dibenzofulvene by-product precipitated from water (20 mL). The milky-mixture was then 
filtered through a pad of Celite with water eluent, and the filtrate condensed in vacuo. Isolation 
of 2 followed through dissolution of the dry filtrate in acetone (10 mL) and then precipitation 
from hexane (30 mL), giving an off-white solid. 350 mg (36.4%). m/z (ESI, +ve) Observed 
511.4 [100%, Na+]. 1H NMR (300 MHz, CH3OH+D2O) δ = 4.18 (t, J = 6.7 Hz, 1H), 3.82 (s, 
1H), 3.55 (s, 3H), 2.90 – 2.77 (m, 4H), 2.02 (d, J = 2.4 Hz, 1H), 1.77 – 1.52 (m, 4H), 1.35 – 
1.09 (m, 26H). 13C NMR (101 MHz, MeOD) δ = 173.76 (MeOC=O), 173.16 (NHC=O), 158.51 
(2 x Boc C=O), 128.50, 127.96, 126.12, 120.72, 79.82 (C-tert), 58.29, 55.94, 54.68, 53.28, 
52.79 (OMe), 41.01, 34.91, 33.63, 31.97, 30.60, 30.44, 28.79 (6 x CH3), 24.12, 23.12, 18.38. 
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Synthesis of methyl N2-(N2-(anthracene-9-carbonyl)-N6-(tert-butoxycarbonyl)-L-lysyl)-
N6-(tert-butoxycarbonyl)-L-lysinate (3) 
 
Anthracene-9-carboxylic acid (356 mg, 1.60 mmol, 2.2 eqv) was dissolved in DMF (30 mL) 
with stirring, and EDCI (154 mg, 0.86 mmol, 1.2 eqv), OxymaPure™ (114 mg, 0.86 mmol, 1.2 
eqv), and TEA (112 µL, 0.86 mmol, 1.2 eqv) were added. 2 (350 mg, 0.72 mmol) was 
subsequently added, and the reaction mixture stirred at RT for 18 hours. The crude mix was 
then condensed to low volume in vacuo ( ~ 5 mL) and diluted with chloroform (30 mL), before 
being extracted with dilute hydrochloric acid solution (x2 , 25 mL, pH 5 – 6), then saturated 
sodium hydrogen carbonate solution (x2, 30 mL), and finally brine (x1, 30 mL). The organic 
phase was then re-acidified to pH 5 – 6 with hydrochloric acid solution (1M) and a column was 
packed with pre-rinsed Amberlyst beads (A26 hydroxide form). The acidified mix was then 
poured through the column, eluting and washing with THF (3 x 10 mL). The collected eluent 
was then dried over MgSO4, filtered, and condensed in vacuo, yielding an orange oil. 140 mg 
(28.2%). m/z (ESI, –ve) Observed 691.4 [100%, M-H+]. 1H NMR (400 MHz, CDCl3) δ = 8.52 
(s, 1H), 8.09 – 7.11 (m, 9H), 5.09 – 4.74 (m, 1H), 4.43 (m, 1H), 4.23 – 3.88 (m, 1H), 3.40 (s, 
3H), 3.23 – 2.97 (m, 5H), 2.11 – 1.58 (m, 9H), 1.55 – 0.76 (m, 26H). 13C NMR (101 MHz, 
CDCl3) δ = 174.54 (MeOC=O), 168.62 (NHC=O), 156.25 (2 x Boc C=O), 154.32 (Anthracene 
NHC=O), 135.56 – 119.72 (Anthracene), 79.07 (C-tert), 57.43, 56.87, 56.49 – 55.84, 54.79, 
52.35 (OMe), 50.32, 46.71, 45.63 – 45.14, 42.30, 41.17, 40.60, 40.02, 39.11, 37.34, 35.60, 
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35.25, 34.06, 33.82, 33.62, 33.47, 32.46, 29.80, 28.45 (6 x CH3), 27.61, 27.42, 26.64, 26.26, 
25.16, 22.60, 22.00, 15.66, 15.43, 15.21, 14.89, 14.23, 13.43. 
 
Synthesis of methyl N2-(N2-(anthracene-9-carbonyl)-N6-(tert-butoxycarbonyl)-L-lysyl)-
N6-(tert-butoxycarbonyl)-L-lysine (4) 
 
3 (140 mg, 0.20 mmol) was dissolved in methanol/water (1:1, 20 mL) and a large excess of 
sodium hydroxide added (500 mg, 62.5 eqv), and the mixture stirred at RT for 18 hours. The 
mixture was then acidified with hydrochloric acid solution (1M), dropwise, until pH 5 – 6. The 
mixture was then condensed in vacuo, and the product precipitated and isolated from acetone, 
giving a pale yellow solid. 100 mg (73.7%). m/z (ESI, -ve) Observed 677.3 [100%, M-H+]. 1H 
NMR (300 MHz, CDCl3) δ = 8.42 – 7.00 (m, 9H), 5.22 (s, 1H), 4.84 (s, 2H), 4.59 – 3.92 (m, 
4H), 3.83 (s, 1H), 3.68 – 3.51 (m, 1H), 3.12 – 2.81 (m, 5H), 2.65 (d, J = 5.5 Hz, 1H), 1.97 – 
1.52 (m, 4H), 1.52 – 1.11 (m, 29H). 13C NMR (75 MHz, CDCl3) δ = 173.95 (NHC=O), 157.74 
(2 x Boc C=O), 156.89 (Anthracene NHC=O), 135.71 – 125.24 (Anthracene), 79.16 (C-tert), 




Synthesis of poly(alanine) 
 
Alanine (0.25 g, 2.81 mmol) was dissolved in ethyl acetate (40 mL) with sodium hydrogen 
carbonate (0.286 g, 5.62 mmol, 2 eqv). 4-Nitrophenylchloroformate (0.689 g, 3.37 mmol 1.2 
eqv) was subsequently added with stirring, and the mixture heated at 45ºC overnight. The solids 
were filtered and the filtrate washed with saturated sodium hydrogen carbonate solution (20 
mL), and then with water (5 x 40 mL). The organic phase was then condensed in vacuo. 
Acetone (30 mL) was then added to the solid residue, and the acetone soluble portion removed 
in solution and condensed once more, to give a white solid (100 mg) which was then dissolved 
in dry DMAc (15 mL). The solution was subsequently sparged under a flow of dry nitrogen 
and heated at 60ºC for 18 hours, in the presence of benzylamine (0.1 mL) under N2. After 
which, the solution was precipitated from water (35 mL) and centrifuged (10k RPM, 10 
minutes), the solution decanted, and the precipitate re-dissolved in acetone (5 mL) and re-
precipitated from water (45 mL) x 5. The precipitate was isolated as an oily brown solid, which 
was dissolved in methanol and negatively dialysed (1 kDa MWCO) to yield 80 mgs of 
poly(alanine). (32%). MnSEC 790 g.mol






PVAc11-NHS (0.85g, 0.66 mmol, Mn 1294 g/mol
-1, 1.2 Đ) was dissolved in DMF (5 mL) and 
N-Boc-ethylenediamine (210 mg, 210 µL, 2 eqv, 1.31 mmol) added, and the mixture stirred 
overnight. The solution was then condensed in vacuo, redissolved in acetone (5 mL) and 
precipitated from water (45 mL) five times, and then centrifuged (11k RPM, 20 minutes). The 
residual mass was taken up into acetone (5 mL) and condensed again, to give an orange/brown 
solid. 470 mg (56.1%). m/z (ESI, +ve) Observed 1320.6 [20%, DP11 + 2H2O + H
+]. 
Synthesis of 23-((2-aminoethyl)amino)-1-((ethoxycarbonothioyl)thio)-22-methyl-23-
oxotricosan-1,3,5,7,9,11,13,15,17,19,21-undecayl undecaacetate (PVAc11-NH2) 
 
PVAc11-NHBoc (0.47g, 0.37 mmol) was dissolved in 1,4-dioxane (20 mL) and 6M HCl added 
(1 mL), and the reaction mixture stirred overnight. The mixture was subsequently condensed 
in vacuo to give a brown solid. 370 mg (85.5%). m/z (ESI, -ve) Observed 1277.4 [20%, DP11 
+ Acetonitrile + H2O + Cl
-]. 
Representative / Optimised Procedure for Conjugative Coupling 
 
4 (30 mg, 0.044 mmol) was dissolved in dry DMF or DMAc and DCM (1:1, 5 mL) under a 
flow of dry nitrogen, and EDCI (17 mg, 2 eqv, 0.088 mmol) added, followed by N-
hydroxysuccinimide (10 mg, 2 eqv, 0.088 mmol). The mixture was allowed to stir for 30 
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minutes to allow for the formation of 5 in-situ. Then, either the antifreeze protein (AFP-
22•TFA, 5 mg) or the poly(vinyl)acetate (111 mg) species for conjugation was dissolved up in 
dry DMF or DMAc (2.5 mL) under a flow of dry nitrogen, and injected into the main flask, 
followed by a large excess of TEA (100 µL). The flask was then stirred for 4 days under dry 
nitrogen, with heating at 50ºC. The flask was subsequently cooled, exposed to air, and a large 
excess of sodium methoxide/methanol solution added (2 mL) – giving pH 12 and a fluorescent 
pink colour change, and then stirred for 1 hour. After which, the flask was acidified to pH 1 
with HCl (6M), resulting in decolourisation, and stirred for 1 further hour. After the removal 
of the protecting/end groups, the mixtures were then diluted with methanol (3 mL) and water 
(50 mL) and dialysed against water for 3 days (1 kDa dialysis tubing), with regular water 
changes. Upon completion, sedimentation was apparent, and the dialysis bags continued to 
fluoresce under long wave ultraviolet light, indicating the presence of a conjugated/large 
molecular weight anthracene unit within the bag. Both species were then reacidified to pH 2 
with HCl (6M), and condensed in vacuo to give the final photoconjugate products, 6b (AFP-
22, 5.7 mg, 5.7%) and 9 (PVA, 12.5 mg, 25.7%). The initial candidates 6a (AFP-11, 1 mg) and 
6c (Ala8, 3.5 mg) were similarly prepared, but through a modified procedure and were low 
yielding. Mass Spectrometry of 6c (as the Di-ε-Lys-Fmoc protected derivative) indicated a 
single peak present at 1613.8 m/z (100%), corresponding to the [Conjugate Mass + Cl• – H+]. 
Redundant Procedure for the Synthesis of 23-((3-azidopropyl)amino)-1-
((ethoxycarbonothioyl)thio)-22-methyl-23-oxotricosan-1,3,5,7,9,11,13,15,17,19,21-
undecayl undecaacetate (PVAc11-N3) 
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PVAc11-NHS (0.85g, 0.66 mmol, Mn 1294 g/mol
-1, 1.2 Đ) was dissolved in DMF (5 mL) and 
3-azido-1-propanamine added (1.2 eqv, 0.792 mmol 77 µL) with stirring. After 16 hours, the 
reaction mixture was condensed in vacuo, dissolved in acetone (5 mL) and precipitated from 
water (45 mL), three times, giving a brown solid. 640 mg (80.1%). m/z (ESI, +ve) Observed 
1259.5 [45%, DP11 + MeOH + H3O
+]. 




PVAc11-N3 (0.64 g, 0.571 mmol) was dissolved in methanol (20 mL) and a large excess of 
sodium methoxide in methanol (10 mL, 25%) added, and the mixture stirred overnight at RT. 
After which, the solution was passed through a column packed with acidic Amberlyst IR120 
resin (hydrogen form) for neutralisation, and the eluent (pH 7) condensed in vacuo yielding a 
brown solid. 220 mg (58.5%). m/z (ESI, +ve) Observed 673.4 [75%, DP10 + 2H2O + Na
+]. 
Redundant Procedure for the Synthesis of prop-2-yn-1-yl N2-(N2-(anthracene-9-
carbonyl)-N6-(tert-butoxycarbonyl)-L-lysyl)-N6-(tert-butoxycarbonyl)-L-lysinate (7) 
 
4 (50 mg, 0.0737 mmol) was dissolved in DMF (10 mL) and EDCI (1.2 eqv, 0.0884 mmol, 17 
mg) added, followed by DMAP (0.1 eqv, 0.00737 mmol, 1 mg) with stirring. Propargyl alcohol 
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(1.2 eqv, 0.0884 mmol, 5 µL) was then added dropwise, and the reaction mixture stirred for 12 
hours at RT. The crude mix was subsequently extracted with dilute hydrochloric acid solution 
(x 2, 25 mL, pH 5 – 6), then saturated sodium hydrogen carbonate solution (x2, 30 mL), and 
finally brine (x1, 30 mL). The organic phase was dried over MgSO4, filtered, and condensed 
in vacuo, yielding a yellow solid. 50 mg (94.6%). 1H NMR (300 MHz, CDCl3) δ 8.45 – 6.83 
(m, 9H), 4.99 – 4.65 (m, 2H), 3.94 – 3.14 (m, 3H), 3.11 – 2.77 (m, 6H), 2.34 (s, 1H), 1.98 – 
1.29 (m, 28H). 13C NMR (101 MHz, CDCl3) δ 183.28 (Ester), 171.58 (NHC=O), 168.69 
(NHC=O), 156.30 (2 x Boc C=O), 134.24 - 125.63 (Anthracene), 79.24 (C-tert), 54.77, 40.08, 
35.48, 33.31, 32.73, 29.80, 29.80, 28.56, 28.47, 28.43 (6 x CH3), 22.92, 22.03, 21.56, 14.76, 
1.12. m/z (ESI, +ve) Observed 834.6 [100%, Mass + Acetone + Acetonitrile + H3O
+]. 
Failed Procedure for the Synthesis of Anthracene-Dilysine•HCl-PVA Conjugate by 
Alkyne-Azide Click Chemistry (8) 
 
Attempt 1: 7 (50 mg, 0.0698 mmol) was dissolved in a 1:1 solution of water/tert-butanol (20 
mL) and the PVA11-N3 (220 mg) was added with stirring. Sodium ascorbate (0.00698 mmol, 
0.1 eqv, 1.4 mg) in water (100 µL) was added, followed by CuSO4•5H2O (0.00698 mmol, 0.1 
eqv, 1.4 mg) in water (100 µL). The reaction mixture was stirred for 36 hours at RT, and then 
condensed in vacuo. 
Attempt 2: The dry residue was re-dissolved in a 2:1 solution of DMF/water (15 mL) and 
further sodium ascorbate (0.1396 mmol, 2 eqv, 28 mg) and CuSO4•5H2O (0.1396 mmol, 2 eqv, 
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28 mg) were added. The reaction mixture was stirred for a further 24 hours at 60ºC, and then 
condensed in vacuo. 
Failed Synthesis of tert-butyl (tert-butoxycarbonyl)-L-asparaginyl-L-asparaginate (11) 
 
EDCI (0.083 g, 0.431 mmol, 1 eqv) was dissolved in DCM (50 mL) with stirring under a flow 
of dry nitrogen. N-α-Boc-L-asparagine (0.1 g, 0.431 mmol, 1 eqv) and OxymaPure™ (0.0612 
mg, 1 eqv, 0.431 mmol) were then added, followed by L-asparagine tert-butyl ester 
hydrochloride (0.0968 g, 0.431 mmol, 1 eqv). TEA was then added (0.1 mL, 1.66 eqv, 0.712 
mmol), and the reaction mixture stirred at RT for 18 hours. The crude reaction mix was then 
condensed in vacuo, re-dissolved in ethyl acetate (50 mL), and washed with 0.1M HCl (3 x 30 
mL), followed by 1M Na2CO3 (3 x 30 mL), and saturated brine (30 mL). The organic phase 
was then dried over MgSO4, filtered, and condensed in vacuo. m/z (ESI, +ve) Observed 466.7 
[100%, Dehydrated Product + H3O
+ + 2 x Acetonitrile].  
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Rationally designed amphipathic glycopolymers for ice 
growth inhibition 
__________________________________________________ 
4.1 – Chapter Abstract 
This chapter describes the synthesis of a series of facially amphipathic glycopolymers with IRI 
potency. Antimicrobial polymers are known to possess many of the desired structural 
characteristics we hypothesised as necessary for IRI potency – hydrophilicity, hydrophobicity, 
and rigidity.1 Taking inspiration from previous work, four amphipathic monomers derived 
from norbornene and featuring different functionalities at the imide bridgehead were prepared. 
These monomers were (co)polymerized to a variety of molecular weights using Ring-opening 
Metathesis Polymerisation (ROMP) with Grubbs 3rd generation catalyst, and acetate protecting 
groups removed by treatment with methanolic sodium methoxide followed by ion exchange. 
The panel of amphipathic polymers were characterized by SEC, NMR and IR. ‘Splat’ analysis 
of the initial facially amphipathic derivative indicated significant IRI activity at low 
concentration (50 % MGA at 500 µg.mL-1), levels of activity which have only been previously 
reported for PVA and naturally occurring AF(G)Ps. Of the sequentially modified architectures 
prepared, the significance of amphipathy is further asserted, with wholly hydrophilic 
derivatives displaying comparably weaker activity to facially amphipathic versions, which will 
be explored in greater detail. Copolymeric derivatives are also discussed, and were prepared in 
an effort to enhance both the solubility and activity profiles of the candidates, the optimised 
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derivative of which is capable of inhibiting ice growth to 40% MGA at 1.3 mg.mL-1. This level 
of activity is remarkable, indicating that rational design of potent IRI species is possible, and 
that such activity can be feasibly incorporated into macromolecular architectures. Furthermore, 
the absence of dynamic ice shaping in the optimised candidate will be reported, in addition to 
SANS data, which suggests a similarity between the flat amphipathic ice binding surface of 
AFPs and the optimised copolymer – potentially suggesting a mechanistic mode of action.  
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4.2 – Chapter Introduction 
Few IRIs are known, despite intense research in the field, due to a lack of understanding of the 
design principles. PVA,2,3,4 metallohelices,5 and some glycopeptides,6 have shown the most 
promise as synthetic IR inhibitors to date. However, toxicity, relatively low potencies, and 
intolerance to (bio)chemical functionalisation thereby leading to loss of activity, have hindered 
the development and exploitation of the next generation of AF(G)P mimetics. It is clear, that 
to access the next class of highly potent IR inhibitors, a rational design blue-print for activity 
must be devised. However, this task is not trivial. Whilst AFPs have been better characterised 
leading to the identification of defined ice-binding faces via structural biology methods7, there 
are no crystal structures available of AFGPs – which are believed to possess substantially 
different architectures.8,9 As such, the exact structural motifs required for IRI are unknown. 
Solution NMR and circular dichroism studies do however suggest that AFGPs form a 
polyproline II type helix, with the glycans (deemed essential for ice shaping)10 on one face, and 
peptides on the opposite, forming a facially amphipathic structure (Figure 4.1).8 It has emerged 
however in recent literature that this segregated display of hydrophobic/hydrophilic groups, 
rather than the presentation of a distinct ‘ice binding site’ may be the essential feature for IRI 
activity.11–13 
 
Figure 4.1 – (AFGP)n Repeat architecture, showing structural features along a PPII helix. 
In particular, our recent work on polyproline serves as a representative example of a very small 





and the presentation of an amphipathic surface structure, polyproline exhibited moderate IRI 
activity and had markedly improved performance versus poly(hydroxy)proline – asserting the 
need for amphipathy over hydroxyl group presentation alone.14 In addition, molecular 
modelling recently revealed that the hydrophobic face, not the glycans, of AFGP interact with 
the ice, and that the spatial segregation along the polyproline II helix is essential.15 In 
conjunction with polyproline, Gibson and co-workers have further shown that self-assembled 
metallohelicies with ‘patchy’ amphipathy are potent IRIs,5 which supports a hypothesis that 
well defined ice binding domains and hydrogen bonding centres are not essential for IRI.16 
Amphipathy has also been seen to be important in ice nucleation.17 This evidence suggests that 
IRI, but not detrimental dynamic ice shaping,18 could be selectively introduced into new and 
emerging (bio)materials, if precise control over hydrophilic/phobic domains is possible. The 
design of macromolecules with solvent-exposed hydrophobic domains is, however, non-trivial. 
Block copolymeric amphiphiles spontaneously self-assemble into micelles/vesicles to reduce 
hydrophobic domain contact with water, and hence only ‘water loving’ surfaces are exposed.19 
 
Figure 4.2 – Structural flexibility compared between active and inactive glycopeptides. 
In the pursuit of structural mimickery of AFGP, a large number of carbohydrate derived species 
have been developed. Ben and co-workers have demonstrated the potential and IRI potency of 
synthetic glycopeptide mimetics of AFGP 6,20,21,22,23,24 and their application to cell 
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cryopreservation (Figure 4.2A).25,26,13,27 Similarly, Cameron and co-workers have previously 
reported on a series of glycopolymers, which had very weak IRI activity (Figure 4.2B).28 
These species were (unlike AFGP and Ben’s amide rich peptides) highly flexible, with little 
spatial segregation of the hydrophobic backbone and hydrophilic glycosyl units. From this, it 
is clear that in order to mirror the complex architecture of AFGP, featuring both rigidity to 
allow for a spatially segregated hydrophilic and hydrophobic domain, but sufficient flexibility 
so as to not be wholly insoluble, traditional radical polymerisation techniques such as RAFT 
(leading to sp3 hybridised centres) are not apposite. Backbone rigidity is therefore 
advantageous, and so an unsaturated polymer chain, featuring sp2 hybridised centres, would be 
desirable. 
Tew and co-workers have explored the use of structural rigidity in the development of a series 
of facially amphipathic cationic polymers, with opposing positive charges and lipophilic 
domains to mimic the function of antimicrobial peptides.1,29,30  These synthetic mimics of 
antimicrobial peptides (SMAMPs) are thought to cause disruption of the bacterial cell 
membrane by charge permeation, with amphipathy as the prerequisite for potency. Specifically, 
the key design step was the use of ROMP to introduce rigid alkene backbones, balancing the 
polymers hydrophobicity/philicity and thereby maintaining both the overall solubility of the 
material and ensuring the presentation of the hydrophobic faces. These candidates have 
ultimately shown particular potency as potential antimicrobials.1,31 Considering the above 
rationale, we aimed to design and synthesise a locally-rigid, facially amphipathic glycopolymer 
series, utilising ROMP to introduce local rigidity. The anticipated potency would represent a 
blue-print in rational IRI design, demonstrating the ability to incorporate high levels of activity 
into simple macromolecular architectures through the optimisation of defined architectural 
motifs.   
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4.3 – Results and Discussion 
4.3i – Synthesis of amphipathic homopolymers 
In order to probe and validate the structural features necessary to incorporate potent ice 
recrystallisation activity into synthetic polymers, sequentially modified polymers were to be 
prepared. In the first instance, it was desirable to synthesise both a wholly hydrophilic 
derivative and an amphipathic derivative, based on the Tew architecture. It was hypothesised 
that a hydrophilic derivative – lacking a significant hydrophobic domain – would produce little 
to no IRI effect, whilst an amphipathic structure would display greater potency, as has been 
previously asserted in the literature. A wholly hydrophobic derivative on the other hand, was 
neither designed or assessed, as it would have likely demonstrated so little solubility as to make 
analysis impossible. 
 
Figure 4.3 – Proposed structural framework. The solution state structure of AFGP,7 with the 
disaccharide units spatially segregated from the hydrophobic peptide backbone. 
Two monomeric candidates were designed, both containing a hydrophilic carbohydrate 
domain, and with one (the intrinsically amphipathic derivative) containing a hydrophobic 
fulvene ‘fulvo’ motif at the ring bridge head (M1). The other more hydrophilic species, 




Figure 4.4 – Rationally designed monomeric architectures. 
The norbornene-imide was selected due to its versatility and regular exploitation as a ROMP 
monomer, with a high propensity to undergo polymerisation. As such, its preparation by Diels-
Alder cycloaddition and subsequent decoration is well understood and readily achieved.  
Initially, a six-step synthetic route was identified based on the retrosynthetic analysis of the 
desired candidates, Figure 4.5 and Scheme 4.1. The ‘fulvo’ and ‘oxo’ bridge heads represented 
simple, large hydrophobic and hydrophilic units respectively, and the Diels-Alder precursors 
were inexpensive and commercially available. Galactose in particular was selected as the 
carbohydrate motif owing to its presence in AFGP,6,10 with activity believed to stem from its 
hydration profile.32 This would further allow for the subsequent analysis and comparison of 
hydrophilic group substitution and tolerance, enabling a conclusion to be drawn on the 
essentiality and role of the galactose motif in particular. 
 
Figure 4.5 – Retrosynthesis of proposed candidates. 
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As per Scheme 4.1, galactose was to be acetylated under standard conditions with pyridine (1), 
and then regioselectively deprotected at the anomeric position to yield the free hydroxyl group 
(2) for amidation. Initial attempts to perform the acetylation step with ZnCl2 were impractical 
as a result of the harsh conditions (heat and Lewis acidic) yielding a difficult to isolate tar 
which failed to crystallise as expected. Additionally, it was not necessary to set the 
stereochemistry at the anomeric centre during acetylation (with ZnCl2 giving the alpha 
product), as the subsequent steps will render this superfluous. Pyridine was therefore opted for 
preferentially. It was however preferable that the final sugar-conjugate (M1) be stereopure at 
the anomeric centre, therefore avoiding obtaining a random and irregular polymer with 
potentially distorted IRI activity. Importantly, earlier work by Ben and co-workers noted that 
inactivity was induced in C-linked AFGP mimetics by substituting the galactose moiety for 
glucose, implying a potential intolerance to epimerisation in some AFGP mimetics.20,32 
Ammonium carbonate was selected due to its reported selectivity during deacetylation of the 
anomeric centre, giving predominately α-stereochemistry.33,34 The acidic norbornene imide 
(3a/b) would be simultaneously prepared via Diels-Alder [4+2] cycloaddition, and the two 
fragments coupled at the imide nitrogen via the Mitsunobu protocol – giving the protected 
monomer products (M1/M2). Polymerisation was to follow, before acetate deprotection with 
sodium methoxide in methanol, to give the final candidates (6a/b). Grubbs’ third generation 
catalyst was selected to perform the olefin metathesis, due to its superior control over molecular 
weight, polymer dispersity, its improved stability profile with respect to air and moisture, and 




Scheme 4.1 – Initial Synthetic Route. 
It was necessary under the above scheme and conditions to specifically deprotect the sugar 
acetates with NaOMe/MeOH instead of hydrazine, owing to the propensity of the imide ring 
system to otherwise undergo Wolff-Kishner reduction or the latter stage of a Gabriel synthesis. 
Furthermore, it was essential to not deprotect prior to polymerisation, due to both cross-linking 
effects and the risk of premature precipitation often encountered during ROMP with exposed 
hydroxyl groups and increasing molecular weight.39 
The Diels-Alder cycloaddition products, 3a/b, were successfully obtained in 
diastereoisomerically pure yields of 69 % and 64 %, respectively, exclusively giving the 
desired (and superiorly stable) exo,exo isomer owing to thermodynamic control (> 81 ºC).40 
Figure 4.6. Isomeric purity is necessary, due to the weaker ability of the endo,endo equivalent 




Figure 4.6 – 1H NMR (CDCl3) of diastereoisomerically pure exo,exo-fulvonorborneneimide. 
Selective deprotection of the anomeric hydroxyl to give species 2, was however problematic 
in practice. The rate of deacetylation with ammonium carbonate was often slow and 
incomplete, the extent of which was inconsistent and irreproducible, and appeared to give a 
substantial mixture of anomers – contrary to literature precedent (Appendix A). Substitution 
for benzylamine 42 furnished a smoother and complete deprotection, but again provided a 
mixture of the α/β diastereoisomers (Appendix A) which are not readily separable due to their 
similarity. The mixture of isomers were however used ‘as is’ and carried forward to the next 
stage (Mitsunobu coupling), where solely β-stereochemistry was obtained, due to the 
supremacy of neighbouring group participation over backside attack (Scheme 4.2). 
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Scheme 4.2 – Attempted Mitsunobu Synthesis of M1. 
Repeated recrystallisation, as recommended by the literature precedent,1 failed however to 
adequately remove the large quantities of the triphenyl phosphine oxide (TPPO) by-product 
present in the reaction mixture, produced 1:1 with the product (Appendix A). Thin layer 
chromatography (TLC) of the crude mixture indicated a significant abundance of additional 
(unknown) components (Appendix A) complicating separation by column chromatography. 
The crude mixture had broad-spectrum solubility in organic solvents, and proximal Rf values 
were observed between the two main spots, suggesting similar polarity between TPPO and M1.  
Complexation with hot, ethanolic-ZnCl2,
43  had little-to-no effect on removing the contaminant, 
with no crystallisation observed. This suggested the reaction was inefficient, incomplete, and 
would prove difficult to purify. Revision of the synthetic route was therefore necessary to 
provide the monomer in isolatable quantities, Scheme 4.3. 
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Scheme 4.3 – Revised Scheme for the synthesis of M1/2. 
M1/2 were to be instead synthesized by Koenigs–Knorr coupling of acetobromo-α-D-galactose 
(6) with exo,exo-[oxo/fulvene]norborneneimide. Bromination of the galactose pentaacetate 
was efficient, providing a reactive tether of defined stereochemistry, α (100 %), in good yield 
(80 %). 
Initial trials to optimise the coupling process of 3 and 8 were carried out. Attempts to generate 
the phthalate salt of the acidic 3a with potassium hydroxide, followed by a simple displacement 
reaction were not fruitful. In the absence of a carbohydrate activator, the salt was ineffective at 
instigating a simple SN2 displacement of the R-Br bond. Additional attempts with potassium 
carbonate in DMF at both 50 and at 90 ºC also produced no observable product by 1H NMR or 
LCMS. This indicated that the reaction would only proceed through an intermediary oxonium 
ion assisted by a carbohydrate promoter.  
159 
 
Scheme 4.4 – Trialed carbohydrate conjugation strategies A) Preparation of the norborneneimide salt 
in-situ. B) Silver carbonate promotion. C) Iodine (Lewis-acid) promotion.44 
As such, in-situ couplings were attempted. The first, using iodine as a Lewis acid catalytic 
promoter 45,46 in conjunction with potassium carbonate (for imide activation), led to the 
formation of the new monomer product M1. However, this procedure was impractical, 
requiring intricate manipulations and separate preparatory techniques for the imide and 
carbohydrate to avoid neutralisation. 
The second was simpler and efficient. Silver carbonate was identified 47 and in a preliminary 
run, was found to be the most suitable catalyst, capable of activating the imide at ½ an 
equivalent without any sign of orthoester formation by 1H NMR.48,49 The β-stereochemistry of 
the product was ensured by the presence of neighbouring group participation at C2, preventing 
the formation of an α-linkage. This led to the clean generation of M1, under mild, basic 
(K2CO3) conditions. As with the prior method of preparation, the stereochemical outcome is 
preferable, as lacking the increased steric hinderance associated with the alpha-form, M1 was 
expected to be more solvent accessible when polymerised. 
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Scheme 4.5 – Optimised coupling route. 
Now optimised as per Scheme 4.5, M1 was obtained in a yield of 32 % (Figure 4.7), whilst the 
oxo-ether derivative, M2 was obtained through the same procedure at 25 % yield. 
 
Figure 4.7 – 1H NMR (CDCl3) of M1. 
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Polymerisation was subsequently attempted, as per the ring opening metathesis polymerisation 
protocol, Scheme 4.6. 
 
Scheme 4.6 – Mechanism of ring-opening metathesis polymerisation. 
The rate of this homopolymerisation with Grubbs’ third generation catalyst was judged to be 
rapid and non-reversible, with a 1H NMR kinetics study of the unconjugated norborneneimide 
starting material (3) showing an absence of the 6.37 ppm monomeric triplet at time zero, 
indicating instantaneous polymerisation (Appendix A). The alkene proton signals stemming 
from the polymeric backbone in the 6.54 ppm region were consistent and unchanged over this 
interval, further suggesting that no ring closing metatheses occurred. 
In order to prepare the macromolecular architectures of interest, polymerisation of the 
candidates M1 and M2, with Grubbs’ 3rd Generation Catalyst in THF under inert atmosphere 
then followed. Table 4.1. Molecular weight targeting yielded two polymeric candidates at 

















poly(Fulvo) 25,000 10,300 1.21 28 100 
poly(Oxo) 10,000 7,300 1.18 22 100 




4.3ii – The IRI activity of the amphipathic homopolymers 
Utilising the ‘splat’ cooling assay, as first pioneered by Knight and co-workers,3 the 
homopolymeric candidates could be assessed for IRI activity. In short, a 10 µL sample of the 
species of interest, dissolved in PBS buffer (pH 7.4), was dropped 1.40 m onto a chilled glass 
coverslip, resting on a thin aluminium block placed on dry ice. Upon hitting the coverslip, a 
frozen wafer with diameter of approximately 10 mm and thickness 10 µm forms 
instantaneously. The glass coverslip is transferred onto the Linkam cryostage and held at -8ºC 
under N2 for 30 minutes. Photographs are obtained of the initial wafer (to ensure that a 
polycrystalline sample had been obtained) and again after 30 minutes. In brief, the number of 
ice crystals in the field of view are measured, and the measurement repeated for three 
independent wafers. The average (mean) of these three measurements was then calculated to 
find the mean grain area (MGA). The average value and error was compared to that of a PBS 
buffer negative control. 
 
Figure 4.8 – A) IRI activity of the initial homopolymeric candidates. B) Difference in surface amphipathy 
of poly(Oxo) and poly(Fulvo), respectively. IRI activity measured as a function of solute concentration. 
MGA = Mean grain area relative to a PBS control, expressed as %. Error bars represent the ± standard 
deviation from three independent measurements. 


























 poly(Fulvo) + 1% DMSO




The poly(Fulvo) derivative was found to be highly insoluble in water, and indeed polymers 
derived from it (the M1 monomer) containing the ‘fulvo’ motif were significantly less soluble 
on the whole, than those derived from M2 (containing the ‘oxo’-ether units). Solubility limits 
of the derived candidates were therefore established through UV-Vis spectroscopy and Beer-
Lambert Plots (Materials & Methods). The hydrophobic nature of the 6,6-dimethylfulvene 
bridge head coupled with the aggregatory effect of sugar hydroxyls likely led to solution phase 
aggregation of the poly(Fulvo) species. This necessitated the addition of 1% DMSO to aid with 
dissolution for IRI assay (with a 1% DMSO/PBS control used accordingly). The poly(Oxo) on 
the other hand lacked a prominent hydrophobic domain, and possessed high water solubility. 
Poly(Oxo) was found to inhibit ice crystal growth by approximately 50% MGA at 
concentrations above 5 mg.mL-1, Figure 4.8A, demonstrating greater activity than many 
previously reported IRI active polymers.50,51 The activity plateau between 5 and 20 mg.mL-1 is 
likely due to aggregation. The poly(Fulvo) derivative featuring the hydrophobic face was 
however, considerably more active, inhibiting ice crystal growth by ~ 50% MGA at just 0.5 
mg.mL-1 (solubility limit), supporting the facially amphipathic hypothesis for IRI. This makes 
clear the core importance of hydrophobic domain inclusion for IRI potency. Molecular models 
corroborate this (Figure 4.8B), and illustrate the relative increase in hydrophobicity across the 
poly(Oxo) and poly(Fulvo) homopolymers. Crucially, this validated our hypothesis that 
rational design of IRI active species was in principle possible, and that hydrophobicity as a 
core design motif may allow us to access highly potent architectures. 
However, the overall low polymer solubility of poly(Fulvo) is self-limiting, ultimately 
preventing sufficient solubilisation of additional fulvo units necessary for accessing greater 
levels of activity. 
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4.3iii – Synthesis and IRI activity of amphipathic 
copolymers 
In an effort to access greater IRI activity whilst benefiting from improved solubility, a series 


























poly(FPEG) 10,000 35,900 1.38 133 100 
poly(Fulvo-co-Diol)-11 5,000 10,700 1.12 14,35 94/97 
poly(Fulvo-co-Diol)-17 10,000 16,800 1.10 22,54 100 
poly(Fulvo-co-Diol)-35 25,000 34,600 1.26 47,112 100 
poly(Fulvo-co-Oxo) 10,000 7,700 1.35 11,11 100/96 
poly(Fulvo-co-FPEG) 10,000 55,600 1.47 76,58 71 




Figure 4.9 – A) Monomers prepared herein and; B) (Co)polymeric library prepared from the 
monomers. 
In the first instance, a 1:1 statistical copolymer was prepared from the M1 and M2 monomeric 
candidates, to give poly(Fulvo-co-Oxo).  We hypothesised that the incorporation of randomly 
interspersed Oxo units (M2), breaking up intramolecular aggregation, would improve 
solubility and consequently enhance activity (stemming from the greater solvated fulvo 
motifs). 
In practice, the poly(Fulvo-co-Oxo) co-polymer had significantly improved solubility as 
anticipated from the introduction of the oxygen bridgehead motif, and slightly improved overall 
IRI activity relative to poly(Fulvo) – 39 % MGA at 20 mg.mL-1. Figure 4.10A. This 
demonstrates that some co-monomer incorporation is tolerated, unlike PVA,2  with example 
ice wafers are shown in Figure 4.10B/C.  
A
B poly(Diol)    poly(Fulvo)  poly(Oxo)   poly(FPEG)    poly(Fulvo-co-Diol)
poly(Fulvo-co-Diol) + H2 poly(Fulvo-co-Oxo)       poly(Fulvo-co-FPEG)
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Figure 4.10 – A) IRI activity of statistical copolymer versus homopolymers. B) Splat wafer of PBS and 
C) poly(Fulvo-co-Oxo) at 20 mg.mL-1. Cryomicrographs taken after 30 mins at –8 C. Scale bars 50 µM 
across. IRI activity measured as a function of solute concentration. MGA = Mean grain area relative to 
a PBS control, expressed as %. Error bars represent the ± standard deviation from three independent 
measurements. 
However poly(Fulvo-co-Oxo) had a relative lack of potency compared to poly(Fulvo) at low 
concentrations, and it is likely that the non-ideal copolymerization kinetics of the oxo (M2) 
and fulvo (M1) co-monomers will have led to a blocky, rather than statistical copolymerization, 
ultimately leading to aggregation.39,52 Previously, Musa and co-workers has highlighted the 
propensity of monomers with diverse bridgeheads to possess vastly different kinetics with 
respect to the oxidative addition step on the adjacent ring alkene.38 SEC analysis – Figure 4.11 
– confirms aggregation, likely as a result of micellization/internalization of hydrophobic 
domains, with a bimodal trace observed depending on eluent. 





































Figure 4.11 – SEC/GPC Trace of poly(Fulvo-co-Oxo) in THF and DMF. 
 
Figure 4.12 – IR Spectra of poly(Fulvo-co-Oxo) indicating incomplete deacetylation. 
In addition, Infrared analysis (Figure 4.12) indicated the incomplete removal of the acetate 
protecting groups (in contrast to the homo polymers) – with a second carbonyl environment 
observed at ~ 1750 cm-1. This would tend to confirm the block like character of the copolymer, 























THF                                                                 DMF






















  p(Oxo-Fulvo) 10k
3k         8k

































suggesting an internalized domain structure and/or aggregation, with some hydrophobic 
surfaces being solvent inaccessible and hence limiting the total activity poly(Fulvo-co-Oxo).  
 
Scheme 4.7 – Polymerisation of a norbornenediol. 
In order to improve solubility and retain activity, a norbornene diol monomer (M3) with a non-
hydrophilic bridgehead was investigated, Scheme 4.7. De-acetylated homopolymers of M3, 
poly(Diol), were found to have surprisingly low solubility and no activity at their solubility 
limit of 0.59 mg.mL-1 (2-8 kDa). A higher molecular weight species (30 kDa) also displayed 
no activity at 52 µg.mL-1. This is presumably due to strong, intramolecular hydrogen bonding. 
However, when M3 was incorporated as a co-monomer with the (IRI active) ‘fulvo’ monomer 
M1 to give poly(Fulvo-co-Diol), an overall increase in solubility was achieved. Poly(Fulvo-
co-Diol)-17 had remarkable IRI activity; 40 % MGA at just 1.3 mg.mL-1, Figure 4.13. This is 
likely due to the diol-units breaking up intramolecular hydrogen bonding as a result of being 
randomly interspersed in the copolymer in a more statistical manner than M2. As such, the 
kinetically proximal, non-electron withdrawing hydrophobic bridgehead of M3, as opposed to 
the polar and highly disruptive nature of the oxygen bridge head present in poly(Fulvo-co-
Diol), has led to greater solvation of the potent fulvo stretches without 
aggregation/encapsulation. This polymer also showed strong molecular weight dependence on 
activity, and a distinct solubility trend. 17 kDa (1.3 mg.mL-1) had significantly more activity 
than 11 kDa (3.4 mg.mL-1). This is in agreement with the effects observed for many AFGPs, 
PVA,53 and IRI active proteins (such as those extracted from the freeze-tolerant plant 




increasing activity observed at higher molecular weights.  Increasing the molecular weight to 
35 kDa lowered the solubility of the copolymer (0.39 mg.mL-1, due to aggregation), and hence 
activity fell, indicating a ‘goldilocks zone’. 
 
Figure 4.13 – IRI activities of the poly(Fulvo-co-Diol) molecular weight series. IRI activity measured as 
a function of solute concentration. MGA = Mean grain area relative to a PBS control, expressed as %. 
Error bars represent the ± standard deviation from three independent measurements. 
In order to probe the tolerance to functionalisation, and the importance of the carbohydrate 
motif as the hydrophilic domain in particular, the glycan unit was replaced with a short 
oligo(ethylene glycol), PEG, chain. Two candidates, poly(Fulvo-co-FPEG) and poly(FPEG), 
were obtained – Scheme 4.8 and Figures 4.14 and 4.15. Monomethylation of the PEG chain 




Scheme 4.8 – Monomethylation and tosylation of PEG and conjugation to the monomer unit. 
At 55 kDa Mw, poly(Fulvo-co-Diol) had comparable solubility (~ 0.43 mg.mL-1) to 
the poly(Fulvo-co-Diol) 35 kDa derivative. However, only very slight activity was observed 
(~ 80 % MGA), much weaker than poly(Fulvo-co-Diol) 17k at similar concentration. Likewise, 
poly(FPEG) was inactive at 36 kDa Mw despite having an improved maximum solubility of 
0.65 mg.mL-1.  The decreased activity observed in both cases may therefore stem from the 
large and flexible PEG pedant being able to adopt numerous confirmations, thereby reducing 
overall amphipathy. 
Crucially, the small molecule monomers of poly(Fulvo), poly(Diol), and poly(FPEG) were all 
very weakly active, with M1 inhibiting at just 83 % MGA (280 µg.mL
-1
) – implying the 
supremacy of long range order and the need for a macromolecular system in IRI. 
90%                                    72%                                             33%    
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Figure 4.14 – IRI activities of weak to inactive candidates. IRI activity measured as a function of solute 
concentration. MGA = Mean grain area relative to a PBS control, expressed as %. Error bars represent 
the ± standard deviation from three independent measurements. 
Similarly, hydrogenation attempts upon the alkene backbone of poly(Fulvo-co-Diol)-17 
(Scheme 4.9) in order to increase flexibility and observe the effect of decreased rigidity on our 
structures, resulted in a wholly insoluble (and un-assayable) polymer. 
 
Scheme 4.9 – Hydrogenation of the poly(Fulvo-co-Diol)-17 species with palladium (II) hydroxide over 
carbon and triethyl silane. 
These observations demonstrate that precise macromolecular engineering is essential to 
achieve a potent IRI mimetic. 
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Figure 4.15 – Inactive modified species. 
AF(G)Ps bind to specific ice crystal faces,58,59 leading to  dynamic ice shaping (unwanted in 
cryopreservation60). In order to elucidate the mode of mechanistic action in inhibiting ice 
crystal growth, and to determine applicability for biomedical translation, DIS assays were 
performed. Performed by Alice E. R. Fayter, Control ice crystals (Figure 4.16A) showed no 
dynamic ice shaping, but addition of AFGPs (Figure 4.16B) produced distinctive spicular 
(needle-like) crystals. Poly(Fulvo-co-Diol)-17 (Figure 4.16C) did not lead to ice shaping, 
ruling out strong / specific ice face recognition and showing that these effects can be separated 
by macromolecular design. Moreover, as no membrane-puncturing spicular needles are 
formed, this study indicates that these species do not possess the same cytotoxic profile as 
AFGPs and may have application in biomedicine. 
 
Figure 4.16 – Ice morphology analysis. A) Water. B) AFGP-8. C) poly(Fulvo-co-Diol)-17 at 0.72 
mg.mL-1. 
Pure Water                     AFGP-8                            Sample
poly(Fulvo-co-Diol) + H2 poly(Fulvo-co-FPEG) poly(FPEG)
INSOLUBLE TOO HYDROPHILIC
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In order to determine the morphology and evaluate the solution conformation and rigidity of 
the lead poly(Fulvo-co-Diol) candidate, small angle neutron scattering (SANS) was employed. 
Figure 4.17 (and Appendix). Performed by Judith E. Houston and Rachel C. Evans, two 
molecular weight derivatives of the poly(Fulvo-co-Diol) series, 11 kDa and 17 kDa were used. 
The estimated persistence lengths (bt) for poly(Fulvo-co-Diol)-11 and poly(Fulvo-co-Diol)-17 
were found to be 38.9 and 44.4 Å, respectively. Whilst the overlap may actually occur at a 
lower q region, and is masked by aggregate scattering, these values should be taken as the 
minimum persistence lengths for each polymer. Each bt is much larger than the monomer length 
(~10 Å) which suggests that the chain backbones are locally stiff.61 Furthermore, given the 
approximate contour length, L, of both polymer chains (490 Å and 760 Å for poly(Fulvo-co-
Diol)-11 and poly(Fulvo-co-Diol)-17, respectively), the large bt suggests rigid rather than 
highly flexible aggregates, of potentially rod-like structures. This rigidity coupled with the 
intrinsic amphipathy of the polymers is aligned with the hypothesized semi-rigid (and generally 
amphipathic) ice binding faces of AFP’s,7,62 and the flexible hydrophilic ‘glycan face’ of 
AFGPs, providing evidence that facial amphipathy is a key motif for introducing IRI activity 
into a diverse range of polymers. 
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Figure 4.17 – SANS data for poly(Fulvo-co-Diol)-11 (100%, red) and poly(Fulvo-co-Diol)-17 (100%, 
blue) in D2O at 25 °C. Straight lines show -3.5 and -1 decays for comparison.  
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4.4 – Conclusions 
We have designed and synthesized facially amphipathic glycopolymers to mimic the solution 
confirmation and function of antifreeze glycoproteins. It was found that the addition of 
hydrophobic faces, opposing the glycan units, introduced potent IRI activity, but that 
substitution with a more hydrophilic ether unit removed activity. These results support a 
mechanism for IRI activity which is dependent upon local water ordering rather than an 
essential ice binding unit, and there was no evidence of dynamic ice shaping; with small angle 
neutron scattering supporting a locally rigid confirmation, as seen for AF(G)Ps, supporting the 
hypothesis of amphipathy as the driver for activity. 
These results further suggest that the presence of hydroxyls alone are not essential for IRI, and 
that amphipathic domain structure is key. It is notable that none of poly(Diol), poly(Fulvo-co-
Diol) or poly(Oxo) were capable of introducing potent IRI activity except poly(Fulvo-co-Diol) 
at very high concentration, implying that hydroxyl units themselves may not infer IRI activity.  
A combination of ice binding assays, modelling and small-angle neutron scattering (SANS) 
ultimately provides compelling evidence that local amphipathy is an essential motif for 
introducing IRI activity, providing design rules for new materials to mimic AFGP function. 
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4.5 – Experimental 
Materials 
6,6-dimethylfulvene, furan, 5-norbornene-2-exo,3-exo-dimethanol, hexaethylene glycol, tosyl 
chloride, maleimide, toluene, diethyl ether, galactose, acetic anhydride, pyridine, p-toluene 
sulfonyl chloride, hexaethylene glycol, methyl iodide, sodium hydride (as a 60% dispersion in 
mineral oil), dichloromethane (DCM), hydrobromic acid in acetic acid (33%), triethylsilane, 
palladium hydroxide/carbon, methanol, ethanol, tetrahydrofuran (THF), triethylamine, 
potassium carbonate, silver carbonate, dimethylformamide (DMF), 4 Angstrom molecular 
sieves, ethanol, ethyl vinyl ether, Grubbs’ 3rd generation metathesis catalyst, sucrose, sodium 
sulphate and deuterium oxide (D2O) were purchased from Sigma Aldrich Co Ltd (Gillingham, 
UK) and used without further purification. Phosphate-buffered saline (PBS) solution was 
prepared using preformulated Figure 4.ts (Sigma Aldrich Co Ltd, Gillingham, UK) in 200 mL 




Physical and analytical methods 
1H and 13C NMR Spectra (300 – 400 MHz and 75 – 100 MHz, respectively) were recorded 
using one of a Bruker DPX-300/400 Spectrometer under standard NMR conditions. Chemical 
shifts were recorded in ppm and referenced to solvent residual peaks, using MestReNova NMR 
Spectroscopy software. 
ESI MS experiments were performed on an Agilent 6130B Single QUAD ESI-LC MS 
spectrometer in either positive or negative mode with an H2O/MeOH (80:20) eluent feed, with 
samples dissolved in water, methanol or ethanol, unless otherwise stated. 
IR experiments were carried out on a Bruker Vector 22 (ATR) FTIR Spectrometer in either the 
solid or thin film (volatile organic solvent) phase, with background subtraction. 
SEC/GPC data was acquired on either a THF or DMF (as applicable) Agilent 390-LC MDS 
instrument equipped with differential refractive index (DRI), viscometry (VS), dual angle light 
scatter (LS) and dual wavelength UV detectors. System equipped with a PL-AS RT/MT2 
autosampler, Shimadzu SPD-M20A microarray detector, a PL-gel 3 μm (50 × 7.5 mm) guard 
column and 2 × PL-gel 5 μm mixed-D columns (300 x 7.5 mm). Samples were filtered and 
suspended in the relevant HPLC grade solvent (THF containing 2% TEA; DMF with 5 mmol 
NH4BF4 additive), with a flow rate of 1 mL/min
-1 at 50ºC. Refractive index recorded. Analyte 
samples were filtered through a nylon membrane with 0.22 μm pore size before injection. 
Respectively, experimental molar mass (Mn,SEC) and dispersity (Đ) values of synthesized 
polymers were determined by conventional calibration (relative to poly(methyl methacrylate) 
standards – Agilent EasyVials, 690 – 271400 Da) using Agilent GPC/SEC software. Refractive 
index recorded. 
Absorption UV/Vis (Ultra-violet/visible spectroscopy) spectra were acquired on an Agilent 
Technologies Cary 60 Variable Temperature UV-Vis spectrophotometer at room temperature 
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fitted with Holographic Grating (27.5 × 35 mm, 1200 lines/mm, blaze angle 8.6° at 240 nm), a 
double beam, Czerny-Turner monochromator, 1.5 nm fixed spectral bandwidth, full spectrum 
Xenon pulse lamp single source, dual silicon diode detectors, quartz overcoated optics, non-
measurement phase stepping wavelength drive, room light immunity. Analysis undertaken 
using Agilent CaryWin UV Scan software. All sample spectra were acquired in Hellma 
Analytics High Precision Quartz UV Cuvettes. 
Small-angle neutron scattering (SANS) experiments were performed by Judith E. 
Houston/Rachel C. Evans on the KWS-2 instrument at FRM-2 research reactor in Garching 
(Germany).63 A q-range of 3.6 × 10-3 to 0.48 Å-1 was achieved utilizing an incident neutron 
wavelength of 5 Å with a spread of / = 20% and sample-to-detector distances of 1.5, 8 and 
20 m, as q = (4π/λ)sin(θ/2), where λ is the wavelength and θ is the scattering angle. The samples 
were prepared in D2O to provide good scattering contrast and placed in rectangular quartz 
cuvettes (Hellma, pathlength = 1 mm) and maintained at 25.0 ± 0.5 C. The two-dimensional 
raw scattering data were corrected for detector sensitivity, electronic and background noise, 
empty cuvette contribution, and then azimuthally integrated to give the one-dimensional 
intensity I(q) using the instrument software QtiKWS. The data was converted to the absolute 
scale (cm-1) through reference to the scattering from a secondary standard sample (Plexiglas). 




Solubilization of insoluble samples for analysis 
Insoluble samples for splat and UV-Vis analyses (see below) were added to a PBS solution and 
centrifuged (10K, 10 minutes) and the supernatant removed – to give a saturated solution of 
unknown concentration in PBS. 
UV-Vis concentration determination of insoluble samples for analysis 
Calibration: The spectrometer was calibrated with a DMSO ‘blank’ (machine zeroed and a 
background scan conducted). A stock solution of the species of interest was prepared (in 
DMSO) at a known concentration and serially diluted, and a spectrum acquired for each 
concentration in the 200 – 800 nm range (600 nm/min scan rate, 1.00 nm data interval, 0.1 s 
average time), to give a Beer-Lambert calibration plot. 
Sample Concentration Analysis: 200 – 400 µL (typically) of the sample of interest was taken 
as a saturated solution in PBS, and condensed in vacuo. The dry residue was subsequently re-
dissolved in the same volume of DMSO, mixed, and drawn up to separate the liquor from the 
insoluble PBS salts. The UV-Vis spectrum was then acquired, as above, with dilution employed 
(and corrected for) where necessary. The λmax of the primary peak was identified and the 
absorbance recorded and intersected against the line of best fit of the Beer-Lambert plot of the 
stock calibrants to give the saturated samples concentration in PBS solution. 
Ice recrystallization inhibition (splat) assay 
Ice recrystallization inhibition was measured using a modified splat assay.1 A 10 µL sample of 
the species of interest, dissolved in PBS buffer (pH 7.4), was dropped 1.40 m onto a chilled 
glass coverslip, resting on a thin aluminium block placed on dry ice. Upon hitting the coverslip, 
a wafer with diameter of approximately 10 mm and thickness 10 µm was formed 
instantaneously. The glass coverslip was transferred onto the Linkam cryostage and held 
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at -8oC under N2 for 30 minutes. Photographs were obtained using an Olympus CX 41 
microscope with a UIS-2 20x/0.45/∞/0-2/FN22 lens and crossed polarizers (Olympus Ltd, 
Southend-on-Sea, UK), equipped with a Canon DSLR 500D digital camera. Images were taken 
of the initial wafer (to ensure that a polycrystalline sample had been obtained) and again after 
30 minutes. Image processing was conducted using Image J, which is freely available (National 
Institutes of Health, Bethesda, MD). In brief, the number of ice crystals in the field of view 
was measured, and the measurement repeated for three independent wafers. The average 
(mean) of these three measurements was then calculated to find the mean grain area (MGA). 
The average value and error was compared to that of a PBS buffer negative control. 
Surface hydrophobicity mapping of polymers 
Polymeric structures (containing 9 homo- or 9 regularly alternating hetero- ring opened 
monomer units) were assembled in ChemDraw Professional 16.0 (PerkinElmer Informatics 
Inc., Waltham, MA), assuming a ‘classic’ Grubbs’ polymer architecture of 3:1 Trans/Cis along 
the unsaturated backbone. Chain end groups were not featured. The structures were then energy 
minimised in Chem3D and the resulting structures rendered in PyMOL (Schrödinger LLC, 
Cambridge, MA), which is freely available for educational use, and the surfaces on the 
structures were displayed. Hydrogens were then removed from the structure. The “color” 
command was then used to colour the polymer surface, with carbon (and so aliphatic hydrogen) 
defined as hydrophobic (red), whilst oxygen and nitrogen (and so imide/alcoholic hydrogens) 
were defined as hydrophilic (blue). 
Sucrose Sandwich Ice Shaping Assay 
Performed by Alice E. R. Fayter, samples dissolved in PBS buffer containing 45% sucrose 
were sandwiched between two glass coverslips and sealed with immersion oil. Samples were 
cooled to −50 °C on a Linkam Biological Cryostage BCS196 with T95-Linkpad system 
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controller equipped with a LNP95-Liquid nitrogen cooling pump, using liquid nitrogen as the 
coolant (Linkam Scientific Instruments UK, Surrey, U.K.). The temperature was then increased 
to −8 °C and held for 1 hour to anneal. The samples were then heated at 0.05 °C.min-1 until 
few ice crystals remained and then cooled at 0.05 °C.min-1 and the shape of ice crystals 
observed. Micrographs were obtained every 0.1 °C using an Olympus CX41 microscope 
equipped with a UIS-2 20x/0.45/∞/0−2/FN22 lens (Olympus Ltd., Southend on sea, U.K.) and 




General Procedure for the Synthesis of (3aR,4R,7R,7aS)-8-(propan-2-ylidene)-3a,4,7,7a-
tetrahydro-1H-4,7-methanoisoindole-1,3(2H)-dione – (exo,exo-fulvonorborneneimide) 
 
6,6-dimethylfulvene (2.4 mL, 2.12 g, 20 mmol) and maleimide (1.94 g, 20 mmol, 2 eqv) were 
dissolved in toluene (100 mL), and the reaction mixture stirred under reflux (135°C) for 24 
hours, transitioning from a translucent orange solution to opaque after 60 minutes. The reaction 
mixture was then cooled to RT and condensed in vacuo to remove excess toluene and fulvene, 
and the solids washed with hot diethyl ether (3 x 20 mL) to yield the pure exo,exo product as a 
pale orange solid. 2.82 g (69%). 1H NMR (300 MHz, CDCl3) δ = 7.61 (1H, s, NH), 6.42 (2H, 
t, J = 1.96 Hz, HC=CH), 3.74 (2H, t, J = 1.88 Hz, Bridge Base 2 x CH), 2.78 (2H, s, Fused 
Ring 2 x CH), 1.57 (7H, s, 2 x Me). 13C NMR (75 MHz, CDCl3) δ = 206.96 (2 x HNRC=O), 
137.67 (HC=CH / R2-C=C-(Me)2), 49.20 (C-C=O), 45.61 (C-HC=CH-C), 30.93 (2 x Me). IR 
(ATR): 3229 (NH), 3000 (C=C / C-H), 1759, 1705 (2 x C=O), 1369, 1345, 1182 (C-H), 689 
cm-1 (C=C). m/z (ESI, -ve) Observed 202.1 [95%, R2N-]. Compound previously reported.64 
General Procedure for the Synthesis of (3aR,4R,7R,7aS)-3a,4,7,7a-tetrahydro-1H-4,7-
epoxyisoindole-1,3(2H)-dione – (exo,exo-oxonorborneneimide) 
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Furan (15 mL, 14.04 g, 206.26 mmol, 10 equiv) and maleimide (2.00 g, 20.60 mmol) were 
dissolved in toluene (20 mL), and refluxed at 95ºC for 48 hours, with the colourless mixture 
becoming white/opaque within 10 minutes. The reaction mixture was then cooled to RT, and 
then solids filtered and washed with cold toluene (100 mL) to give a white solid, and dried in 
vacuo. 2.19 g (64%). Characterization as previously reported. 65 1H NMR (300 MHz, CDCl3) 
δ = 8.00 (1H, s, NH), 6.52 (2H, t, J = 0.91 Hz, HC=CH), 5.32 (2H, t, J = 0.92 Hz, Bridge Base 
2 x CH), 2.89 (2H, s, Fused Ring 2 x CH). 13C NMR (75 MHz, CDCl3) δ = 162.34 (2 x C=O), 
136.59 (HC=CH), 80.99 (C-O-C), 48.71 (2 x C-C=O). IR (ATR): 3194 (NH); 3101, 3065, 
2866, 2724 (CH); 1834, 1801; 1773, 1702 (2 x C=O); 1626, 1579 (C=C); 1345, 1301 (CH); 
1148; 1065, 938, 842 cm-1 (C=C). m/z (ESI, -ve) Observed 164.1 [100%, M-H+]. 
General Procedure for the Synthesis of D-galactose pentaacetate 
 
To a solution of D-galactose (1.00 g, 5.55 mmol) in pyridine (20 mL) on ice, acetic anhydride 
(20 mL) was added slowly with stirring, and allowed to warm to RT overnight. To the resulting 
reaction mix, CHCl3 (30 mL) was added and the mixture extracted from a chilled solution of 
HCl (3 x 30 mL, 1M). The combined organic phases were then extracted with saturated 
NaHCO3 solution (3 x 30 mL), washed with brine (30 mL), dried over Na2SO4, and condensed 
in vacuo to give a thick colourless oil. 2.26 g (Quant%). Characterization as previously 
reported. 66 1H NMR (300 MHz, CDCl3) δ = 6.38 (1H, s, Anomeric H-1), 5.50 (1H, s, H-4), 
5.34 (2H, s, H-2,3), 4.43 – 4.01 (3H, m, H-5,6’,’’), 2.27 – 1.92 (15H, m, 5 x OAc). 9:1 α:β. 13C 
NMR (75 MHz, CDCl3) δ = 170.14 – 168.92 (C=O-CH3), 89.72 (C-1), 68.96 – 65.99 (C-
5,4,3,2), 61.25 (C-6), 21.26 – 19.87 (5 x C-OCH3). m/z (ESI, +ve) Observed 412.9 [100%, 
M+Na+]. 
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General Procedure for the Synthesis of Acetobromo-α-D-galactose 
 
To a solution of D-galactose pentaacetate (1.62 g, 4.15 mmol) in anhydrous dichloromethane 
(20 mL) on ice, a large excess of hydrobromic acid in acetic acid (33% w/w, 5 mL, 27.81 mmol, 
6.7 eqv) was added dropwise with stirring, and the reaction mix allowed to equilibrate for 1 
hour with protection from ambient light. The resulting translucent orange solution was then 
extracted from a saturated solution of ice-cold NaHCO3 (3 x 30 mL), leading to effervescence 
and a discolouration of the organic phase. The organic phase was then washed with ice-cold 
brine (30 mL), dried over Na2SO4, and condensed in vacuo, yielding a thick colourless oil, 
which slowly crystallised. 1.37 g (80%). Characterisation as previously reported. 67 1H NMR 
(300 MHz, CDCl3) δ = 6.70 (1H, d, J = 3.20 Hz, Anomeric H-1), 5.52 (1H, d, J = 2.9 Hz, H-
3), 5.40 (1H, dd, J1 = 10.70 Hz, J2 = 3.40 Hz, H-4), 5.10 – 4.99 (1H, m, H-2) 4.54 – 4.04 (3H, 
m, H-5,6’,’’), 2.19 – 1.96 (12H, m, 4 x OAc). 1:0 α:β. 13C NMR (75 MHz, CDCl3) δ = 163.12 
(C=O-CH3), 88.11 (C-1), 71.06 – 66.97 (C-5,4,3,2), 60.83 (C-6), 20.75 – 20.55 (C-OCH3).  
m/z (ESI, -ve) Observed 427.1, 428.1 [100%, M+H2O–H
+]. 
General Procedure for the Synthesis of ((1R,2S,3S,4R)-bicyclo[2.2.1]hept-5-ene-2,3-
diyl)bis(methylene) diacetate – (5-Norbornene-2-exo,3-exo-dimethylacetate) – ‘M1’ 
 
5-Norbornene-2-exo,3-exo-dimethanol (215.3 mg, 1.40 mmol) was dissolved in ethyl acetate 
(20 mL) on ice, and a large excess of acetic anhydride (10 mL) was added slowly with stirring, 
and allowed to equilibrate for one hour. The reaction mixture was subsequently condensed in 
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vacuo, re-dissolved in DCM (30 mL), and extracted from a saturated solution of NaHCO3 (3 x 
30 mL). The combined organic phases were then dried over Na2SO4, and condensed in vacuo¸ 
to give a thick colourless oil. Subsequent chilling at –20°C yielded a white crystalline solid. 
140 mg (42%). 1H NMR (300 MHz, CDCl3) δ = 6.05 (2H, d, J = 2.3 Hz, H-1), 4.20 – 3.83 (4H, 
m, H-4), 2.61 (2H, s, H-2), 1.98 – 1.89 (6H, m, H-6), 1.73 (2H, d, J = 11.4 Hz, H-3), 1.44 – 
1.17 (2H, m, H-5). 13C NMR (75 MHz, CDCl3) δ = 169.84 (2 x C=O), 136.27 (HC=CH), 64.39 
(2 x C-OC=O), 43.79 (C-C=C), 41.55 (R2CH2), 38.68 (C-C-OC=O), 29.83, 19.98 (OAc). 
Compound previously reported.68 
General Procedure for the Synthesis of (2R,3S,4S,5R,6R)-2-(acetoxymethyl)-6-
((3aR,4R,7R,7aS)-1,3-dioxo-8-(propan-2-ylidene)-1,3,3a,4,7,7a-hexahydro-2H-4,7-
methanoisoindol-2-yl)tetrahydro-2H-pyran-3,4,5-triyl triacetate – (exo,exo-
fulvonorborneneimide galactopyranoside peracetate) – ‘M2’ 
 
exo,exo-fulvonorborneneimide (326 mg, 1.61 mmol), K2CO3 (111 mg, 0.80 mmol, 0.5 eqv), 
and acetobromo-α-D-galactose (600 mg, 1.46 mmol, 0.91 eqv) were dissolved in dry, 
deoxygenated DMF (20 mL) with 4 Å molecular sieves. Ag2CO3 (201 mg, 0.73 mmol, 0.46 
eqv) was subsequently added with stirring, the reaction protected from light, and allowed to 
equilibrate at 60°C overnight. The dark green/brown reaction crude was then filtered, and 
condensed in vacuo until a thick suspension remained, and re-dissolved in ethanol to precipitate 
the insoluble black solids of the silver oxide/bromide by-products, and again filtered. The 
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filtrate was dissolved in CHCl3 (30 mL) and extracted with saturated NaHCO3 solution (3 x 30 
mL), and the organic phase washed again with saturated NaCl solution (30 mL), water (30 mL), 
dried over Na2SO4 and condensed in vacuo. Solids were then taken up into hot diethyl ether 
(30 mL), filtered, and the filtrate condensed again to give an off-white/beige solid. 250 mg 
(32%). 1H NMR (300 MHz, CDCl3) δ = 6.37 (2H, d, J = 10.5 Hz, HC=CH), 5.73 – 5.36 (2H, 
m, H-1,4), 5.36 – 4.97 (2H, m, H-3,2), 4.76 – 3.90 (4H, m, H-5,6’,’’), 3.71 (2H, s, Bridge Base 
2 x CH), 2.74 (2H, s, Fused Ring 2 x CH), 2.09 – 1.94 (12H, m, 4 x OAc), 1.54 (4H, s, 2 x 
Me). 13C NMR (75 MHz, CDCl3) δ = 207.03 (2 x HNRC=O), 177.47 (R2-C=C-(Me)2), 170.36 
– 168.92 (4 x C=OAc + R2-C=C-(Me)2), 89.69 (C-1), 70.87 (2 x C-OC=O), 68.74 – 66.43 (C-
2,3,4,5; 4 x C-C=OAc), 61.24 (C-6), 49.21 (C-C=O),  45.58 (C-HC=CH-C), 30.90 (2 x Me), 
20.87 – 19.61 (4 x OAc). 
General Procedure for the Synthesis of (2R,3S,4S,5R,6R)-2-(acetoxymethyl)-6-
((3aR,4R,7R,7aS)-1,3-dioxo-1,3,3a,4,7,7a-hexahydro-2H-4,7-epoxyisoindol-2-
yl)tetrahydro-2H-pyran-3,4,5-triyl triacetate – (exo,exo-oxonorborneneimide 
galactopyranoside peracetate) – ‘M3’ 
 
Synthetic procedure as described in the General Procedure for the Synthesis of exo,exo-
fulvonorborneneimide galactopyranoside peracetate. 
exo,exo-oxonorborneneimide (498 mg, 3.02 mmol), K2CO3 (210 mg, 1.51 mmol, 0.5 eqv), and 
acetobromo-α-D-galactose (1.13 g, 2.75 mmol, 0.91 eqv) were dissolved in dry, deoxygenated 
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DMF (20 mL) with 4Å molecular sieves. Ag2CO3 (380 mg, 0.73 mmol, 0.46 eqv) addition 
followed as previously prescribed. Workup as per previous, with the exception that toluene was 
used for the final wash in place of hot diethyl ether. Brown oil obtained, 340 mg (25%). 1H 
NMR (300 MHz, CDCl3) δ = 6.37 (1H, s, HC=CH), 5.73 – 4.99 (5H, m, H-1,4, 2 x HC-O), 
4.53 – 3.90 (5H, m, H-2,3,5,6’,’’), 2.12 – 1.95 (14H, m, 4 x OAc). 13C NMR (75 MHz, CDCl3) 
δ = 174.57 – 167.20 (4 x C=OAc), 162.31 (2 x HNRC=O), 95.92 (HC=CH), 92.62 – 88.45 (C-
O-C, C-1), 73.30 – 64.71 (C-2,3,4,5), 61.62 (C-6), 61.46 (2 x C-C=O), 24.59 – 18.45 (4 x 
OAc). 





exo,exo-fulvonorborneneimide galactopyranoside peracetate (200 mg, 0.375 mmol) was 
dissolved in THF/Methanol (2:1, 15 mL) and a large excess of methanolic sodium methoxide 
(30%, 5 mL) added with stirring at 0°C. After 1 hour, the mixture (pH ~ 10) was neutralised 
on an Amberlite Ion Exchange column and flushed sequentially with THF (20 mL) and 
methanol (20 mL). The collected fraction (pH ~ 6–7) was subsequently condensed in vacuo to 
yield an off-white solid. 50 mg (36%). 1H NMR (300 MHz, CDCl3) δ = 6.17 (2H, s, HC=CH), 
4.19 (4H, s, Carbohydrates), 3.45 (2H, s, Carbohydrates), 3.09 (2H, s, Bridge Base 2 x CH), 
2.50 (2H, s, Fused Ring 2 x CH), 1.30 (3H, s, 2 x Me). 13C NMR (75 MHz, CDCl3) δ = 140.31 
(2 x HNRC=O), 52.16 – 50.45 (C-1,2,3,4,5,6), 48.26 (C-C=O), 21.95(2 x Me). 
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General Procedure for the Synthesis of 2,5,8,11,14,17-hexaoxanonadecan-19-ol – 
(Monomethoxyhexaethylene glycol) 
 
Hexaethylene glycol (1g, 0.89 mL, 3.54 mmol) was dissolved in THF (10 mL) and cooled on 
ice, and sodium hydride (60% dispersion in mineral oil, 142 mg, 1 eqv, 3.54 mmol) added. 
Methyl iodide (503 mg, 0.22 mL, 1 eqv, 3.54 mmol) was then added slowly, dropwise, and 
stirred for 1 hour. The reaction mixture was quenched with NH4Cl, warmed to RT, and diethyl 
ether added (30 mL). The aqueous phase was separated and extracted with diethyl ether (3 x 
30 mL), the organic phases combined, dried over Na2SO4, and condensed in vacuo to give a 
clear, off-yellow oil. 940 mg (89.5%).  1H NMR (300 MHz, CDCl3) δ = 3.75 – 3.46 (27H, m, 
((CH2CH2O)5(CH2)2OH), 3.32 (3H, s, OMe). 
13C NMR (75 MHz, CDCl3) δ = 72.48 – 69.89 
(COR), 61.46 – 61.31 (Me), 58.64 – 31.38 (CH). m/z (ESI, -ve) Observed 313.9 [100%, 
M+H2O–H
-]. Compound previously reported.69 
General Procedure for the Synthesis of 2,5,8,11,14,17-hexaoxanonadecan-19-yl 4-
methylbenzenesulfonate – (Monomethoxyhexaethylene glycol monotosylate) 
 
Monomethoxyhexaethylene glycol (920 mg, 3.10 mmol), triethylamine (0.52 mL, 1.2 eqv, 3.73 
mmol), and tosyl chloride (710 mg, 1.2 eqv, 3.73 mmol) were dissolved in DCM (30 mL) and 
stirred for 16 hours. Water (30 mL) was subsequently added, and the aqueous phase separated 
and extracted with DCM (3 x 30 mL). Organic phases were combined, condensed in vacuo, 
and solids precipitated from a minimal volume of cold THF (2 x 5 mL) and filtered. The organic 
liquor was then re-condensed, dissolved in DCM (30 mL), and washed with saturated NaHCO3 
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solution (3 x 30 mL), dried over Na2SO4, and condensed again to yield a brown oil. 1 g (72%). 
1H NMR (400 MHz, CDCl3) δ = 7.83 – 7.30 (4H, m, Aromatic), 4.16 (2H, td, J1 = 4.9, J2 = 1.7 
Hz, PEG CH2), 3.80 – 3.50 (26H, m, (CH2CH2O)5), 3.37 (3H, t, J = 1.5 Hz, OMe), 2.72 (2H, 
s, Ar-Me). 13C NMR (75 MHz, CDCl3) δ = 144.80 (Aromatic), 132.96 – 126.32 (Aromatic), 
72.38 – 68.64 (COR), 61.64 (Me), 58.99 – 30.31 (CH), 21.63 (Ar-Me). m/z (ESI, +ve) 
Observed 473.1 [100%, M+Na+]. Compound previously reported.70 
General Procedure for the Synthesis of (3aR,4R,7R,7aS)-2-(2,5,8,11,14,17-
hexaoxanonadecan-19-yl)-8-(propan-2-ylidene)-3a,4,7,7a-tetrahydro-1H-4,7-
methanoisoindole-1,3(2H)-dione – (exo,exo-fulvonorborneneimide-PEG6) – ‘M4’ 
 
Monomethoxyhexaethylene glycol monotosylate (1 g, 3.33 mmol) was dissolved in DMF (50 
mL) with 4Å molecular sieves, K2CO3 (470 mg, 1.5 eqv, 5.00 mmol), and exo,exo-
fulvonorborneneimide (677 mg, 1.5 eqv, 5.00 mmol) at 60°C with stirring for 24 hours. The 
crude was filtered, condensed in vacuo, and re-dissolved in ethyl acetate (30 mL). Saturated 
NaHCO3 solution (30 mL) was added, the organic phase separated, and washed a further three 
times (3 x 30 mL) with saturated NaHCO3 solution, and brine (1 x 30 mL). The organic phase 
was then dried over Na2SO4 and reduced to a small volume (~ 5 mL), before being precipitated 
from diethyl ether to yield an off-white solid. 530 mg (33%). 1H NMR (300 MHz, CDCl3) δ = 
6.34 (2H, q, J = 1.9 Hz, HC=CH), 3.74 – 3.36 (27H, m, (CH2CH2O)5, Bridge Base 2 x CH), 
3.30 (1H, 2, OMe), 2.68 (2H, d, J = 10.4 Hz, Fused Ring 2 x CH), 1.46 (7H, d, J = 16.0 Hz, 
C=C(Me)2),. 13C NMR (75 MHz, CDCl3) δ = 177.88 – 177.39 (Imide 2 x RC=ON), 162.31 
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(Me2-C=C), 140.9 (Me2-C=C), 137.6 (HC=CH), 115.88, 71.87 – 67.09 (COR), 61.57 (Me), 
58.95 – 14.11 (CH, CNR). m/z (ESI, +ve) Observed 504.1 [100%, M+Na
+], 473.0 [75%, 
SM+Na+]. 
General Procedure for the (co)polymerisation of the M1–M4 monomer libraries 
The monomer(s) and Grubbs’ 3 metathesis catalyst (See Table 4.3, below) were weighed into 
separate Schlenk flasks (or for some monomers, as a solution of known concentration in dry 
THF) and each made up to 10 mL and 5 mL with anhydrous THF, respectively, and 
purged/degassed with N2 for 20 minutes. Mesitylene (3 drops) was added to the monomer 
solution prior to degassing. The catalyst and monomer solutions were then combined and 
heated at 50°C for 1 hour under nitrogen, with stirring. The Schlenk flask was subsequently 
cooled under liquid nitrogen (–196°C), a drop removed (for 1H NMR conversion), and a large 
excess of ethyl vinyl ether (5 mL) introduced, with stirring for a further 30 minutes. The 
polymer was then precipitated with a large excess (~ 45 mL) of an appropriate solvent (Table 
4.3), and isolated by centrifugation (10K RPM, 10 minutes), to yield a solid mass (polymers 
generally brown through grey/beige). Polymers not containing acetate groups were then 
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reprecipitated under the same conditions at least twice, and finally dried under compressed air. 
(Table 4.3 and Figures 4.14 and 4.18 – 4.20, below, for further polymer characterisation data). 
poly(Fulvo): 1H NMR (300 MHz, CDCl3) δ = 5.35 (s, Carbohydrates + Backbone), 4.34 (br s, 
Carbohydrates + Backbone), 3.65 (br s, Carbohydrates), 3.27 (br s, Carbohydrates), 2.92 – 2.22 
(m, Carbohydrates + Norbornene Ring), 2.06 – 1.78 (m, Carbohydrates + Norbornene Ring), 
1.75 – 1.53 (m, Norbornene Ring), 1.50 – 1.16 (m, Norbornene Ring + Methylene’s), 1.07 – 
0.75 (m, Norbornene Ring + Methylene’s). Cis/Trans n/d. 
poly(Oxo): 1H NMR (300 MHz, CDCl3) δ = 6.98 (m), 6.60 – 6.47 (m), 5.59 – 5.06 (m, 
Carbohydrates + Backbone), 4.77 – 4.31 (m, Carbohydrates), 4.26 – 3.90 (m, Carbohydrates + 
Norbornene Ring), 3.85 – 3.38 (m, Carbohydrates), 3.25 – 2.98 (m, Carbohydrates), 2.92 – 
2.39 (m, Carbohydrates + Norbornene Ring), 2.24 – 1.94 (m, Ac), 1.01 – 0.77 (m, Norbornene 
Rings + Methylene’s). Cis/Trans n/d. 
poly(Fulvo-co-Oxo): 1H NMR (400 MHz, d-DMSO) δ = 11.13 (s), 8.28 (s), 7.57 – 6.06 (m, Ph 
Chain End), 5.82 – 4.49 (m, Carbohydrates + Backbone), 4.26 – 3.86 (m, Carbohydrates + 
Norbornene Rings), 2.33 – 0.52 (m, Norbornene Rings + Methylene’s). Cis/Trans n/d. 
poly(Fulvo-co-Diol): 1H NMR (400 MHz, d-DMSO) δ = 11.14 (br s), 7.36 (m, Ph Chain End), 
5.54 – 4.62 (m, Carbohydrates + Backbone), 4.28 – 2.58 (m, Fulvo Norbornene Ring + 
Carbohydrates), 2.38 – 0.76 (m, Diol Norbornene Ring + Fulvo Methylene’s). Cis/Trans n/d. 
poly(Fulvo-co-FPEG): 1H NMR (400 MHz, d-DMSO) δ = 11.13 (br s), 7.09 (s, Ph Chain End), 
5.65 – 5.17 (m, Carbohydrates + Backbone), 4.43 (m), 4.20 – 3.95 (m, Carbohydrates + 
Norbornene Rings), 3.63 – 3.37 (m, PEG Pedant), 3.27 – 2.90 (m, PEG Pedant), 2.74 – 2.53 
(m), 2.41 – 2.12 (m), 2.01 – 1.42 (m, Norbornene Ring + Methylene’s), 1.34 – 0.82 (m). 
Cis/Trans n/d. 
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poly(Diol): 1H NMR (400 MHz, d-DMSO) δ = 7.68 (s, Ph Chain End), 5.32 – 5.09 (m, 
Backbone), 4.98 – 4.86 (m, Backbone), 4.16 – 3.89 (m), 2.32 – 1.52 (m, Norbornene Ring), 
1.39 – 0.76 (m, Methylene’s). Cis/Trans 1:1. 
poly(FPEG): 1H NMR (400 MHz, d-DMSO) δ = 11.13 (br s), 7.09 (s, Ph Chain End), 5.60 – 
5.20 (m, Backbone), 4.59 – 4.40 (m), 4.18 – 3.93 (m), 3.67 – 3.36 (m, PEG Pedant), 3.31 – 
2.93 (m, PEG Pedant), 2.66 (s), 2.34 – 2.29 (m, Norbornene Ring) 1.83 – 1.41 (br s, Norbornene 
Ring + Methylene’s). Cis/Trans 1:4. 
poly(Fulvo-co-Diol) + H2: 
1H NMR (400 MHz, d-DMSO) δ = 11.08 (s), 7.25 (br. s, Ph Chain 
End), 5.67 – 4.62 (m, Carbohydrates), 4.15 – 2.64 (m, Fulvo Norbornene Ring + 
Carbohydrates), 2.37 – 0.97 (m, Diol Norbornene Ring + Fulvo Methylene’s), 0.96 – 0.76 (q, 
J = 7.7 Hz, Hydrogenated Fulvene), 0.66 – 0.32 (dq, J1 = 43.6, J1 = 7.9 Hz, Hydrogenated 
Fulvene). Cis/Trans n/d. 
* n/d – Not possible to determine the cis/trans ratio in these instances due to unsaturated 
















(mg) Monomer A Monomer B 
poly(Fulvo) M2 (191.1, 0.358) - 7.1, 8.03 25,000 46.9:0:1 Diethyl ether 54.1 
poly(Oxo) M3 (184.3, 0.372) - 16.3, 18.43 10,000 20.2:0:1 Pentane 8.1 
poly(Fulvo-co-Oxo) M2 (100, 0.187) M3 (97.1, 0.196) 17.7, 20.01 10,000 19.4:19.4:1 Hexane 39.3 
poly(Fulvo-co-Diol)-17 * M2 (100, 0.187) M1 (45, 0.187) 16.6, 18.74 10,000 10:10:1 Diethyl ether 8.5 
poly(Fulvo-co-FPEG) M2 (52.6, 0.0986) M4 (47.4, 0.0984) 8.9, 10.06 10,000 19.7:19.7:1 Diethyl ether 63.4 
poly(Diol) M1 (50, 0.210) - 9, 10.18 10,000 20.6:0:1 Ethanol 33.1 
Non-Acetylated 
poly(FPEG) M4 (100, 0.208) - 8.9, 10.06 10,000 20.7:0:1 Hexane 66.5 
 
Table 4.3 – Polymer preparation summary † Derived from MnTHEO = [M]/[C]•(Mw)•Y, where [M] is the initial monomer(s) concentration, [C] is initial catalyst 







Dissolution Solvent * 
Post-Deprotection 
Precipitation Solvent 
poly(Fulvo) 50.8 THF Diethyl ether 
poly(Oxo) 3.3 THF Pentane 
poly(Fulvo-co-Oxo) 9.1 THF Diethyl ether 
poly(Fulvo-co-Diol)-17 3.6 THF Hexane 
poly(Fulvo-co-FPEG) 12.8 THF Hexane 
poly(Diol) 8.2 MeOH/THF (1:1) Diethyl ether 
 




General Procedure for the postpolymerisation modification (deacetylation) of acetylated 
polymer derivatives 
 
The acetylated polymeric materials (See Table 4.3, above) were dissolved in THF/Methanol 
(2:1, 15 mL) and a large excess of methanolic sodium methoxide (30%, 5 mL) added with 
stirring at 0°C. After 1 hour, the mixture (pH ~ 10) was neutralised on an Amberlite Ion 
Exchange column, and flushed sequentially with THF (20 mL) and methanol (20 mL). The 
collected fraction (pH ~ 6–7) was subsequently condensed in vacuo, and the deprotected 
polymer re-dissolved in an appropriate solvent (Table 4.4), and precipitated with a large excess 
(~ 45 mL) of an appropriate solvent (Table 4.4), and isolated by centrifugation (10K RPM, 10 
minutes) to yield a solid mass (polymers generally brown through grey/beige). Polymers were 
then reprecipitated under the same conditions at least twice, and finally dried under compressed 
air. (Tables 4.3–4, above, and Figures 4.18 – 4.20, below, for polymer characterisation data). 




Deacetylated poly(Fulvo-co-Diol) 17k (13 mg) was dissolved in methanol (5 mL) in a sealed 
system, under a nitrogen atmosphere. A solution of Pd(OH)2/C (10 mg) in methanol (5 mL) 
was introduced with stirring, and nitrogen bubbled through the mix for 5 minutes. 
Triethylsilane (0.5 mL) was then added in whole, leading to instantaneous effervescence and 
the in-situ generation of molecular H2. The reaction mix was allowed to stir for 16 hours, with 
balloons attached for back pressure. The reaction was then subsequently filtered through a 
Celite plug, flushed with methanol (20 mL) and THF (20 mL), and condensed in vacuo to give 
the hydrogenated copolymeric derivative as a red mass. 14.7 mg. 
UV-VIS/Beer-Lambert plots of (insoluble) polymers and calibration curves 
 
Figure 4.118 – Beer Lambert Plots (TOP) and UV-Vis spectra (BOTTOM) of the poly(Fulvo), 
poly(Fulvo-co-Diol)-11 and -17 polymer series, respectively 














Equation y = a + b*x
Plot ABS
Weight No Weighting
Intercept 0.14382 ± 0.03045
Slope 2.43053 ± 0.16934





0.125 x 10 = 1.3 mg.mL
-1

















Equation y = a + b*x
Plot Abs
Weight No Weighting
Intercept 0.20898 ± 0.03914
Slope 3.28686 ± 0.24301












































































Equation y = a + b*x
Plot A
Weight No Weighting
Intercept 0.04248 ± 0.02156
Slope 0.50139 ± 0.05802





0.34 * 10 = 3.4
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Figure 4.19 – Beer Lambert Plots (TOP) and UV-Vis spectra (BOTTOM) of poly(Fulvo-co-Diol)-35, 
poly(Fulvo-co-FPEG), and poly(Diol) polymer series, respectively. 
 
Figure 4.20 – Beer Lambert Plots (TOP) and UV-Vis spectra (BOTTOM) of the poly(FPEG) and 
poly(Fulvo-co-Diol)-17 + H2 polymer series, and deacetylated Fulvo-Gal monomer series, 
respectively. 
poly(Fulvo-co-Diol)-35












Equation y = a + b*x
Plot ?$OP:A=1
Weight No Weighting
Intercept -0.01604 ± 0.00179
Slope 1.1087 ± 0.01203





0.098 * 4 = 0.392




























Equation y = a + b*x
Plot B
Weight No Weighting
Intercept 0.08269 ± 0.02982
Slope 1.70603 ± 0.09875





0.185 * 4 = 0.74
poly(Fulvo-co-FPEG)








































































 Sample (Half Saturation)
 Concentrated DMSO Stock
CANDIDATE INSOLUBLE IN PBS















Equation y = a + b*x
Plot ABS
Weight No Weighting
Intercept 0.04785 ± 0.00486
Slope 2.46237 ± 0.03672





0.1615 * 4 = 0.65 mg/ml







































0.071 x 4 = 0.284
Deacetylated Fulvo-Gal Small
Molecule Monomer



















Figure 4.21 – UV/Vis spectrum of DMSO (background zeroed) and DMSO containing PBS salt 
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Unsuccessful and redundant general procedures 
I. Example procedure for the syntheses of glycosyl (Glc/Gal/GalNAc) peraacetates 
 
Zinc chloride (0.96 g, 7.04 mmol) was added quickly to acetic anhydride (20 mL) and the 
mixture heated to and stirred at 85ºC for five minutes, resulting in a dark brown solution. D-
Glucose (4.00 g, 22.2 mmol) was added slowly with stirring and the mixture was heated for 1 
further hour. The resulting thick black oil which was poured into chilled water (200 mL) and 
stirred vigorously to give a dark green solution and an off-white precipitate. The solid was 
recovered at the pump, washed with ice cold water (40 mL), and recrystallised from hot ethanol 
(20 mL). White crystals were isolated, washed with cold ethanol (10 mL) and dried in vacuo. 
4.06 g (46.8 %). 1H NMR (300 MHz, CDCl3) δ = 6.32 (1H, d, J1,2 = 3.7 Hz, Anomeric), 5.47 
(1H, t, J3,2 = J3,4 = 9.9 Hz, H-3), 5.19 – 5.05 (2H, m, H-2,4), 4.26 (1H, dd, J6,6’ = 12.5, J6,5 = 
4.1 Hz, H-6), 4.10 (2H, m, H-5,6’), 3.70 (q, EtOH), 3.48 (s, EtOH) 2.18 (3H, s, OAc), 2.09 
(3H, s, OAc), 2.05 – 1.99 (9H, s, 3 x OAc), 1.24 (t, EtOH). m/z (ESI) 413.0 (95%, M+Na+). 
Compound previously reported – as above. 
II. Example procedure for the attempted syntheses of glycosyl (Glc/Gal/GalNAc) 
tetraacetates 
 
The glycosyl peracetate (1.00 g) was dissolved in DMF (20 mL) and ammonium carbonate 
(506 mg) or benzylamine (2 mL) added, and the mixture stirred at 30ºC for 48 hours. 
Chloroform (30 mL) was added and the mixture poured into ice cold HCl (1M, 20 mL). The 
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organic phase extracted and the aqueous washed with CHCl3 (3 x 20 mL). The combined 
organic phases were washed with water (15 mL) and saturated NaHCO3 solution (15 mL), dried 
over Na2SO4 and condensed in vacuo with an excess of n-Butanol, resulting in a yellow/brown 
gum. Glc (NH4)2CO3: 
1H NMR (300 MHz, CDCl3) δ = 5.51 (2H, dt, J = 7.2, 6.7 Hz), 5.26 (1H, 
t, J = 9.5 Hz), 5.00 – 4.65 (2H, m), 4.37 – 4.06 (3H, m, H-5,6’,’’), 2.13 – 1.99 (12H, m, 4 x 
OAc). m/z (ESI) 371.0 (100%, M+Na+). GalNAc (BnNH2): 
1H NMR (300 MHz, CDCl3) δ 5.71 
(d, J = 9.5 Hz, 1H, Anomeric), 5.65 – 5.59 (m, 1H), 5.43 – 5.33 (m, 2H), 5.27 (dd, J = 11.2, 
3.3 Hz, 1H), 4.60 (d, J = 9.6 Hz, 1H), 4.40 (dt, J = 14.1, 6.4 Hz, 3H), 4.19 – 3.93 (m, 4H), 3.76 
(s, 2H), 2.16 – 1.95 (m, 13H,  1 x NHAc, 3 x Ac). Compounds previously reported.71 
III. Example procedure for the attempted syntheses of glycosyl (Glc/Gal/GalNAc) exo-
fulvonorborneneimide monomers (via mitsunobu coupling) 
 
To the crude mono-deacetylated sugar (Galactose, 0.44 g) and exo,exo-fulvonorborneneimide 
(0.12g, 0.63 mmol, 0.5 eqv) were dissolved in dry THF (50 mL) under N2 with triphenyl 
phosphine (0.17 g, 0.63 mmol, 0.5 eqv) and cooled to zero degrees. DIAD (0.13 mL, 0.13g, 
0.63 mmol, 1 eqv) was added drop wise to the reaction mixture with stirring, and the reaction 
mixture kept at 0ºC for five minutes, before being warmed to RT and stirred for 48 hours. The 
crude orange solution obtained was condensed in vacuo to give a dark brown syrup, and was 
recrystallised from hot toluene to precipitate the excess TPPO, exo,exo-fulvonorborneneimide, 
and tetraacetate, and the filtrate again condensed.  The residue was recrystallised from warm 
diethyl ether to afford an off-white crystalline product (20 mg), which was isolated and washed 
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with cold ether (100 mL), and the remaining solution condensed down to a yellow gum. Gum 
filtered through a plug of silica (Hexane/Ethyl acetate, 1:2), yielding a white crystalline solid 
(Trace %). 1H NMR (300 MHz, CDCl3) δ = 7.72 - 7.44 (m, TPPO), 6.41 (1H, t, J 1.9, HC=CH), 
6.32 (s, Unknown), 5.59 – 4.83 (8H, m, Sugar), 4.47 (1H, t, J 6.6, Sugar), 4.27 – 3.89 (4H, m, 
Sugar), 3.74 (1H, t, J 1.9, Bridge 2 x CH), 3.48 (q, Diethyl ether), 2.77 (1H, s, Ring 2 x CH), 
2.21 – 1.93 (17 H, m), 1.56 (s, H2O), 1.43 (t, Et2O), 1.29 - 1.20 (m, Unknown). 13C NMR (100 
MHz, CDCl3) δ = 132.18, 128.60, 21.96. m/z (ESI): 227.1 (80%, M+Na
+), 279.1 (30%), 301.0 
(100%, TPPO+Na+), 371.0 (55%), 579.0 (95%, M+2Na+-H+), 857.1 (90%). 
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Engineering ice inhibitory activity into new synthetic 
materials 
__________________________________________________ 
5.1 – Chapter Abstract 
Building upon the work of Chapter 4, this chapter outlines the development of a series of IRIs. 
Sequentially modified derivatives of simvastatin, and a chenodeoxycholic acid series, were 
synthesised. The bile acid series was rationally designed to feature the key properties and 
design motifs present in AFGP; helicity, amphipathy, and rigidity (with a defined domain 
structure). Likewise, intended as a mimic of the aromatically stacked Safranin O (a potent IRI), 
the statin series was used to probe the boundaries of IRI activity for hydrophobic small 
molecules, in order to determine whether activity can be modulated through minor structural 
modifications (as previously observed). Neither series demonstrated any meaningful IRI 
activity. However, this study has contributed to our understanding of the IRI structure-activity 
relationship, indicating that simple mimicry of core structural properties observed in AFGP 




5.2 – Chapter Introduction 
The discovery of novel AF(G)P mimetics has, to date, almost exclusively focussed on the 
development of simplistic polymers and synthetic polypeptides, many of which have been 
identified through serendipity or trial-and-error screening.1–3 Recently however, evidence of 
more rationally designed architectures have been presented in the literature and have been 
shown to possess significant IRI potency.  
Ben and co-workers have worked extensively on the development of synthetic glycopeptides, 
with IRI activity similar to AFGP.4 Recently they have shown small molecule inhibitors, with 
an optimised O-aryl-glycoside and N-aryl-D-aldonamide showing significant IRI activity (5 % 
MGA and 3 % MGA, respectively) at 22 mM (7.81 and 6.36 mg.mL-1, respectively). Slow 
freezing (-40 ºC, with storage at -80 ºC) of red blood cells in the presence of the optimum 
brominated O-aryl-galactoside candidate + 15 % glycerol saw a 60 % recovery of red blood 
cells post-thaw, contrasted to 28 % without.5,6 Similarly, a fluorinated N-aryl-D-aldonamide 
showed promise at enhancing the post-thaw colony forming ability of umbilical cord red blood 
cells (by ~ 15 % with 5 mM / 1.45 mg.mL-1 doping).7 These species clearly demonstrate 
potential application, but they are however not the most potent small molecule IRI candidates 
to have been prepared, and cryopreservative ability is ultimately limited with statistically 
identical post-thaw cellular recoveries to DMSO alone. 
Most notably, is the work of Scott and Gibson and co-workers who have shown that 
enantiomerically pure amphipathic metal-organic frameworks – metallohelices – are capable 
of potently inhibiting ice crystal growth to 20 % MLGS at 20 µM.8 These levels of activity are 
unprecedented amongst synthetic mimics, and comparable to hyper-potent AFGP-8 (~ 15 % 
MLGS at 5 µM). Likewise, Dori and co-workers recently reported on the activity of Safranine 
O, a small molecule IRI which is capable of supramolecular assembly in solution.9 These 
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species are however inapplicable to biomedical translation, due to the potential cytotoxicity of 
transition metals and quaternised ammonium centres, respectively. However, in the absence of 
a definitive mechanism of action and given the common structural profile of these candidates 
(namely rigidity, amphipathy, and defined domain structure), a question is presented as to 
whether a more finite, considered approach to IRI design maybe employed in order to access 
clinically useful candidates with excellent IRI potency. 
The potency of Safranine O is thought to stem from intramolecular pi-pi stacking, facilitating 
the formation of an extended – amphipathic – macromolecular architecture.9 Contrarily, Ben 
and co-workers have successfully demonstrated the IRI activity of numerous (non-assembling) 
O-aryl-glycosides, indicating that potent IRI activity may not be the reserve of macromolecules 
alone.6,10 
Without a universally established rational design blue print or mechanism of action, the 
potential synthetic space which may be explored in the process of discovering a, new, potent 
IRI inhibitor is prohibitively expansive. Recent work by Gibson and co-workers,8 in addition 
to Chapters 2 and 4 herein, have however identified amphipathy (aided by structural rigidity) 
as potential design rationale in the preparation of IRI active species. As such, here we further 
explore these core structural motifs believed to be responsible for IRI activity, and investigate 
their incorporation into IRI inactive species by structural modification, with the aim of 
introducing IRI potency.  
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5.3 – Results and Discussion 
5.3i – Synthesis and IRI analysis of Simvastatin derivatives 
In order to explore the IRI activity field and further establish a range of small molecules which 
possess IRI potency (and which have been comparatively underexplored to date), attention was 
turned to the DrugBank archive. The repurposement of legacy pharmaceutical agents is of 
particular relevance, and the abundance of data present within the DrugBank provided a viable 
starting point for the initial assessment of potential chemical structures. A query was executed 
resulting in the display of a series of potential candidates of interest, matching the 
desired/prescribed criteria; Small molecule = true, LogP > 2 – and therefore possessing 
prominently hydrophobic character, regulatory approval = true – and therefore commercially 
sourceable. Results were then inspected and solubilities compared between the candidates. Of 
these results, Simvastatin represented the most intriguing candidate. Given its status as a small, 
rigid, hydrophobic small molecule – with some hydrophilic character – the IRI activity 
assessment of a small series of Simvastatin and its key metabolites was of specific interest, 
with the core structural motifs supposedly matching our hypothesised design rationale. 
 
Figure 5.1 – Synthesis of the panel of simvastatin derivatives prepared for IRI activity assessment. 
30%                              87%                           97%    
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Due to Simvastatin’s (1) low water solubility, three further synthetic derivatives were prepared, 
to i) enhance solubility (and potentially access greater magnitudes of activity) and ii) to explore 
the effect upon IRI activity by sequential modification and amplification of the hydrophilic 
domain (Figure 5.1). 
In the first instance, a ring-opened candidate (2) was synthesised through the selective 
hydrolysis of the lactone ring by samarium iodide, in the presence of the butyric ester, cleanly 
affording the desired compound after chromatography in moderate yield (30%). 4 was 
subsequently accessed through saponification of 2 in 97% yield, whilst saponification of 1 
yielded product 3 in equally excellent yield (87%). Importantly, these candidates have disparate 
hydrogen bonding capacities, potentially impacting upon IRI activity, and aqueous solubilities 
of 2, 3, and 4 were determined by UV-Visible spectroscopy. Subsequent IRI activity analysis 
indicated no activity across the series and comparable to a PBS control, Figure 5.2.  
 
Figure 5.2 – IRI activities of the statin series at their saturated solution concentrations. IRI activity 
measured as a function of solute concentration. MGA = Mean grain area relative to a PBS control, 
expressed as %. Error bars represent the ± standard deviation from three independent measurements. 
 








































 4: ROP + Hydrolysed
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Simvastatin itself possessed no activity at a saturated solution concentration of 30 µg.mL-1,11 
and so enhancing solubility to access greater levels of potency was clearly vital. However, 
whilst the modified candidates demonstrated substantially increased solubility across the 
series, they too possessed weak activity. The ring opened and hydrolysed derivative (4) 
demonstrated enhanced solubility to Simvastatin itself (0.65 mg.mL-1) but was comparatively 
less soluble than the other synthetic candidates – presumably due to aggregation facilitated by 
the free hydroxyl groups. The ring opened equivalent on the other hand (2) possessed 
substantially increased solubility, and further removal of the butyric acid ester and lactone 
hydrolysis (3) gave the highest solubility of the series at 12.45 mg.mL-1, likely enhanced by 
salt formation in buffer. Whilst unable to form a supramolecular architecture, these candidates 
were unable to show potency in the same manner as non-assembling equivalents of proximal 
size and hydrophobicity. This indicates that designing a new IRI around simple design rules is 
astonishingly difficult, and a more elegant strategy is ultimately required.  
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5.3ii – Synthesis and IRI analysis of poly(bile acids) 
Antifreeze glycoproteins are unique in their structural conformation, both intrinsically flexible 
and rigid, they are also amphipathic, featuring well defined regions of hydrophobicity and 
hydrophilicity. Mirroring these key structural properties on a simple framework may yield a 
viable candidate with enhanced IRI activity. However, rational design has thus far proven 
problematic. Amphipathic species have a tendency to aggregate and micellise, making 
exposure of both domains in solution – a crucial prerequisite for IRI function – challenging to 
achieve. As shown in Chapter 4, a rigid amphiphile has potential to infer enhanced IRI activity. 
Naturally occurring bile acids, synthesised by the liver and found in the bile of mammals, have 
numerous biological functions, and are primarily involved in cholesterol metabolism. These 
species are unique, in that they are amphipathic and structurally rigid due to the presence of a 
conjugated hydrophobic ring system. Depending on the particular derivative, bile acids have a 
degree of flexibility due to the presence of alkyl chains, with hydrophilicity inferred from the 
presence of spatially segregated alcohol groups. 
These properties make bile acids an interesting proposition for investigation herein, featuring 
highly analogous structural properties to AFGP, it is possible that certain bile acids may have 
IRI potency, particularly when polymerised. In addition, below the critical micelle 
concentration, bile acids are known for their ability to sit at the water/oil interface – due to the 
established importance of the hydrophobic domain in IRI activity – this property is of particular 





Figure 5.3 – Comparison of structural motifs of AFGP and chenodeoxycholic acid. 
The preparation of macromolecular architectures of bile acids therefore warrants the use of a 
species with multiple sites of functionality. Chenodeoxycholic acid, Figure 5.3, represents an 
ideal bile acid candidate for investigation. It’s spatially distinct hydroxyls, protruding from 
segregated positions on the rigid conjugated rings, and a flexible carboxylic acid tail, allow for 
polyesterification whilst retaining amphipathy and the core design criteria. Its synthetic 
versatility – and the recognised ability to easily and selectively functionalise at the C-3 






Scheme 5. 1 – Initial synthetic route for the generation of a poly bile acid-carbohydrate conjugate. 
A strategy involving the selective mono-glycosylation of a chenodeoxycholic acid framework 
was devised, with the sugar acting as an ‘enhanced’ hydrophilic domain, larger and more 
pronounced than a lone free hydroxyl group. As per Chapter 4, galactose in particular was 
selected due to its natural occurrence as a constituent unit of the hydrophilic domain in AFGP. 
Scheme 5.1. It was hypothesised that, when polymerised as poly(chenodeoxycholic acid-3-
galactopyranose), this system would be a predominantly hydrophobic rigid structure, with 
facially distinct ‘patches’ of hydrophilicity, and a degree of flex, representative of AFGP. 
1                                                         8
76%                                                   47%
2                                                               9                                                                                                              10
95%                                                                               
8
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Figure 5.4 – Energy minimized model of the polymeric conjugate (featuring axes). 
Furthermore, energy minimisation modelling (ChemDraw) of an N=20 stretch of the 
amphipathic poly(chenodeoxycholic acid-3-galactopyranose) indicated that the structure may 
have a propensity to adopt a helical structure (partly driven by the sugar unit), Figure 5.4. This 
is particularly interesting, given the PPII helix adopted by AFGP, the role which it plays in 
ensuring amphipathic domain presentation, and by extension, IRI activity. 
In pursuit of the monomer 9, stereopure 1,2:3,4-Di-O-isopropylidene-α-D-galactopyranose 
was first synthesised in good yield (76 %) with 2,2-dimethoxypropane in dry acetone, in the 
presence of a sulphuric acid catalyst. Iodination followed, giving the iodosugar for conjugation 
in reasonable yield (47 %). The chenodeoxycholic acid methyl ester was prepared in parallel 
(95 %), and in combination with the iodosugar, was subsequently subjected to Williamson 
conditions for ether synthesis, as per the literature precedent. 
Despite the employ of dry solvents, air free-technique, and heating, mass spectrometry 
indicated the absence of the desired product, and instead showed a starting material dimer at 
779.3 m/z [CDCA+Gal-6-OH+I-]. Column chromatography of the crude mixture resulted in 
the isolation of the two distinct – unconjugated – reactants. 
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Although ether syntheses have the potential to be low yielding, and are heavily dependent upon 
the presence of moisture, solvent, kinetics, and the propensity of the reactants to undergo side 
reactions (such as E1cb of the alkylating agent), the outright failure of the step was surprising. 
The literature precedent has however only effectively demonstrated the use of methyl iodide 
as the alkylating agent – a comparatively smaller species to the iodosugar. Consequently, 
considering the steric bulk of the bile acid, it is possible that the formation of such an ether is 
highly unfavourable, given the resulting congestion around the C-3 position by the forcing 
together of the two ring systems. Furthermore, despite the inherent stability of ethers, given the 
close proximity of the sugar and bile acid when conjugated, it is possible that any ether formed 
would be so puckered and/or crowded as to render it particularly susceptible to hydrolysis. In 
addition, evidence of elimination by-products in the isolated carbohydrate were also observed, 
with characteristic alkene signals present in the 5.5 – 6.1 ppm range and complex epimer 
multiplets between 3 – 4 ppm, indicating that inactivation of the iodosugar may have also 




Scheme 5.2 – Revised synthetic scheme for the production of the poly bile acid-carbohydrate conjugate 
featuring a malonate spacing-linker, 7. 6 was not isolated and was prepared in-situ. 
Due to the failure of the selective coupling route, an alternative synthesis was therefore 
proposed, Scheme 5.2. As a result of the steric bulk hindering both hydroxyl positions, it was 
considered necessary to introduce a ‘spacing’ linker, which would give sufficient separation 
from the backbone ring system and the carbohydrate unit, so as to not slow or inhibit the 
conjugative glycosylation step. For conjugation, an ester at the more synthetically accessible 
ring-7 position was preferentially opted for, due to the failure to selectively install an ether at 
ring-3. Importantly, molecular modelling of this amended route suggested that the final 
product, 7, would also possess the propensity to form a solvent accessible helical structure, 












Figure 5.5 – Energy minimized model of 7 at varying molecular weights. A) DP10 Simulation, B) 
DP20 Simulations (Two angles). 
As such, chenodeoxycholic acid methyl ester (2) was stereoselectively oxidised at the ring-7 
position using N-bromosuccinimide to give 7-ketolithocholic acid methyl ester in 48% yield. 
The ring-7 position has fewer repulsive interactions and ease of accessibility towards bases 
across the unhindered equatorial face due to its axial conformation, this enhances its proclivity 
towards oxidation relative to the equatorial ring-3 position.13 This temporary installation of a 
ketone, effectively acting as a protecting group, would allow for the stereoregular 
polymerisation of chenodeoxycholic acid through the ring-3 hydroxyl only. As per literature 
precedent, the 13C NMR of the crude material, Figure 5.6, identified the 7-keto isomer as the 
major product of this step, and was easily isolated from the 3-ketolithocholic acid methyl ester 








Figure 5.7 – 13C NMR (CDCl3) of 7-ketolithocholic acid methyl ester (Purified). 
Subsequent ester hydrolysis and polycondensation via carbodiimide coupling yielded the 7-
ketolithocholic acid derived polyester, 5, Table 5.1.  
Mass (mg) Yield (%) MnTHEO (g.mol-1) a MnOBS (g.mol-1) a Đ a DP a 













Table 5.1 – GPC/SEC and Yield data for poly(7-ketolithocholic acid). a MnTHEO = molar mass assuming 
100% condensation of starting material, MnOBS = molar masses as observed experimentally, Đ = 
dispersity, and DP = degree of polymerization, determined by SEC. 
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Due to the step-growth nature of polyesterification, a propagative series of molecular weights 
was obtained, giving a resolvable polydisperse mixture, Figure 5.8. This was of serendipitous 
importance in the rational design process, given that AFGP exists in nature as a polydisperse 
protein, as we believed that the production of a mixture of chain lengths may provide a more 
proximal mimic of AFGP. 
























Figure 5.8 – SEC trace of poly(7-ketolithocholic acid). 
Reduction of the 7-keto group was then necessary to restore the unmasked hydroxyl group, to 
which the glycosyl unit and linker were to be conjugated. In the pursuit of preparing a well-
defined AFGP mimetic, stereoregularity was to be maintained. As such, it was necessary to 
determine an optimum method for effective reduction, and the return of uniform 




Figure 5.9 – Stereoselective reduction of 7-ketolithocholic acid methyl ester to CDCA methyl ester. 
Utilising a sample of 7-ketolithocholic acid, it was found (as per literature precedent) that an 
excess of sodium borohydride in methanol was sufficient to return the original R 
stereochemistry of the ring-7 position, without any evidence of racemisation. Figure 5.10. 
 
Figure 5.10 – 13C NMR (CDCl3) of chenodeoxycholic acid methyl ester (Post NaBH4 Reduction). 
Whilst the ability of sodium borohydride to reduce esters is limited in extent – often failing to 
do so entirely, except under harsh conditions or elevated temperature – the use of a 2-fold 







resulting in degradation. However, after four hours of exposure, the small molecule trial 
showed no evidence of hydrolysis of the terminal methyl ester, implying synthetic resilience. 
Nevertheless, in the interests of preventing polymer hydrolysis, exposure to sodium 
borohydride was limited to half the time employed for the small molecule. 
Following the reduction of the ketone containing polymer, subsequent SEC analysis of the 
intermediate species indicated a shift in the molecular weight profile of the polymer mixture. 
The mixture contained DP10, DP5 and some smaller oligomeric fragments, as previous, whilst 
the DP20 derivative was seemingly absent. The strength of the DP10 signal was further 
intensified, implying that the DP20 stretch may have undergone significant hydrolysis. Figure 
5.11A and B. This may suggest that, should it have formed an extended helical-like structure 
as hypothesised, that the strain of its coiling may have predisposed the DP20 stretch to ester 
reduction and degradation to a more stable chain length. 
Now reduced, functionalisation of the disperse poly(chenodeoxycholic acid) mixture with the 
malonic acid linker and galactose unit by carbodiimide coupling was to follow. Conjugation of 
the previously prepared sugar, 1,2:3,4-Di-O-isopropylidene-α-D-galactopyranose, through the 
free 6-hydroxy position to the poly(chenodeoxycholic acid) mixture was achieved in-situ with 
1 equivalence of malonic acid. In order to avoid any inadvertent backbone ester cleavage, the 
malonic acid was first incubated in the presence of a large excess of EDCI, in order to ensure 
no solution acidity remained. pH testing confirmed the neutrality of the coupling mixture, 
before introduction to the bile acid polymer. This further ensured the malonic acid carboxylic 
acids were activated, prior to attack by the bile acid alcohol groups. Delayed addition of a large 
excess of Gal-6-OH then ensured quantitative glycosylation to the activated, but uncoupled, 
malonic acid chain ends. Fleeting exposure to a dilute acidic solution in order to cleave the 
sugar acetal protecting groups followed, yielding the final “Deprotected” candidate. 
Subsequent SEC analysis, Figure 5.11B, showed little change in the molecular weight profile 
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of the polymer, indicating that the transient acid exposure did not result in significant ester 
backbone cleavage. 
 
Figure 5.11 – A) Overlaid SEC RI traces of the polymeric bile acid series synthesised. B) Comparison 
between poly(7-ketolithocholic acid) and the reduced poly(CDCA). 
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Unusually, an expected shift in molecular weight associated with glycosylation was not 
observed, however, 1H and 13C NMR analysis indicated near quantitative glycosylation and 
successful installation of the malonic acid linker, Figure 5.12 and 5.13, respectively. Integration 
of the anomeric galactose C1 peak at 4.61 ppm relative to a bile acid C-3H signal at 2.29 ppm, 
indicated a ratio of ~ 1:3, respectively. Furthermore, the absence of the acetal signals in the 1H 
NMR confirmed sugar deprotection. Importantly, repeated washing & precipitation from water 
– in which the final species had poor solubility – ensured the removal of any excess and 
unconjugated galactose and malonic acid. 
 







Figure 5.13 – Comparative 13C NMR (CDCl3) of the deprotected poly(chenodeoxycholic acid-7-
malonate galactose) (Brown) and chenodeoxycholic acid methyl ester (Blue). 
Once dried, the poly(chenodeoxycholic acid-7-malonic-6-galactopyranoside) candidate, A, 
along with the unconjugated poly(chenodeoxycholic acid) B, and poly(chenodeoxycholic acid-
7-one) C, intermediates, and the chenodeoxycholic acid, D, starting material, were carried 
forward for splat testing and analysis, Figure 5.15. Due to low solubilities, the samples were 




Figure 5.14 – Series of bile acid derivatives and polymers assayed for IRI activity. 
Chenodeoxycholic acid (CDCA) was found to have very weak IRI activity, inhibiting the 
growth of ice crystals to ~ 80% of their original size at 90 µg.mL-1 (the CDCA solubility limit), 
Figure 5.15. 



































 C: poly(Ketolithic acid)
 D: CDCA
 
Figure 5.15 – IRI activities of the bile acid series. IRI activity measured as a function of solute 
concentration. MGA = Mean grain area relative to a PBS control, expressed as %. Error bars represent 
the standard deviation from three independent measurements. 
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In contrast, the synthetic candidates exhibited comparatively greater solubilities across the 
board, with polymeric CDCA (B) showing a near x2.5 increase in solubility in aqueous 
solution. This solubility jump would likely indicate that the formation of a rigid extended 
structure – potentially helical in nature – has resulted in a greater degree of solvent accessibility. 
Intriguingly, the poly(ketolithocholic acid) equivalent – differing only by the presence of a 
ketone group (in place of a hydroxyl) at the C-7 position – further demonstrates a near 10-fold 
increase in solubility. As a hydrogen bond acceptor only, C lacks the same H-bonding capacity 
as donor and acceptor B. This may infer that the poly(ketolithocholic acid) likely has a 
substantially different polarity profile and solution structure, aiding and abetting solubilisation. 
However, whilst neither candidate demonstrated any appreciable IRI activity, this may suggest 
it is possible to perform minor structural ‘tweaks’ to potent, but insoluble, IRI candidates in 
order to significantly enhance solubility (and potentially activity) without significant structural 
modification or amphipathic distortion (which has been shown to destroy potency – Chapter 
4). 
Conjugation of the malonic acid linker and galactose motif did little to rescue IRI activity. 
Whilst still possessing greater solubility than poly(CDCA), this bile acid-carbohydrate 
conjugate (A) was less soluble than poly(ketolithocholic acid) – suggesting that the free 
hydroxyl groups acted to both solubilise and aggregate, lowering overall solution concentration 







5.4 – Conclusions 
A series of poly(bile acids) and corresponding small molecules were synthesised, as were a 
series of hydrophobic, small molecule, simvastatin derivatives. IRI activity was not induced in 
any of the prepared species, despite the inclusion of specific design motifs observed in other 
hyper-potent IRIs of both synthetic and natural origin. 
The preparation of AFGP inspired poly(chenodeoxycholic acid) derivatives, which were 
designed to be; intrinsically amphipathic, polydisperse, highly rigid with some slight 
flexibility, and containing spatially segregated and defined hydrophobic / hydrophilic faces – 
mimicking AFGP – did not show the anticipated potency. These results indicate that simply 
replicating the baser structural properties of hyper-active species is not necessarily sufficient 
to effectively inhibit ice crystal growth. Furthermore, the observations reported herein may 
further suggest that a model of ice recrystallisation inhibition dependent upon ice-face binding 
is the primary mechanism by which crystal growth is actually impeded. AFGP and PVA have 
both been reported to bind to ice, whilst AFP is thought to order clathrate waters and therefore 
bind indirectly. In all cases, the three-dimensional spacing of both methyl and hydroxyl groups 
are thought to play a significant role – and despite the stereopurity of the prepared candidates 
– the lack of specific engineering of the geometric presentation of domains may be responsible 
for the observed failure of activity. 
Similarly, sequentially modified Simvastatin derivatives – intended to mimic other small 
molecule species such as Safranine O – did not effectively inhibit ice crystal growth. Although 
unable to form a supramolecular architecture, the lack of potency when compared to other non-
assembling small molecules would clearly indicate a fundamental presentative disparity – with 
functional groups potentially not optimised for specific ice facing binding. 
Collectively, these results show that rational IRI design is unpredictable, and highly difficult.  
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5.5 – Experimental 
Materials 
Physical and analytical methods 
1H and 13C NMR Spectra (300 – 400 MHz and 75 – 100 MHz, respectively) were recorded 
using one of a Bruker DPX-300/400 Spectrometer under standard NMR conditions. Chemical 
shifts were recorded in ppm and referenced to solvent residual peaks, using MestReNova NMR 
Spectroscopy software. 
ESI MS experiments were performed on an Agilent 6130B Single QUAD ESI-LC MS 
spectrometer in either positive or negative mode with an H2O/MeOH (80:20) eluent feed, with 
samples dissolved in water or methanol, unless otherwise stated. 
SEC/GPC data was acquired on either a DMF Agilent 390-LC MDS instrument equipped with 
differential refractive index (DRI), viscometry (VS), dual angle light scatter (LS) and dual 
wavelength UV detectors. System equipped with a PL-AS RT/MT2 autosampler, Shimadzu 
SPD-M20A microarray detector, a PL-gel 3 μm (50 × 7.5 mm) guard column and 2 × PL-gel 
5 μm mixed-D columns (300 x 7.5 mm). Samples were filtered and suspended in the relevant 
HPLC grade solvent (DMF with 5 mmol NH4BF4 additive), with a flow rate of 1 mL/min
-1 at 
50ºC. Refractive index recorded. Analyte samples were filtered through a nylon membrane 
with 0.22 μm pore size before injection. Respectively, experimental molar mass (Mn,SEC) and 
dispersity (Đ) values of synthesized polymers were determined by conventional calibration 
(relative to poly(methyl methacrylate) standards – Agilent EasyVials, 690 – 271400 Da) using 
Agilent GPC/SEC software. Refractive index recorded. 
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Absorption UV/Vis (Ultra-violet/visible spectroscopy) spectra were acquired on an Agilent 
Technologies Cary 60 Variable Temperature UV-Vis spectrophotometer at room temperature 
fitted with Holographic Grating (27.5 × 35 mm, 1200 lines/mm, blaze angle 8.6° at 240 nm), a 
double beam, Czerny-Turner monochromator, 1.5 nm fixed spectral bandwidth, full spectrum 
Xenon pulse lamp single source, dual silicon diode detectors, quartz overcoated optics, non-
measurement phase stepping wavelength drive, room light immunity. Analysis undertaken 
using Agilent CaryWin UV Scan software. All sample spectra were acquired in Hellma 





Solubilization of insoluble samples for analysis 
Insoluble samples for splat and UV-Vis analyses (see below) were added to a PBS solution and 
centrifuged (10K, 10 minutes) and the supernatant removed – to give a saturated solution of 
unknown concentration in PBS. 
UV-Vis concentration determination of insoluble samples for analysis 
Calibration: Depending on sample solubility, the spectrometer was calibrated with either a 
Acetone or Methanol ‘blank’ (machine zeroed and a background scan conducted). A stock 
solution of the species of interest was prepared (in Acetone or Methanol) at a known 
concentration and serially diluted, and a spectrum acquired for each concentration in the 200 – 
800 nm range (600 nm/min scan rate, 1.00 nm data interval, 0.1 s average time), to give a Beer-
Lambert calibration plot. 
Sample Concentration Analysis: 200 – 400 µL (typically) of the sample of interest was taken 
as a saturated solution in PBS, and condensed in vacuo. The dry residue was subsequently re-
dissolved in the same volume of Acetone or Methanol, mixed, and drawn up to separate the 
liquor from the insoluble PBS salts. The UV-Vis spectrum was then acquired, as above, with 
dilution employed (and corrected for) where necessary. The λmax of the primary peak was 
identified and the absorbance recorded and intersected against the line of best fit of the Beer-
Lambert plot of the stock calibrants to give the saturated samples concentration in PBS 
solution. 
Ice recrystallization inhibition (splat) assay 
Ice recrystallization inhibition was measured using a modified splat assay.1 A 10 µL sample of 
the species of interest, dissolved in PBS buffer (pH 7.4), was dropped 1.40 m onto a chilled 
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glass coverslip, resting on a thin aluminium block placed on dry ice. Upon hitting the coverslip, 
a wafer with diameter of approximately 10 mm and thickness 10 µm was formed 
instantaneously. The glass coverslip was transferred onto the Linkam cryostage and held 
at -8oC under N2 for 30 minutes. Photographs were obtained using an Olympus CX 41 
microscope with a UIS-2 20x/0.45/∞/0-2/FN22 lens and crossed polarizers (Olympus Ltd, 
Southend-on-Sea, UK), equipped with a Canon DSLR 500D digital camera. Images were taken 
of the initial wafer (to ensure that a polycrystalline sample had been obtained) and again after 
30 minutes. Image processing was conducted using Image J, which is freely available (National 
Institutes of Health, Bethesda, MD). In brief, the number of ice crystals in the field of view 
was measured, and the measurement repeated for three independent wafers. The average 
(mean) of these three measurements was then calculated to find the mean grain area (MGA). 
The average value and error was compared to that of a PBS buffer negative control. 
Surface hydrophobicity mapping of polymers 
Structures of interest were assembled in ChemDraw Professional 16.0 (PerkinElmer 
Informatics Inc., Waltham, MA). The structures were then energy minimised in Chem3D and 
the resulting structures rendered with the surfaces displayed and hydrogens removed from the 
structure. Carbon (and so aliphatic hydrogen) defined as hydrophobic (grey), whilst oxygen 






1,2,6,7,8,8a-hexahydronaphthalen-1-yl)heptanoic acid (Hydrolysed Simvastatin, 3) 
 
Simvastatin (100 mg) was dissolved in THF (10 mL) and a large excess of NaOH dissolved in 
H2O was subsequently added (10 mL, 160 mg, 16.7 eqv). The reaction mixture stirred at RT 
for 36 hours, and then condensed in vacuo. The dry residue was dissolved in CHCl3 (30 mL) 
and 1M HCl (30 mL), the organic phase separated, and extracted with water (3 x 30 mL). The 
organic phase was then dried over MgSO4, filtered, and condensed in vacuo, to give a clear 
crystalline solid (70 mg, 86.6%). 1H NMR (400 MHz, MeOD) δ = 6.00 (dd, J = 9.3, 5.8 Hz, 
1H), 5.86 – 5.76 (m, 1H), 5.52 (s, 1H), 5.36 (s, 1H), 4.87 (s, 3H), 4.64 (d, J = 7.3 Hz, 1H), 4.27 
(s, 1H), 4.23 – 4.11 (m, 1H), 3.70 (s, 1H), 3.62 (q, J = 7.1 Hz, 1H), 3.37 (s, 1H), 3.01 (s, 1H), 
2.88 (s, 1H), 2.74 (dd, J = 17.7, 4.5 Hz, 1H), 2.60 – 2.27 (m, 5H), 2.08 – 1.91 (m, 3H), 1.89 – 
1.69 (m, 2H), 1.65 – 1.49 (m, 4H), 1.41 (dd, J = 22.5, 10.5 Hz, 2H), 1.24 (ddd, J = 20.2, 14.3, 
6.9 Hz, 3H), 1.15 – 1.03 (m, 8H), 0.96 – 0.80 (m, 7H). 13C NMR (101 MHz, MeOD) δ 179.30, 
175.35, 173.31, 134.16, 133.89, 133.15, 130.31, 129.52, 78.12, 71.76, 69.74, 68.29, 63.24, 
44.7, 44.09, 43.03, 39.63 – 39.35, 39.63 – 38.56, 38.28, 38.04, 36.62, 35.96, 35.03 – 33.98, 
33.76, 31.89, 30.69, 28.59, 25.80, 25.27, 23.67, 18.38, 14.14, 9.82. m/z (ESI, ̶ ve) Observed 






1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate (Ring Opened 
Simvastatin, 2) 
 
Simvastatin (100 mg) was dissolved in dry THF (5 mL) and samarium (II) iodide/THF solution 
(0.1M, 20 mL) was added under dry nitrogen, and the reaction mixture stirred at RT. After 36 
hours, the reaction was exposed to air and saturated NH4Cl solution was added slowly. The 
mixture was filtered, dissolved in ethyl acetate (50 mL) and extracted with saturated NH4Cl 
solution (1 x 50 mL), followed by water (1 x 50 mL). The organic phase was subsequently 
condensed in vacuo, and the reduced syrup loaded onto silica gel and purified by column 
chromatography (EtOAc, 100%; Rf = 0.22, Fractions 17 – 23). The condensed fractions yielded 
a clear crystalline solid (30 mg, 29.7%). 1H NMR (400 MHz, CDCl3) δ 5.95 (d, J = 9.4 Hz, 
1H), 5.76 (d, J = 5.8 Hz, 1H), 5.42 (d, J = 35.9 Hz, 2H), 4.08 (s, 1H), 3.96 – 3.61 (m, 4H), 2.47 
– 2.18 (m, 4H), 2.04 – 1.84 (m, 2H), 1.75 – 1.45 (m, 10H), 1.42 – 1.30 (m, 1H), 1.21 (d, J = 
12.9 Hz, 6H), 1.12 – 1.00 (m, 9H), 0.91 – 0.73 (m, 7H). 13C NMR (101 MHz, CDCl3) δ 178.49, 
133.15, 131.65, 129.68, 128.39, 124.84, 72.79, 71.29, 68.29, 61.11, 43.06, 38.91, 37.86, 36.17, 
35.15, 33.14, 31.00, 30.54, 30.07, 29.44, 27.36, 24.83, 24.23, 22.99, 22.71 – 22.32, 13.99, 9.39. 







hexahydronaphthalen-1-yl)heptane-1,3,5-triol (Ring Opened and Hydrolysed 
Simvastatin, 4) 
 
A sub-sample of 2 (20 mg) was dissolved in THF (10 mL) and a large excess of NaOH 
dissolved in H2O was subsequently added (10 mL, 195 mg, 103 eqv). The reaction mixture 
stirred at RT for 36 hours, and then condensed in vacuo. The dry residue was dissolved in 
CHCl3 (30 mL) and 1M HCl (30 mL), the organic phase separated, and extracted with water 
(3 x 30 mL). The organic phase was then dried over MgSO4, filtered, and condensed in vacuo, 






Galactose (1.00 g, 5.55 mmol) was dissolved in dry acetone (30 mL) and followed by 2,2-
dimethoxypropane (1 mL, 1.5 eqv, 8.33 mmol) with stirring. A catalytic volume of H2SO4 (0.1 
mL, 12M) was then added and the reaction mixture was stirred at RT overnight. The crude 
mixture was then neutralised with solid NaHCO3 until pH 7 and the solution had decolourised. 
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The slurry was then condensed in vacuo and taken up into diethyl ether (30 mL) and filtered, 
with ether washing (5 x 20 mL). The ether was then removed by rotary evaporation yielding a 
clear, colourless oil. 1.1 g (76.1%). 1H NMR (400 MHz, CDCl3) δ 5.40 (s, 1H), 4.46 (d, J = 7.4 
Hz, 1H), 4.31 – 4.03 (m, 2H), 3.89 (ddd, J = 16.1, 13.2, 5.8 Hz, 2H), 3.72 – 3.50 (m, 2H), 3.31 
(dd, J = 31.4, 28.5 Hz, 2H), 3.12 (s, 1H), 2.82 (s, 1H), 1.48 – 1.00 (m, 12H). 13C NMR (101 
MHz, CDCl3) δ 109.21, 108.45, 104.93, 103.70, 102.02, 96.04, 88.82 – 87.49, 86.95, 84.58, 
81.56, 79.26, 78.22, 77.72, 76.74 – 75.01, 71.07, 70.40, 69.64, 69.29 – 68.72, 68.14, 68.14, 
69.29 – 62.36, 61.57, 55.00, 54.53, 27.33 – 26.85, 26.65, 26.71 – 25.16, 24.78, 24.72, 24.12. 
m/z (ESI, +ve) Observed 283.2 [40%, M+Na+]. Compound previously reported.15 
 
Synthesis of methyl 4-((3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate 
(Chenodeoxycholic acid methyl ester) 
 
Chenodeoxycholic acid (1.00 g, 2.46 mmol) was dissolved in methanol (25 mL) and 6M HCl 
(10 mL) added, and the reaction mixture stirred at room temperature for 24 hours. After which, 
the reaction mixture was condensed in vacuo. The dry residue was then redissolved in ethyl 
acetate and extracted from water (3 x 20 mL), and brine (1 x 30 mL). The combined organic 
phases were then dried over MgSO4, filtered, and condensed in vacuo to give an off-yellow oil. 
940 mg (94.5%). 1H NMR (400 MHz, CDCl3) δ 3.73 (s, 1H), 3.56 (s, 3H), 3.24 (d, J = 66.7 
Hz, 2H), 2.39 (s, 1H), 2.32 – 2.01 (m, 4H), 1.72 (dd, J = 57.0, 45.6 Hz, 8H), 1.48 – 0.94 (m, 
14H), 0.81 (s, 6H), 0.56 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 174.64 (Ester), 71.69 (C3-
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OH), 68.14 (C7-OH), 55.79, 51.39, 50.34, 42.52, 41.54, 39.63, 39.33, 36.35 – 34.75, 34.70, 
32.78, 30.78, 29.38, 28.11, 23.16, 20.56, 18.23, 11.68. m/z (ESI, +ve) Observed 429.4 [100%, 
M+Na+]. Compound previously reported.12 
 
Synthesis of methyl 4-((3R,5S,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-7-
oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate (7-ketolithocholic 
acid methyl ester) 
  
Chenodeoxycholic acid methyl ester (0.44 g, 1.08 mmol) was dissolved in acetone/saturated 
sodium hydrogen carbonate solution (20 mL, 1:1) and shielded from light. N-
bromosuccinimide (0.241 g, 1.35 mmol, 1.25 eqv) was added, and the reaction mixture stirred 
at room temperature for 24 hours. After which, the reaction mixture was quenched with 
saturated sodium thiosulphate solution (10 mL), and then condensed in vacuo. The dry residue 
was then redissolved in diethyl ether (30 mL) and extracted from saturated sodium hydrogen 
carbonate solution (3 x 20 mL), and water (1 x 30 mL). The combined organic phases were 
then dried over MgSO4, filtered, and condensed in vacuo to give an off-yellow oil which was 
loaded onto silica gel and purified by column chromatography (Et2O/CHCl3, 7:3; Rf = 0.42, 
Fractions 15 – 23, KMnO4). The condensed fractions yielded a clear crystalline oil (210 mg, 
48.1%). 1H NMR (300 MHz, CDCl3) δ 3.56 (s, 3H), 3.54 – 3.41 (m, 1H), 2.76 (dd, J = 12.6, 
6.1 Hz, 2H), 2.36 – 2.01 (m, 4H), 1.96 – 1.52 (m, 9H), 1.47 – 0.94 (m, 14H), 0.86 (dd, J = 17.1, 
5.8 Hz, 4H), 0.56 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 212.35 (C=O), 174.59 (Ester), 70.52 
(C3-OH), 54.69, 51.42, 51.03, 49.50, 49.09, 46.05, 45.33, 42.66, 38.04, 38.04, 35.37 – 30.04, 
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29.75, 28.29, 24.94, 23.56, 21.60, 18.28, 14.02 – 11.05. m/z (ESI, +ve) Observed 427.4 [100%, 
M+Na+]. Compound previously reported.12,16  
 
Stereoselective Reduction of methyl 4-((3R,5S,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-
dimethyl-7-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate 
(Chenodeoxycholic acid-7-one methyl ester) 
 
7-ketolithocholic acid methyl ester (0.03 g, 0.074 mmol) was dissolved in methanol (5 mL), 
and sodium borohydride (0.0056 g, 0.15 mmol, 2 eqv) added, and stirred for 4 hours. Saturated 
ammonium chloride solution (5 mL) was then added, followed by water (20 mL) and the 
mixture extracted with diethyl ether (2 x 30 mL). The combined organic phases were then 
condensed in vacuo to give a white solid. 30 mg (99.7%). 1H NMR (400 MHz, CDCl3) δ 4.50 
(s, 4H), 3.73 (s, 1H), 3.58 (d, J = 8.2 Hz, 3H), 3.43 – 3.09 (m, 1H), 2.62 (s, 1H), 2.50 – 2.00 
(m, 4H), 1.98 – 1.49 (m, 10H), 1.20 (dd, J = 100.1, 36.4 Hz, 14H), 0.72 (dd, J = 97.3, 7.8 Hz, 
12H). 13C NMR (101 MHz, CDCl3) δ 174.59 (Ester), 70.96 (C3-OH), 67.21 (C7-OH), 55.28, 
50.54, 49.67, 48.43, 48.18, 48.03 – 47.34, 47.22, 47.00, 41.87, 41.12, 39.09, 38.65, 38.07 – 
37.74, 34.81, 34.57, 34.06, 32.12, 30.31, 29.93 – 28.95, 28.69, 27.47, 22.84, 21.93, 19.96, 
17.31, 10.76. m/z (ESI, -ve) Observed 441.3 [100%, M+Cl-]. 









7-Ketolithocholic acid methyl ester (0.21 g, 0.52 mmol) was dissolved in MeOH/water (1:1, 
20 mL) and a large excess of sodium hydroxide (0.2 g) added. The mixture was stirred at 60ºC 
overnight, and then acidified to pH 1 with 6M HCl (30 mL) and extracted with DCM (3 x 30 
mL). The combined organic phases were then washed with water (1 x 20 mL), dried over 
MgSO4, filtered, and condensed in vacuo to give a white foam (150 mg, 74.0%). 
1H NMR (400 
MHz, CDCl3) δ 3.58 (s, 1H), 3.45 (s, 1H), 2.83 (dd, J = 12.1, 5.3 Hz, 1H), 2.64 (s, 1H), 2.37 
(t, J = 11.2 Hz, 3H), 2.28 – 2.18 (m, 2H), 2.03 – 1.73 (m, 8H), 1.68 (s, 3H), 1.53 – 1.05 (m, 
18H), 0.94 (t, J = 20.6 Hz, 6H), 0.63 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 212.58 (C=O), 
179.26 (Acid), 70.90 (C3-OH), 54.87, 49.63, 48.99, 46.22, 45.47, 42.81, 39.04, 37.26, 35.28, 
34.23, 31.81 – 30.27, 29.79, 28.37, 24.91, 23.15, 21.79, 18.45, 12.16, 1.11. m/z (ESI, +ve) 





General Procedure for the homo-polymerisation of 7-ketolithocholic acid 
  
7-Ketolithocholic acid (0.440 g, 1.13 mmol) was dissolved in DCM/DMF (1:1, 20 mL) and 
EDCI hydrochloride added (0.432 g, 2.26 mmol, 2 eqv), followed by DMAP (5 mg, 0.05 eqv, 
0.056 mmol) with stirring. The mixture was heated at 60ºC for 72 hours, and then condensed 
in vacuo. The dry residue was then dissolved in acetone (5 mL) and precipitated from water 
(45 mL) and centrifuged (20 minutes, 10K RPM), twice over, to give the product – poly(7-
ketolithocholic acid) –  as an off-beige solid. (240 mg, 54.5%). Polymer weight analysed by 
SEC. 
General Procedure for the glycosylation of poly(7-ketolithocholic acid) 
  
Poly(7-ketolithocholic acid) (240 mg, 0.070 mmol, 3446 g/mol-1 Mn) was dissolved in 
methanol (10 mL) and sodium borohydride (50 mg, 1.32 mmol, 2 eqv) added, and stirred for 2 
hours. Saturated ammonium chloride solution (5 mL) was then added, followed by water (20 
mL) and the mixture extracted with dichloromethane (2 x 30 mL). The combined organic 
phases were then condensed in vacuo and redissolved in DMF/DCM (1:1, 10 mL). 
Concurrently, malonic acid (32 mg, 0.31 mmol, 0.5 eqv) was also dissolved in DMF/DCM 
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(1:1, 10 mL), and EDCI hydrochloride (235.6 mg, 1.23 mmol, 2 eqv) added with stirring, 
followed by DMAP (1 mg, 8.19 µmol, 0.1 eqv). The DMF/DCM solution of the poly bile acid 
was then simultaneously introduced via syringe to the malonic acid-carbodiimide coupling 
flask, along with a DMF/DCM (1:1, 5 mL) solution of 1,2:3,4-Di-O-isopropylidene-α-D-
galactopyranose (590 mg, 2.27 mmol, 3.7 eqv). The mixture was then stirred for 48 hours at 
60ºC. The reaction mixture was then concentrated in vacuo, dissolved in acetone (5 mL) and 
precipitated from water (45 mL) and centrifuged (20 minutes, 10K RPM), twice over, and the 
precipitate dried under vacuum and redissolved in a solution of MeOH, acidified dropwise with 
TFA (10 mL, pH 3 – 4), in which it was stirred at RT for 15 minutes. After which, the crude 
mix was precipitated from water (40 mL) and centrifuged (20 minutes, 10K RPM), twice over, 
and then dried under vacuum to give the product – poly(chenodeoxycholic acid-7-malonic-6-
galactopyranoside) –  as a thick orange oil. (130 mg, 33.9%). 1H NMR (400 MHz, CDCl3) δ 
4.83 – 4.42 (m, 5H, Gal-C1), 3.81 (s, 9H, Gal-C3,4), 3.62 (s, 7H, Gal-C2) 3.42 – 3.12 (m, 55H, 
Gal-C5,6, Malonic-CH2), 2.37 – 2.15 (m, 27H, Bile Acid), 2.02 – 1.59 (m, 97H, Bile Acid), 
1.51 – 1.34 (m, 69H, Bile Acid), 1.34 – 1.18 (m, 99H, Bile Acid), 1.18 – 0.79 (m, 136H, Bile 
Acid), 0.74 (s, 5H, Bile Acid), 0.62 (s, 31H, Bile Acid). 13C NMR (101 MHz, CDCl3) δ 174.86, 
174.44 (Polyester C=O), 168.89 (Malonic C=O), 167.34 (Malonic C=O), 124.80, 96.29 (Gal-
C1), 75.99 (Gal-C5), 72.04 –  70.50 (Gal-C2,3,4), 68.57 – 68.39 (Polyester C-O, C7-O), 64.29, 
60.27 (Gal-C6), 55.88, 53.89, 51.55, 50.47, 42.73 (CH2-Malonic), 41.76, 41.27, 39.68, 39.62, 
39.46, 35.40, 35.13 - 34.97, 34.62, 34.40, 32.86, 32.81, 31.37, 31.04, 30.96, 30.55, 29.74, 









1,2:3,4-Di-O-isopropylidene-α-D-galactopyranose (1.10 g, 4.23 mmol) was dissolved in 
toluene (75 mL), and iodine (1.65g, 6.50 mmol, 1.54 eqv) added, followed by 
triphenylphosphine (1.66g, 6.35 mmol, 1.5 eqv) and imidazole (863 mg, 12.69 mmol, 3 eqv). 
The mixture was then stirred at 70ºC for 24 hours, cooled to RT, and filtered. The filtrate was 
then extracted with saturated sodium hydrogen carbonate solution (3 x 30 mL), brine (1 x 30 
mL), and the organic phase dried over MgSO4, filtered, and then condensed in vacuo. The crude 
mix was then dissolved in chloroform (2 mL) and diethyl ether added (6 mL) with swirling, 
resulting in near instantaneous precipitation of triphenylphosphine oxide. The slurry was 
cooled on ice and then filtered through a plug of silica (diethyl ether eluent) and washed with 
ether. This process was repeated three times (from precipitation onwards), before the combined 
filtrate was condensed to give a colourless/off-white oil, which crystallised upon cooling. 740 
mg (47.3%). 1H NMR (400 MHz, CDCl3) δ 5.44 (d, J = 4.7 Hz, 1H), 4.52 (d, J = 7.8 Hz, 1H), 
4.35 – 4.13 (m, 2H), 3.85 (t, J = 6.9 Hz, 1H), 3.37 (t, J = 2.9 Hz, 1H), 3.22 (dd, J = 9.7, 7.0 Hz, 
1H), 3.10 (t, J = 8.5 Hz, 1H), 1.51 – 1.06 (m, 15H). 13C NMR (101 MHz, CDCl3) δ 109.35, 
108.68, 103.77, 96.55, 71.41, 70.99, 70.53, 68.86, 68.19, 25.93, 24.88, 24.36, 2.31. m/z (ESI, 





Failed Procedure for the Synthesis of methyl 4-((3R,5R,7R,8R,9S,10S,13R,14S,17R)-7-
hydroxy-10,13-dimethyl-3-(((3aR,5S,5aS,8aS,8bR)-2,2,7,7-tetramethyltetrahydro-5H-
bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl)methoxy)hexadecahydro-1H-
cyclopenta[a]phenanthren-17-yl)pentanoate (Chenodeoxycholic acid methyl ester-3-
1,2:3,4-Di-O-isopropylidene-α-D-galactopyranose) 
 
Chenodeoxycholic acid methyl ester (460 mgs, 1.13 mmol) was dissolved into dry THF (5 mL) 
under a flow of dry nitrogen and sodium hydride (60% dispersion in mineral oil, 83.6 mg, 2.49 
mmol, 2.2 eqv) added as a solution in dry THF (5 mL) with stirring. After 15 minutes, 1,2:3,4-
Di-O-isopropylidene-6-iodo-α-D-galactopyranose (970 mg, 2.3 eqv, 2.60 mmol) was added as 
a solution in dry THF (10 mL), dropwise, and the mixture was then stirred under nitrogen at 
40ºC for 2.5 hrs, and then cooled to RT, with stirring continued overnight. After which, the 
flask was opened to air, and saturated ammonium chloride solution (10 mL) was added. The 
mixture was then extracted from ethyl acetate (3 x 10 mL), and the combined organic phases 
were then washed with water (1 x 10 mL), dried over MgSO4, filtered, and condensed in vacuo. 
Attempted purification of the resultant oil by loading on to silica gel for column 
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This thesis has used synthetic organic, peptide, and polymer chemistries to explore the 
fundamental design rules for IRI activity. In particular, we have probed the role of amphipathy 
and have further shown it to be essential in the design of IRI active species. 
Poly(proline) was prepared by a variety of methods (including condensation and ring opening 
of N-carboxyanhydrides) and was shown to adopt a similar solution conformation to AFGP – 
a polyproline type II helix. It is ultimately this conformation, along which exists a fine balance 
of hydrophilic/phobic groups, which is responsible for poly(proline)’s inherent IRI activity 
(and the previously assumed activity of poly(L-hydroxy proline). This conformation features 
an optimal degree of facial amphilicity and domain segregation. It is clear that arbitrary or 
random introduction of hydroxyl groups will not meaningfully enhance IRI and may well 
deprecate it, as the additional hydroxyl groups in poly(L-hydroxy proline) distort the surface 
philicity, and upsets the carefully tuned amphipathic balance. The lack of ice shaping by 
poly(proline) may further indicate that direct ice face binding by some IRI active AFGP 
mimetics is not required, and that the energetic disruption of long-range water ordering is 
sufficient to impart IRI potency.  
Similarly, our development of a series of amphipathic monomers and facially amphipathic rigid 
glycopolymers has added further validity to this hypothesis. Designed to maintain a distinct 
amphipathic balance and domain segregation, it was found that the hydrophobic poly(Fulvo) 
derivative, prepared through ROMP, had enhanced IRI activity (of the order of ~ 60 % MGA 
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at 0.5 µg.mL-1), but required 1 % DMSO for solubilisation. Attempts to sequentially modified 
this structure by varying the bridgehead (from hydrophobic to hydrophilic), copolymerisation, 
and alteration of the hydrophilic ‘pendant’ group, indicated several key observations. 
Substitution of the dimethylfulvene bridgehead with an oxo-ether indicated the importance of 
amphipathy, with a loss of activity observed in the wholly hydrophilic derivative, poly(Oxo). 
Crucially, when assessed in conjunction with the lack of ice shaping and therefore ice face 
binding by the optimised candidate, poly(Fulvo-co-Diol), this implied that hydroxyl group 
presentation is insufficient to induce IRI activity, as poly(Oxo) was unable to impart IRI even 
at very high concentration. This would again indicate a mechanism for IRI activity dependent 
upon the amphipathic disruption of long-range water ordering, that the presence of an (ice 
orientated) hydrophobic domain is key (which has been heavily asserted previously), and that 
hydroxyl group presence alone is of no benefit to IRI potency. This study also affirmed the 
principle of rigidity, in that other ‘amphipathic’ species – such as flexible glycopolymers 
featuring sp3 hybridisation – have many degrees of freedom and so the amphipathic balance is 
distorted, explaining weak activity in candidates of this kind. To this end, the introduction of 
PEG chains (as a large, flexible hydrophilic domain) in place of the glycosyl motif caused 
complete loss of activity, due to the large, flexible chains obscuring the domain segregation. 
Rigidity, amphipathy, and their careful engineering to give an effective, segregated solution 
conformation can therefore be mooted as key design motifs in effective IRI design. 
However, attempts to advance this further were fundamentally challenged. The synthesis of a 
series of poly(disperse bile acid derivatives featuring; rigidity, amphipathy, and suspected 
helicity (giving the segregated domain thought necessary), similar to AFGP, did not impart IRI 
potency. This shows that the structure produced was not precise enough and suggests that 
replication of core AFGP structural motifs alone is insufficient to install IRI. On the contrary, 
this could even suggest an underlying mechanism of inhibition reliant upon some type of ice 
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binding / interaction (such as hydrophobic binding), for which the prepared candidates were 
unoptimized. 
In Chapter 3, conjugates of antifreeze proteins with dimerizable anthracene units were also 
prepared, in order to study the possibility of achieving spatio-temporal control over IRI activity 
and function. This led to the isolation of PC-AFP22, featuring a (TAANAAAAAAA)2 repeat 
unit, representative of wild-type AFP I, conjugated to a dilysine-anthracene motif. This had 
comparable activity to the hyper potent PVA at DP56. Unusually, when irradiated, activity was 
slightly lost by the conjugate, although it remained statistically similar. This is potentially due 
to the disruption of supramolecular ordering / pi-pi stacking interactions caused via the UV 
cycloaddition. However, this work represents the first example of its kind, and may represent 
potential strategies for controlling and tuning IRI activity with a non-invasive photo stimulus. 
To summarise, a series of studies have been carried out, which have served to expand our 
understanding of the structure-activity relationship in IRI design. Acting as blue-print / proof-
of-concept work, the observations herein have elucidated several key design rules and 
properties, and have shown the importance of both amphipathy and rigidity, whilst also 
demonstrating the potential to tune and exert remote control over activity – providing potential 
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APENDIX A: CHAPTER II 
 
Figure A2.1 – Circular dichroism spectra of the synthesised proline polypeptides compared to a 
polyproline II helical reference (PPro (II) Helix)1, not corrected for concentration to enable comparison 
against reference standard. 
 
Figure A2.2 – SPLAT assays. A) PBS control; B) L-proline, 20 mg.mL-1. Scale bar = 100 µm 
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Figure A2.3 – ESI LC-MS of PPro10 (Commercial) 
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APENDIX A: CHAPTER III 
 
Figure A3.1 – Native AFP22 peptide ESI LC/MS from Peptide Protein Research Limited 
Free AFP22
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Figure A3.2 – CD Spectra of PC-PVA Dimer and Monomer 
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APENDIX A: CHAPTER IV 
 
Figure A4.1 – Attempted anomeric deacetylation of glucose pentaacetate using ammonium 
carbonate in DMF 
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Figure A4.3 – Triphenylphosphine oxide by-product with M1 
 
Figure A4.4 – TLC Plate of the Mitsunobu Reaction, Featuring > 4 Spots and Heavy Streaking 
(Difficult to Isolate) in 4:1 Hexane/Ethyl acetate 
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Comprehensive small-angle neutron scattering (SANS) data analysis 
Contribution from Dr. Rachel C. Evans and Dr. Judith E. Houston: SANS is a popular 
characterization technique employed to yield structural information at the nanometre length 
scale. The standard equation for absolute neutron scattering by macromolecules in solution 
combines form factor, P(q) of the polymer with the interparticle scattering factor, S(q), 
represented in the equation:  





= (𝛥𝜌)2(𝛷𝑣𝑜𝑙𝑉𝑐ℎ𝑎𝑖𝑛𝑃(𝑞) 𝑆(𝑞))                         Eq. 1 
where (Δρ)2 = (ρHA – ρH2O)
2 is the contrast factor per unit volume between the polymer and the 
solvent. Vchain is the volume of the N monomers in a chain and Φvol is the volume fraction of 
monomer. In a dilute polymer solution, where intermolecular effects should be diminished, the 
scattering can be assumed to be arising from isolated chains without interactions and without 
excluded volume (i.e. S(q) ≈ 1 and therefore, I(q) ≈ P(q)). 
A Porod plot (I(q) vs. q) yields an exponent that suggests a sub-structural dimensionality from 
which the overall particle shape can be estimated. The SANS data of poly(Fulvo-co-Diol)-11 
and poly(Fulvo-co-Diol)-17 (Figure 4.19) displayed Porod exponents in the low q region (q < 
0.02 Å-1) of ~q-3.5, suggesting the formation of mass fractals.3 Fractals are self-similar structures 
that appear analogous at different length scales. Furthermore, poly(Fulvo-co-Diol)-11 and 
poly(Fulvo-co-Diol)-17 exhibit characteristic crossovers in the q dependence of the scattering 
intensity from that of aggregates (q-3) to that typical for rigid rods (q-1),4 which is characteristic 
of polymer associations.5 
For high molecular weight polymers, such as these, the only pertinent quantity, which can be 
determined, is the persistence length, bt, which accounts for the effective rigidity of the 
uncharged chain. In this case, the bt is best estimated from the point where the characteristic 
slopes intersect each other (marked with q* in Figure 5), using the following equation:5 
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               𝑏𝑡 = ≈  
1.91
𝑞∗
                    Eq. 2 
Given the transition between the q-1 region and q-3 (q*) is approximate, this method should be 
taken with care. However, it still gives our best estimate for bt. The estimated persistence 
lengths for poly(Fulvo-co-Diol)-11 and poly(Fulvo-co-Diol)-17 are 38.9 and 44.4 Å, 
respectively. It should be noted that the overlap may actually occur at a lower q region, but is 
masked by aggregate scattering. Thus, these values should be taken as the minimum persistence 
lengths for each polymer. Nevertheless, each bt is much larger than the monomer length (~10 
Å), which suggests that the chain backbones are locally stiff.5 Furthermore, given the 
approximate contour length, L, of both polymer chains (490 Å and 760 Å for poly(Fulvo-co-
Diol)-11 and poly(Fulvo-co-Diol)-17, respectively), the large bt suggests rigid rather than 
highly flexible aggregates of potentially rod-like structures. 
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Trial Coupling Reactions and for the Synthesis of the Galactose Fulvonorborneneimides 
 
Attempted promoter free synthesis of the exo,exo-fulvonorborneneimide: 
exo,exo-fulvonorborneneimide (0.599g, 2.947 mmol), acetobromo-α-D-galactose (1.86 eqv), 
and K2CO3 (2.1 eqv) were dissolved into dry, deoxygenated DMF (20 mL) under nitrogen, and 
stirred at 50ºC and 90ºC for 24 hours, respectively. The crude mixtures were co-evaporated 
with an excess of toluene (x 3), and the solid residues extracted with DCM/Brine (1:1, 100 
mL), which produced emulsions in both instances. Addition of nButanol failed to resolve 
phases, and mixtures were recondensed – characterisation of the solid residue indicated no 
product, and the fulvene starting material was wholly recovered in each case. m/z (ESI): 202.0 
(100%, SM-H+). 
Iodine Catalysed exo,exo-fulvonorborneneimide: 
Acetobromo-α-D-galactose (91.3 mg), 4Å molecular sieves, and iodine (71 mg) were dissolved 
into dry, deoxygenated DMF (10 mL) under nitrogen, and stirred at 60ºC for 1 hour. A separate 
flask was prepared concurrently of exo,exo-fulvonorborneneimide (50.4 mg) in dry, 
deoxygenated DMF (10 mL) with K2CO3 (17.1 mg) and was also stirred at RT for 1 hour. Upon 
elapse, the two mixtures were combined and stirred at 60ºC overnight whilst protected from 
light. The reaction crude was then neutralised with Na2S2O4, condensed in vacuo with a large 
excess of toluene to azeotrope DMF, and redissolved in CHCl3. The mixture was subsequently 
washed with saturated NaCl solution (2 x 30 mL) and the organic phase dried over Na2SO4 and 
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condensed in vacuo to give an orange gum 65.5 mg (55%). Characterisation as fulvene 
derivative, main text. 
Silver Catalysed exo,exo-fulvonorborneneimide and exo,exo-oxonorborneneimide: 
Acetobromo-α-D-galactose (0.1506 g / 0.1424 g), 4Å molecular sieves, exo,exo-
fulvonorborneneimide (83.9 mg) or exo,exo-oxonorborneneimide (63 mg), and Ag2CO3 (57 
mg / 53.4 mg) were dissolved in dry, deoxygenated DMF (10 mL) and stirred under nitrogen 
at RT overnight, with protection from light. The dark green reaction crude was then condensed 
in vacuo with a large excess of toluene to azeotrope the DMF, re-dissolved in ethanol and 
filtered to remove the black silver bromide by-product. The filtrate was subsequently 
recondensed, dissolved in CHCl3 (30 mL) and extracted with saturated NaHCO3 solution (2 x 
30 mL), and the organic phase washed again with saturated NaCl solution (30 mL), dried over 
Na2SO4 and condensed in vacuo to give an off-white solid. Fulvene: 20.5 mg (10%), Oxo: 17.6 
mg (10%). Characterisation as fulvene and oxo derivatives, main text.  
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Trial Syntheses of Glucose, Galactose, and N-Acetylgalactosamine Acetates 
 
Glucose pentaacetate: Zinc chloride (0.960g, 7.04 mmol) was added quickly to acetic 
anhydride (20 mL) and the mixture heated to and stirred at 85ºC for five minutes, resulting in 
a dark brown solution. D-Glucose (4.000g, 22.2 mmol) was added slowly with stirring and the 
mixture was heated for 1 further hour. The resulting thick black oil which was poured into 
chilled water (200 mL) and stirred vigorously to give a dark green solution and an off-white 
precipitate. The solid was recovered at the pump, washed with ice cold water (40 mL), and 
recrystallised from hot ethanol (20 mL). White crystals were isolated, washed with cold ethanol 
(10 mL) and dried in vacuo. 4.06 g (46.8%). 1H NMR (300 MHz, CDCl3) δ = 6.32 (1H, d, J1,2 
= 3.7 Hz, Anomeric), 5.47 (1H, t, J3,2 = J3,4 = 9.9 Hz, H-3), 5.19 – 5.05 (2H, m, H-2,4), 4.26 
(1H, dd, J6,6’ = 12.5, J6,5 = 4.1 Hz, H-6), 4.10 (2H, m, H-5,6’), 2.18 (3H, s, OAc), 2.09 (3H, s, 
OAc), 2.05 – 1.99 (9H, s, 3 x OAc). m/z (ESI) 413.0 (95%, M+Na+). 
Galactose pentaacetate: Zinc chloride (0.998g, 7.32 mmol) was added quickly to acetic 
anhydride (20 mL) and the mixture stirred and heated to 85ºC for five minutes, resulting in a 
dark brown solution. D-Galactose (1.005g, 5.55 mmol) was added slowly with stirring and the 
mixture heated for a further 2 hours, resulting in a dark brown solution, and was poured into 
chilled water (200 mL). No precipitation was observed with vigorous perturbation. Mixture 
was condensed in vacuo and chilled to 5°C overnight, no crystallisation was observed, and so 
the crude residue was extracted with dichloromethane (100 mL) and chilled water (100 mL). 
The aqueous phase was washed twice with dichloromethane (2 x 50 mL), and the combined 
organic phases washed once with chilled water (50 mL), dried over MgSO4, filtered, and 
condensed in vacuo, yielding an orange/brown oil. m/z (ESI) 413.12 (100%, M+Na+). 
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Glucose: Glucose pentaacetate (1.005g) was dissolved in DMF (20 mL) with ammonium 
carbonate (0.5060g) or benzylamine (2 mL) and stirred at 30ºC for 48 hours. Chloroform (30 
mL) was added and the mixture poured into ice cold HCl (1M, 20 mL). The organic phase 
extracted and the aqueous washed with CHCl3 (3 x 20 mL). The combined organic phases were 
washed with water (15 mL) and saturated NaHCO3 solution (15 mL), dried over Na2SO4 and 
condensed in vacuo with an excess of n-Butanol, resulting in a yellow/brown gum. 1H NMR 
(300 MHz, CDCl3) δ = 5.51 (2H, dt, J = 7.2, 6.7 Hz), 5.26 (1H, t, J = 9.5 Hz), 5.00 – 4.65 (2H, 




APENDIX A: CHAPTER V 
 
Figure A5.1 – UV/Vis Traces and Beer-Lambert solubility determination of poly(chenodeoxycholic 
acid) 
 
Figure A5.2 – UV/Vis Traces and Beer-Lambert solubility determination of poly(7-ketolithocholic acid) 
 















Equation y = a + b*x
Plot B
Weight No Weighting
Intercept -0.16264 ± 0.0156
Slope 2.80671 ± 0.06588
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Equation y = a + b*x
Plot B
Weight No Weighting
Intercept 2.14798E-4 ± 0.02825
Slope 0.58581 ± 0.03501
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Figure A5.3 – UV/Vis Trace of Simvastatin 
 
Figure A5.4 – UV/Vis Trace and Beer-Lambert solubility determination of Hydrolysed Simvastatin 
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Equation y = a + b*x
Plot B
Weight No Weighting
Intercept 0.04163 ± 0.0246
Slope 0.06759 ± 0.0050
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Figure A5.5 – UV/Vis Trace and Beer-Lambert solubility determination of Ring Opened and 
Hydrolysed Simvastatin 
 
Figure A5.6 – UV/Vis Trace and Beer-Lambert solubility determination of Ring Opened Simvastatin 
  
ROP + Hydrolysed Simvastatin













Equation y = a + b*x
Plot B
Weight No Weighting
Intercept 0.03 ± 0.01648
Slope 0.14254 ± 0.0145
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Equation y = a + b*x
Plot B
Weight No Weighting
Intercept 0.0806 ± 0.0167
Slope 0.0676 ± 0.0039
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Optimised procedure for the synthesis of p-azido-L-phenylalanine (Fmoc Protected) 
Step 1: 
 
N-Fmoc-4-amino-L-phenylalanine (9.4 g, 23.36 mmol) was suspended in DMF (300 mL), with 
stirring and cooling to 0°C. t-BuONO (4 mL, 33.63 mmol, 1.43 eqv) was subsequently added, 
followed by TMS azide (3.3 mL, 25.01 mmol, 1.07 eqv).  The ice bath was removed, and the 
mixture allowed to warm to RT, and stirring continued for 60 minutes. The reaction mixture 
was concentrated under vacuum (65°C, 50 mbar) until dry, to yield the Fmoc-protected-product 
as an orange-brown solid. 10 g (100%). 1H NMR (400 MHz, DMSO-d6) δ 7.88 (d, J = 7.5 Hz, 
2H), 7.73 – 7.46 (m, 3H), 7.45 – 7.24 (m, 4H), 7.05 – 6.85 (m, 2H), 6.47 (d, J = 8.1 Hz, 2H), 
4.29 – 4.11 (m, 3H), 4.12 – 4.00 (m, 1H), 2.87 – 2.81 (m, 1H), 2.68 (dd, J = 13.9, 10.1 Hz, 1H). 
13C NMR (101 MHz, DMSO-d6) δ 174.06 (C=O), 156.37 (NHC=O), 147.49 – 141.12 
(Aromatics), 129.97 –114.24 (Aromatics), 66.07 (CH2, Ala), 56.53 (CH, Ala), 47.05. m/z (ESI, 
–ve) Expected 427.1, Observed 427.2 [100%, M–H+]. Analytical RP-HPLC: 98%, 7.08 min, 
tR = 60 min (Water/Acetonitrile 0 : 100 for 5 minutes, to 70 : 30 by 15 min, to 100 : 0 by 55 
min, λ = 315 nm). 
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Figure B1 – NMR of N-Fmoc-4-azidophenylalanine hydrochloride from protected azidation 
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To the ring azidated N-Fmoc-4-azido-L-phenylalanine (80 mg, 0.187 mmol), 20% 4-methyl 
piperidine/DMF was added (10 mL) with stirring and protection from light. After one hour, the 
reaction mixture was condensed in vacuo (80°C, 50 mbar) until dry, dissolved in H3O
+ (pH 2, 
10 mL) and the acidified mixture extracted with hexane (4 x 30 mL), and the aqueous phase 
condensed again in vacuo, to give the product as a pale-yellow solid, the hydrochloride salt. 70 
mg (Quant %). Analytical RP-HPLC (Slow): tR = 30 min (Water/Acetonitrile 100 : 0 to 70 : 30 
by 2 min to 0 : 100 by 25 min, λ = 324 nm). Analytical RP-HPLC (Fast): 98%, 7.08 min, tR = 
60 min (Water/Acetonitrile 0 : 100 for 5 minutes, to 70 : 30 by 15 min, to 100 : 0 by 55 min, λ 
= 324 nm). 1H NMR (300 MHz, D2O) δ 7.33 (d, J = 8.2 Hz, 2H), 7.12 (d, J = 8.1 Hz, 2H), 3.97 
(t, J = 6.4 Hz, 1H), 3.32 – 3.03 (m, 2H). 13C NMR (101 MHz, D2O) δ 171.54 (C=O), 164.87, 
139.42 (Aromatic), 135.53 (Aromatic), 131.06 (Aromatic), 123.63 –119.51, 54.23 (CH2, Ala), 
























Optimised procedure for the synthesis of p-azido-L-phenylalanine (No Fmoc Protection) 
 
4-Amino-L-phenylalanine (50 mg, 0.278 mmol) was dissolved in DMSO with sonication (25 
mL), with stirring and cooling to 0°C. The flask was protected from light, and t-BuONO (50 
µL, 0.416 mmol, 1.5 eqv) was subsequently added, followed by timethylsilyl azide (42 µL, 
0.306 mmol, 1.1 eqv), and equilibrated for 60 minutes. The reaction mixture was concentrated 
under vacuum (65°C, 50 mbar) and precipitated from ethyl acetate, to give an off-white/orange 
solid, which was isolated by centrifugation (10K RPM, 10 minutes). 40 mg (60%). Analytical 
RP-HPLC: tR = 30 min (Water/Acetonitrile 100 : 0 to 70 : 30 by 2 min to 0 : 100 by 25 min λ 
= 324 nm). 1H NMR (400 MHz, D2O) δ 7.12 (d, J = 7.8 Hz, 2H), 6.84 (d, J = 7.8 Hz, 2H), 3.92 
(dd, J = 8.1, 5.0 Hz, 1H), 3.19 – 3.12 (m, 1H), 3.02 (dd, J = 14.8, 7.8 Hz, 1H). 13C NMR (101 
MHz, D2O) δ 176.56, 174.03 (C=O), 145.35, 130.28, 125.63 (Aromatic), 116.85 (Aromatic), 





Figure B5 – NMR of para-azidophenylalanine hydrochloride from direct azidation 
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Polyproline as a Minimal Antifreeze Protein Mimic That Enhances the
Cryopreservation of Cell Monolayers
Ben Graham, Trisha L. Bailey, Joseph R. J. Healey, Moreno Marcellini, Sylvain Deville, and
Matthew I. Gibson*
Abstract: Tissue engineering, gene therapy, drug screening,
and emerging regenerative medicine therapies are fundamen-
tally reliant on high-quality adherent cell culture, but current
methods to cryopreserve cells in this format can give low cell
yields and require large volumes of solvent “antifreezes”.
Herein, we report polyproline as a minimum (bio)synthetic
mimic of antifreeze proteins that is accessible by solution,
solid-phase, and recombinant methods. We demonstrate that
polyproline has ice recrystallisation inhibition activity linked to
its amphipathic helix and that it enhances the DMSO
cryopreservation of adherent cell lines. Polyproline may be
a versatile additive in the emerging field of macromolecular
cryoprotectants.
Tissue engineering, gene therapy, therapeutic protein pro-
duction, and transplantation rely on the successful storage
and transport of donor cells.[1] For example, in the production
of therapeutic proteins, a specific cell line must be developed
for each protein.[2] Given that any in vitro culture will
undergo phenotypic and genotypic changes when propagated
for long periods of time, it is neither possible nor practical to
maintain a continuous culture of cells.[3] The only solution to
this is the cryopreservation of cells using significant volumes
of cryoprotectants, such as DMSO (dimethyl sulfoxide),
which are intrinsically toxic.[4] The repeated use of DMSO
has an impact on the epigenetic profile of cells, specifically the
alteration of DNA methylation profiles, which results in
phenotypic changes.[5,6] There is a real need for robust
methods to cryopreserve cells in monolayer (adhered to
tissue culture scaffolds) format to provide phenotypically
identical cells for assays, obviating the need for replating
between freeze–thaw cycles. Formulations containing 5–10%
DMSO reduce cryoinjury by moderating the increase in
solute concentration during freezing[7–9] but for adhered
embryonic stem cells, their use results in just 5% cell
recovery.[10, 11] A key contributor to cell death during cryo-
preservation is ice recrystallisation (growth) and additives
that can inhibit recrystallisation have the potential to redefine
cell storage and hence biomedicine.
Antifreeze (glyco)proteins (AF(G)Ps) are potent ice
recrystallisation inhibitors (IRIs), but are unsuitable for
cryopreservation applications owing to their potential tox-
icity/immunogenicity and their secondary effect of dynamic
ice shaping (DIS), which leads to needle-like ice crystals that
pierce cell membranes.[12] Synthetic polymers that are potent
IRIs have emerged as new tools for controlling ice growth.[13]
The most studied one is poly(vinyl alcohol) (PVA), which can
inhibit ice growth at concentrations below 0.1 mg mL@1 and
enhances the cryopreservation of cells in suspension.[14–16] It is
hypothesized that the activity of PVA is related to its
regularly spaced hydroxyl groups.[17] Matsumura and Hyon
have developed polyampholytes[18] that are cryoprotective but
have moderate IRI activity.[19, 20] Wang and co-workers have
demonstrated the significant IRI activity of graphene
oxide.[21] Ben and co-workers have developed low-molecu-
lar-weight surfactants that also inhibit ice growth.[22] A major
setback is that the above synthetic IRIs are neither biode-
gradable nor bioresorbable and have not been applied to the
significant challenge of cell monolayer storage.
There are no crystal structures for AFGPs but solution-
state NMR and circular dichroism (CD) spectroscopy suggest
a polyproline II (PP II)-type helix.[23] Polyproline is unique
amongst the canonical amino acids in that it has no amide
N@H, meaning that it cannot form intramolecular hydrogen
bonds. Therefore, it is water-soluble and quite hydrophobic at
the same time, as is the case for AFP I, which contains 70%
alanine (a hydrophobic amino acid). We thus hypothesised
that polyproline could be a minimal AF(G)P mimic owing to
its amphiphilicity.[24] Homopolypeptides are appealing targets
compared to vinyl polymers as they can be prepared by solid-
phase synthesis,[25] solution-phase polymerisation,[26] or
recombinant methods,[27] proving vast (bio)synthetic space.
Herein, we introduce polyproline as a minimum (bio)-
synthetic antifreeze protein mimic. We demonstrate that
polyproline has ice recrystallisation inhibition activity, which
is linked to its amphipathic PP II helix structure. Polyproline
was found to improve the post-cryopreservation recovery of
cell monolayers compared to DMSO alone, demonstrating
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a new macromolecular approach for the storage of complex
cells to enable next-generation therapies.
l-, d-, and (racemic) d/l-polyproline were synthesised by
condensation polymerisation using 1-ethyl-3-(3-dimethylami-
nopropyl) carbodiimide (EDC, Scheme 1), alongside several
commercial samples. Following dialysis, the polymers were
characterised by size exclusion chromatography (SEC;
Table 1). The polymers were less disperse than expected
owing to fractionation during dialysis.
CD spectroscopy confirmed that PPro15 adopted a PP II
helix (Figure 1A; see also the Supporting Information, Fig-
ure S1)[31] with characteristic signals present at 207 and
228 nm, whilst a random coil would exhibit slight peak
shifting, with signals absent in the 220 nm region.[32] P(d-
Pro)15 gave the mirror spectrum whilst the d/l racemic
mixture showed no secondary structure. This series of
peptides were subsequently tested for IRI activity using
a splat assay.[33] This involved seeding a large number of small
ice crystals, which were annealed for 30 min at @8 8C before
being photographed. The average crystal size was measured
relative to a PBS control, with smaller values indicating more
IRI activity (Figure 1B, C).
All polyproline variants were found to display dose-
dependent activity but weak molecular-weight dependence in
the range tested (Figure 1B). The shortest peptide (PPro10)
lost activity below 10 mgmL@1, but the longer ones retained
activity at 5 mgmL@1. The magnitude of activity was signifi-
cantly smaller than for AF(G)Ps, which function at concen-
trations as low as 0.14 mgmL@1,[34] but comparable to that of
polyampholytes.[19, 20] Knight and co-workers have observed
that poly(hydroxyproline) has IRI activity, which was
assumed to be due to the regularly spaced hydroxyl groups
along the backbone.[35] However, the observations made here
suggest that the PP II helix, rather than (or in addition to) the
hydroxyl groups, gives rise to the observed activity. Figure 1C
compares the IRI activity of poly(hydroxyproline) with those
of PPro15 and two a-helical poly(amino acid)s.
[36] Polylysine
(PLys50) and poly(glutamic acid) (PGlu110) showed no IRI
activity. PPro15 was found to be more active than poly(hy-
droxyproline) of higher molecular weight. This finding
confirmed that hydroxyl groups are not essential for activity
in IRI-active compounds. P(d-Pro15) and P(d/l-Pro21) had
statistically identical activity to PPro15, suggesting that local
rather than long-range order is crucial for activity.
We hypothesise that IRI activity requires segregated
hydrophilic and hydrophobic domains (amphipathy).[37, 22,24]
PPro10 was compared to a non-glycosylated type I sculpin
AFP[38] and also to PGlu10 by mapping their hydrophobic/
hydrophilic domains (Figure 2). The type I sculpin AFP
(Figure 2A) possesses “patches” of hydrophobic/hydrophilic
groups. PPro10 (Figure 2B) also possesses this facial amphi-
Scheme 1. Condensation polymerisation of proline. The materials were
used in stereopure form but both the l- and d-isomers were used,
hence no stereocentres are shown.
Table 1: Polyproline characterisation.
Mn
[g mol@1]









[a] 1.01 15 enantiomeric PP II
P(d/l-Pro)21 2400
[a] 1.01 21 random coil
PPro10-100 1–10000
[b] – 10–100 PP II[e]
PPro10 900
[c] [d] 10 PP II[e]
PPro10-25 1–3000 1.01–1.03 10–25 PP II
[e]
PPro20 2000
[c] [d] 20 PP II[e]
[a] Determined by SEC. [b] Value from supplier. [c] Determined by mass
spectrometry. [d] Single species. [e] From Ref. [28–30].
Figure 1. A) Circular dichroism spectra. B) IRI activity of the polypro-
line series. C) IRI activity compared to other homopolypeptides.
D) Cryomicrograph of a PBS negative control. E) Cryomicrograph of
20 mgmL@1 polyproline. Photographs taken after 30 min at @8 8C.
Error bars represent : standard deviation from a minimum of three
replicates. Images shown are 1.2 mm across. MLGS=mean largest
grain size.
Figure 2. Hydrophobic surface mapping of A) recombinant type I scul-
pin AFP, B) PPro10, and C) PGlu10, showing charged hydrophilic surfa-
ces. Hydrophobic regions (red), hydrophilic regions (white).
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philicity. In comparison, PGlu10 (no IRI activity) has charged
groups around the core of the helix, which prevents the
presentation of hydrophobic domains. This agrees with our
previous study on nisin A, which has IRI activity associated
with segregated domains,[37] and also the results obtained with
amphiphiles developed by Ben et al., which only function
below the critical micelle concentration.[22]
Aside from IRI activity, AF(G)Ps display unwanted ice
shaping, which promotes the formation of needle-like ice
crystals, which damage cell membranes.[12] Cryo-confocal
microcapillary microscopy has emerged as a tool for mon-
itoring ice crystal shaping,[39] and was also employed here
(Figure 3). A non-IRI-active dye, sulforhodamine B, provided
contrast against the ice (which appears dark). A control using
pure PBS showed no shaping whilst zirconium acetate
(ZrAc), which is a strong ice shaper, produced hexagonal
crystals.[39] PPro19 did not induce shaping, supporting the
concept that polyproline inhibits ice crystal growth without
inhibiting the formation of a specific plane of ice; however, as
these are relatively weak IRIs, the concentrations needed for
ice shaping would be very high.
To explore polyproline as a macromolecular cryopreser-
vative, A549 cells were employed as a prototypical adherent
cell line.[40] The protective osmolyte proline (which has no IRI
activity; see the Supporting Information) was used as
a secondary cryoprotectant. A549 cells were incubated with
200 mm (23 mgmL@1) proline (blue bars; Figure 4) or medium
alone (red bars; Figure 4) for 24 h. The medium was then
removed and replaced with a medium containing 10%
DMSO with varying concentrations of PPro11 (1250 gmol
@1,
Y = 1.03). After 10 min exposure to this solution, all excess
solvent was removed, and the cells were subjected to
controlled-rate freezing at 1 8C min@1 to @80 8C. Following
storage at @80 8C, the cells were thawed by addition of warm
medium (37 8C), and the total number of viable cells was
determined by trypan blue staining 24 h after thawing.
Figure 4 shows that the use of DMSO alone led to 27% cell
recovery. Addition of polyproline alone to 10 % DMSO failed
to give any additional protection. However, for cells that had
been preconditioned with 200 mm proline for 24 h before
treatment with 10 mgmL@1 PPro11/10% DMSO, the cell
recovery doubled to 53%. Increasing the concentration of
polyproline beyond 10 mgmL@1 did not increase recovery
further, suggesting that the additive benefits plateau at
10 mg mL@1.[14] It should be highlighted that the cell viability
assays measure intact cells, and that detailed functional
analysis will be needed in the future for demonstration of
complex function. For comparison with other macromolecu-
lar cryopreservatives, Matsumura and co-workers have
reported poly(ampholyte)-enhanced monolayer storage
using vitrification solutions, giving near-quantitative cell
recovery.[41] However, this required very high DMSO con-
centrations of 6.5m (> 500 mgmL@1) plus 10 wt % (ca.
100 mgmL@1) of the polymer, and there was a reduction in
the post-thaw proliferation rate associated with the large
solvent volumes, which may limit practical applications. In our
PPro system introduced here, the total recovery levels were
less, but far lower concentrations of DMSO were employed
(10 wt %/ca. 100 mgmL@1), and the total exposure time to this
potentially toxic component was only 10 min. To critically
compare PPro, another batch (PPro10–25) was synthesised and
tested for cytotoxicity and heamocompatibility. A549 mono-
layers were exposed to PPro for 24 h, and the cell viability was
assessed (see the Supporting Information). This extended
exposure period led to a reduction in alamar blue to 60 % for
5 mgmL@1 PPro, suggesting some cytotoxicity if exposed to
elevated concentrations for long periods of time. It is
important to note that in this cryopreservation procedure,
PPro is only in contact with the cells for 10 min before the
excess is removed and the cells are frozen. Red blood cell
heamolysis experiments (see the Supporting Information)
Figure 3. Cross-section of ice crystals perpendicular to the temperature
gradient: A) ZrAc (positive control), B) PPro19, C) PBS (negative con-
trol). The ice crystals expel the dye while growing, appearing in black,
while the remaining liquid fluoresces.
Figure 4. A549 cryopreservation. Cell recovery determined by trypan
blue assays. Cells were first incubated either in the medium alone or
with 200 mm proline for 24 h. They were subsequently cryopreserved
by addition of 10% DMSO with the indicated PPro11 concentration.
Error bars : S.E.M. from n =3 with two nested replicates. # P<0.05
compared to 10 % DMSO treatment; * P<0.05 compared to 200 mm
proline exposure with 10 % DMSO treatment.
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showed this was not due to any inherent membrane activity of
the (amphipathic) PPro.
In summary, we have demonstrated that polyproline is
a potent additive for cell-monolayer cryopreservation when
appropriate freezing conditions are employed. Polyproline
has moderate ice recrystallisation inhibition activity, which
was hypothesised to be due to its “patchy” amphipathic
structure associated with its PP II helix. Addition of polypro-
line to adherent cell cultures led to an increase from 20 % to
> 50% in total cell recovery post-cryopreservation, which is
significantly better than for the use of DMSO alone. This
increase in recovery is thought to be associated with the
inhibition of ice recrystallisation. Short exposure times of just
10 min to the polyproline/DMSO solution, followed by
removal of the excess solvent, reduced the cytotoxicity
associated with long-term (24 h) exposure to elevated levels
of polyproline. The minimal solvent exposure times may give
benefits in downstream processing and biomedical applica-
tions compared to current high-solvent-concentration meth-
ods using vitrification. Polyproline is appealing compared to
other macromolecular cryoprotectants as it only comprises
native amino acids and can be obtained by chemical and
biochemical methods.
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ABSTRACT: Antifreeze glycoproteins (AFGPs) from
polar fish are the most potent ice recrystallization (growth)
inhibitors known, and synthetic mimics are required for
low-temperature applications such as cell cryopreservation.
Here we introduce facially amphipathic glycopolymers that
mimic the three-dimensional structure of AFGPs. Glyco-
polymers featuring segregated hydrophilic and hydro-
phobic faces were prepared by ring-opening metathesis
polymerization, and their rigid conformation was con-
firmed by small-angle neutron scattering. Ice recrystalliza-
tion inhibition (IRI) activity was reduced when a
hydrophilic oxo-ether was installed on the glycan-opposing
face, but significant activity was restored by incorporating a
hydrophobic dimethylfulvene residue. This biomimetic
strategy demonstrates that segregated domains of distinct
hydrophilicity/hydrophobicity are a crucial motif to
introduce IRI activity, which increases our understanding
of the complex ice crystal inhibition processes.
Antifreeze glycoproteins (AFGPs) are found in the tissuesand blood serum of extremophile fish species and act to
modulate the growth of extracellular ice.1 A key property of
AFGPs is ice recrystallization inhibition (IRI), which slows ice
crystal growth (distinct from nucleation2).3 Ice recrystallization
is a major cause of cell death during the freezing of cells and
tissue for transfusion, fundamental biomedicine, and cell
biology. Hence, AFGPs (or their mimics) have many potential
applications.4 Cryopreservation with AFGPs (and non-glyco-
sylated antifreeze proteins, AFPs)5 is limited, however, by their
secondary property of dynamic ice shaping, whereby the
AFGPs shape the ice into needle-like (spicular) morphologies,
which can pierce cell membranes.3 AFGPs are also challenging
to synthesize, requiring multistep procedures.6,7 Gibson and co-
workers have developed synthetic polymers8,9 based upon
poly(vinyl alcohol) and poly(ampholytes) which have been
found to enhance the cryopreservation of blood10−12 and
nucleated cells.4,13
In the case of AFPs, defined ice-binding faces have been
identified using structural biology methods.14 Conversely, there
is no crystal structure available for AFGPs, and the exact
structural motifs required for IRI are unknown, although the
glycan unit is essential for ice shaping.7 Solution NMR studies
suggest that AFGPs form a polyproline II type of helix, with the
glycans on one face and peptides on the opposite, forming a
facially amphipathic structure.15 It is emerging that this
segregated display of hydrophobic/hydrophilic groups, rather
than a “binding site”, is the essential feature for IRI
activity.8,16,17 Molecular modeling recently revealed that the
hydrophobic face, not the glycans, of AFGPs interacts with the
ice, and that the spatial segregation along the polyproline II
helix is essential.18 Gibson and co-workers have shown that
homopolyproline has a weak IRI,4 and that self-assembled
metallohelicities with “patchy” amphipathy are potent IRIs,19
which supports a hypothesis that well-defined ice-binding
domains are not essential for IRI.20 Amphipathy has also been
seen to be important in ice nucleation.21 This evidence suggests
that IRI, but not ice shaping,22 could be selectively introduced
into new and emerging (bio)materials, if precise control over
hydrophilic/hydrophobic domains is possible.
The design of polymers with solvent-exposed hydrophobic
domains is, however, nontrivial. Block copolymeric amphiphiles
spontaneously self-assemble into micelles/vesicles to reduce the
hydrophobic domain’s contact with water, and hence only
“water-loving” surfaces are exposed.23 Tew and co-workers have
developed facially amphipathic cationic polymers, with
opposing positive charges and lipophilic domains to mimic
the function of antimicrobial peptides.24,25 A crucial design step
was the use of ring-opening metathesis polymerization
(ROMP), which introduces rigid alkene backbones, while
balancing the hydrophobicity/hydrophilicity to maintain both
solubility and the presentation of hydrophobic faces. These
have shown particular potency as potential antimicrobials.26
Considering the above, we designed and synthesized locally
rigid, facially amphipathic glycopolymers. A combination of ice
binding assays, modeling, and small-angle neutron scattering
(SANS) provides compelling evidence that local amphipathy is
an essential motif for introducing IRI activity, providing design
rules for new materials to mimic AFGP function.
Figure 1A shows the solution-state structure of AFGP,7 with
the disaccharide units spatially segregated from the hydro-
phobic peptide backbone. Our approach was to use ROMP to
introduce local rigidity,27 in contrast to flexible backbones
obtained from radical polymerization. Four monomers were
synthesized to give a range of amphipathies: M1 was prepared
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by acetylation of a commercial norbornenediol; M2 and M3
were synthesized by Koenigs−Knorr coupling of acetobromo-
α-D-galactose with exo,exo-[oxo/fulvene]norborneneimide; and
M4 was synthesized by substitution of monomethoxyhexa-
ethylene glycol monotosylate (Figure 1B). The hydrophilic
galactose and hydrophobic fulvene motifs were selected in
particular due to their intrinsic rigidities, giving monomers with
structurally distinct domains of opposing polarity. These
monomers were polymerized using Grubbs’s third-generation
catalyst, and acetate protecting groups were subsequently
removed by treatment with sodium methoxide followed by ion
exchange (Figure 1C). The panel of amphipathic polymers was
characterized by size-exclusion chromatography (SEC; Đ < 1.4)
and NMR (nuclear magnetic resonance) and IR (infrared)
spectroscopy (see Supporting Information (SI) and Table 1).
The polymer library was assessed for IRI activity using a
“splat” assay, where ice crystals are nucleated and their growth
after 30 min at −8 °C was recorded. Activity is expressed as the
mean grain area (MGA) relative to a phosphate-buffered saline
(PBS) control, with smaller values representing more activity.
Polymers derived from M2 containing the “fulvo” motif were
significantly less soluble than those derived fromM3 containing
the “oxo”-ether units. Their solution concentrations were
therefore determined by UV−vis absorption spectroscopy (see
SI for Beer−Lambert plots) at saturation. In the case of
poly(Fulvo), 1% v/v dimethylsulfoxide was required, and
controls were adjusted to account for this.
Poly(Oxo) was found to inhibit ice crystal growth by ∼50%
MGA at concentrations above 5 mg·mL−1 (Figure 2A), which
makes it more active than many previously reported IRI-active
polymers.28,29 The poly(Fulvo) derivative featuring the hydro-
phobic face, however, was considerably more active, inhibiting
by ∼50% MGA at just 0.5 mg·mL−1 (solubility limit),
supporting the facially amphipathic hypothesis for IRI.
Molecular models corroborate this (Figure 2B) and illustrate
the relative increase in hydrophobicity across the poly(Oxo)
and poly(Fulvo) homopolymers. To improve the solubility, a
1:1 statistical copolymer of M2/M3, poly(Fulvo-co-Oxo), was
prepared. This co-polymer had significantly improved solubility
and comparable overall IRI activity to poly(Fulvo), showing
that some co-monomer incorporation is tolerated, unlike
PVA,30 and example ice wafers are shown in Figure 2C.
However, the non-ideal copolymerization kinetics of the oxo
(M2) and fulvo (M3) co-monomers led to a blocky rather than
statistical copolymerization.31,32 Infrared analysis confirmed
incomplete acetate removal (in contrast to the homopolymers),
suggesting an internalized domain structure and/or aggrega-
tion, with some (hydrophobic) surfaces being solvent
inaccessible and hence limiting the total activity of poly-
(Fulvo-co-Oxo). The monomers alone also had no activity (SI),
confirming that a macromolecular architecture is essential.
To improve solubility, a norbornenediol monomer, M1, with
a non-hydrophilic bridgehead was investigated. De-acetylated
homopolymers of M1, poly(Diol), were found to have
surprisingly low solubility and no activity at their solubility
limit of 0.5 mg·mL−1. However, whenM1 was incorporated as a
co-monomer with the (IRI-active) “fulvo” monomerM2 to give
Figure 1. (A) Concept of facially amphipathic ROMP polymers to
mimic AFGP. Adapted from ref 7. (B,C) Monomers and polymers
synthesized here; hydrophilic groups are indicated in blue, and
hydrophobic in red.
Table 1. Polymer Characterization
Mn (g mol
−1)
theor exptla Đ (−)a DP (−)a conv (%)b
poly(Diol)c 10 000 2 200 1.01 14 100
5 300 1.01 34
8 400 1.02 54
poly(Fulvo) 25 000 10 300 1.21 28 100
poly(Oxo) 10 000 7 300 1.18 22 100
poly(FPEG) 10 000 35 900 1.38 133 100
poly(Fulvo-co-Diol)-11 5 000 10 700 1.12 14, 35 94/97
poly(Fulvo-co-Diol)-17 10 000 16 800 1.10 22, 54 100
poly(Fulvo-co-Diol)-35 25 000 34 600 1.26 47, 112 100
poly(Fulvo-co-Oxo) 10 000 7 700 1.35 11, 11 100/96
poly(Fulvo-co-FPEG) 10 000 55 600 1.47 76, 58 71
aMn = molar mass, Đ = dispersity, and DP = degree of polymerization, determined by SEC.
bConversion, determined by 1H NMR. cSingle species.
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poly(Fulvo-co-Diol), an overall increase in solubility was
achieved. Poly(Fulvo-co-Diol)-17 had remarkable IRI activity:
40% MGA at just 1.3 mg·mL−1 (Figure 3). This polymer
showed some molecular weight dependence on activity, with 17
kDa being more active than 11 kDa (and far more than the
monomer, indicating the need for a macromolecular
architecture). Increasing the molecular weight further to 35
kDa lowered the solubility of the copolymer, and hence the
activity, highlighting a “sweet spot”. Work undertaken by Inada
et al. described the molecular weight dependence on IRI of
PVA.33 Similarly, a previous study by Deswal et al. reported on
the IRI activity of proteins extracted from the leaves of the
freeze-tolerant plant Seabuckthorn, of which superior antifreeze
activity was observed only for polypeptides of elevated
molecular weights.34 Replacing the glycan with a short
oligo(ethylene glycol) PEG chain, to give both poly(Fulvo-co-
FPEG) and poly(FPEG), decreased activity, as the (flexible)
PEG can access numerous conformations, reducing the overall
amphipathy (see SI). Hydrogenation of the alkene backbone to
increase flexibility resulted in a wholly insoluble polymer (see
SI). These observations demonstrate that precise macro-
molecular engineering is essential to achieve a potent IRI
mimetic.
AF(G)Ps bind to specific ice crystal faces,35,36 leading to
dynamic ice shaping (unwanted in cryopreservation3). Control
ice crystals (Figure 4A) showed no dynamic ice shaping, but
addition of AFGPs (Figure 4B) produced distinctive spicular
(needle-like) crystals. Poly(Fulvo-co-Diol) (Figure 4C) did not
lead to ice shaping, ruling out strong and specific ice face
recognition and showing that these effects can be separated by
macromolecular design.
SANS was employed to evaluate the solution conformation
and rigidity of the poly(Fulvo-co-Diol) series (Figure 5 and SI).
The persistence lengths, bt, were estimated from the position of
the characteristic crossover between the scattering profile
typical for fractal aggregates (q−3.5) and that of rigid rods (q−1)
(see SI).37,38 The estimated bt values for poly(Fulvo-co-Diol)-
11 and poly(Fulvo-co-Diol)-17 are 38.9 and 44.4 Å,
respectively. It should be noted that the overlap may actually
occur at a lower q region, but is masked by aggregate scattering.
Thus, these values should be taken as the minimum persistence
length for each polymer. Nevertheless, each bt is much larger
Figure 2. (A) IRI activities of the poly(Fulvo), poly(Oxo), and
copolymer series. (B) Hydrophobic surface map of poly(Fulvo) and
poly(Oxo). (C,D) Optical microscopy of ice crystal wafers of PBS and
poly(Fulvo-co-Oxo).
Figure 3. IRI activities of the poly(Fulvo-co-Diol) molecular weight
series.
Figure 4. Optical microscopy ice morphology analysis: (A) water, −6
°C; (B) AFGP-8, −5 °C; (C) poly(Fulvo-co-Diol)-17 (0.72 mg·mL−1),
−8 °C.
Figure 5. SANS data for poly(Fulvo-co-Diol)-11 (1 mg.mL−1, red) and
poly(Fulvo-co-Diol)-17 (1 mg.mL−1, blue) in D2O at 25 °C. Straight
lines show −3.5 and −1 decays for comparison.
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than the monomer length (∼10 Å), which suggests that the
chain backbones are locally stiff.38 Furthermore, given the
approximate contour length, L, of both polymer chains (490
and 760 Å for poly(Fulvo-co-Diol)-11 and poly(Fulvo-co-Diol)-
17, respectively), the large bt suggests rigid rather than highly
flexible aggregates of potentially rod-like structures. This
rigidity, coupled with the intrinsic amphipathy of the polymers,
is aligned with the hypothesized semi-rigid (and generally
amphipathic) ice binding faces of AFPs,14,39 and the flexible
hydrophilic “glycan face” of AFGPs, providing evidence that
facial amphipathy is a key motif for introducing IRI activity into
a diverse range of polymers.
To conclude, we have designed and synthesized facially
amphipathic glycopolymers to mimic the solution confirmation
and selective functions of antifreeze glycoproteins. It was found
that the addition of hydrophobic faces, opposing the glycan
units, introduced potent IRI activity, but that substitution with
a more hydrophilic ether unit removed activity. These results
support a mechanism for IRI activity which is dependent upon
local water ordering rather than an essential ice binding unit,
and there was no evidence of dynamic ice shaping. Small-angle
neutron scattering supports a locally rigid confirmation, as seen
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